Early treatments for COVID-19

Munafò et al., Quercetin and Luteolin Are Single-digit Micromolar Inhibitors of the SARS-CoV-2 RNA-dependent RNA Polymerase, Research Square, doi:10.21203/rs.3.rs-1149846/v1

Biswas et al., Antiviral Phytocompounds Against Animal-to-Human Transmittable SARS-CoV-2, Ethnopharmacology and Drug Discovery for COVID-19: Anti-SARS-CoV-2 Agents from Herbal Medicines and Natural Products, doi:10.1007/978-981-99-3664-9_7

Capra et al., Efficacy of Palmitoylethanolamide and Luteolin Association on Post-Covid Olfactory Dysfunction: A Systematic Review and Meta-Analysis of Clinical Studies, Biomedicines, doi:10.3390/biomedicines11082189

Di Stadio et al., Ultramicronized Palmitoylethanolamide and Luteolin Supplement Combined with Olfactory Training to Treat Post-COVID-19 Olfactory Impairment: A Multi-Center Double-Blinded Randomized Placebo- Controlled Clinical Trial, Current Neuropharmacology, doi:10.2174/1570159X20666220420113513

He et al., Recent advances towards natural plants as potential inhibitors of SARS-Cov-2 targets, Pharmaceutical Biology, doi:10.1080/13880209.2023.2241518

Mandal et al., In silico anti-viral assessment of phytoconstituents in a traditional (Siddha Medicine) polyherbal formulation – Targeting Mpro and pan-coronavirus post-fusion Spike protein, Journal of Traditional and Complementary Medicine, doi:10.1016/j.jtcme.2023.07.004

Onyango, O., In Silico Models for Anti-COVID-19 Drug Discovery: A Systematic Review, Advances in Pharmacological and Pharmaceutical Sciences, doi:10.1155/2023/4562974

Akter et al., Plausibility of natural immunomodulators in the treatment of COVID-19–A comprehensive analysis and future recommendations, Heliyon, doi:10.1016/j.heliyon.2023.e17478

Rafiq et al., A Comprehensive Update of Various Attempts by Medicinal Chemists to Combat COVID-19 through Natural Products, Molecules, doi:10.3390/molecules28124860

Corbo et al., Inhibitory potential of phytochemicals on five SARS-CoV-2 proteins: in silico evaluation of endemic plants of Bosnia and Herzegovina, Biotechnology & Biotechnological Equipment, doi:10.1080/13102818.2023.2222196

Fan et al., Pharmaceutical approaches for COVID-19: An update on current therapeutic opportunities, Acta Pharmaceutica, doi:10.2478/acph-2023-0014

Yang et al., In silico evidence implicating novel mechanisms of Prunella vulgaris L. as a potential botanical drug against COVID-19-associated acute kidney injury, Frontiers in Pharmacology, doi:10.3389/fphar.2023.1188086

CHEN et al., Deciphering suppressive effects of Lianhua Qingwen Capsule on COVID-19 and synergistic effects of its major botanical drug pairs, Chinese Journal of Natural Medicines, doi:10.1016/S1875-5364(23)60455-8

Wang et al., Inflammasomes: a rising star on the horizon of COVID-19 pathophysiology, Frontiers in Immunology, doi:10.3389/fimmu.2023.1185233

Abou Baker et al., An overview on medicinal plants used for combating coronavirus: Current potentials and challenges, Journal of Agriculture and Food Research, doi:10.1016/j.jafr.2023.100632

Xue et al., Repurposing clinically available drugs and therapies for pathogenic targets to combat SARS‐CoV‐2, MedComm, doi:10.1002/mco2.254

Akanchise et al., Ginkgo Biloba and Long COVID: In Vivo and In Vitro Models for the Evaluation of Nanotherapeutic Efficacy, Pharmaceutics, doi:10.3390/pharmaceutics15051562

Toigo et al., Flavonoid as possible therapeutic targets against COVID-19: a scoping review of in silico studies, DARU Journal of Pharmaceutical Sciences, doi:10.1007/s40199-023-00461-3

Srivastava et al., A Brief Review on Medicinal Plants-At-Arms against COVID-19, Interdisciplinary Perspectives on Infectious Diseases, doi:10.1155/2023/7598307

Patel et al., Bioprospecting phytochemicals of Rosmarinus officinalis L. for targeting SARS-CoV-2 main protease (Mpro): a computational study, Journal of Molecular Modeling, doi:10.1007/s00894-023-05569-6

Nguyen et al., The Potential of Ameliorating COVID-19 and Sequelae From Andrographis paniculata via Bioinformatics, Bioinformatics and Biology Insights, doi:10.1177/11779322221149622

Giordano et al., Food Plant Secondary Metabolites Antiviral Activity and Their Possible Roles in SARS-CoV-2 Treatment: An Overview, Molecules, doi:10.3390/molecules28062470

Xing, H., Current situation of COVID-19 treating with combination of traditional Chinese and Western medicine, TMR Integrative Medicine, doi:10.53388/TMRIM202307009

England et al., Plants as Biofactories for Therapeutic Proteins and Antiviral Compounds to Combat COVID-19, Life, doi:10.3390/life13030617

Yang et al., A Comprehensive Review of Natural Flavonoids with Anti-SARS-CoV-2 Activity, Molecules, doi:10.3390/molecules28062735

Trivedi et al., Antiviral and Anti-Inflammatory Plant-Derived Bioactive Compounds and Their Potential Use in the Treatment of COVID-19-Related Pathologies, Journal of Xenobiotics, doi:10.3390/jox12040020

Ibeh et al., Computational studies of potential antiviral compounds from some selected Nigerian medicinal plants against SARS-CoV-2 proteins, Informatics in Medicine Unlocked, doi:10.1016/j.imu.2023.101230

Wu et al., Polyphenols as alternative treatments of COVID-19, Computational and Structural Biotechnology Journal, doi:10.1016/j.csbj.2021.09.022

Heleno et al., Plant Extracts and SARS-CoV-2: Research and Applications, Life, doi:10.3390/life13020386

Guerra et al., Critical Review of Plant-Derived Compounds as Possible Inhibitors of SARS-CoV-2 Proteases: A Comparison with Experimentally Validated Molecules, ACS Omega, doi:10.1021/acsomega.2c05766

Glaab et al., Pharmacophore Model for SARS-CoV-2 3CLpro Small-Molecule Inhibitors and in Vitro Experimental Validation of Computationally Screened Inhibitors, Journal of Chemical Information and Modeling, doi:10.1021/acs.jcim.1c00258

de Matos et al., Bioactive compounds as potential angiotensin-converting enzyme II inhibitors against COVID-19: a scoping review, Inflammation Research, doi:10.1007/s00011-022-01642-7

Sperry et al., Target-agnostic drug prediction integrated with medical record analysis uncovers differential associations of statins with increased survival in COVID-19 patients, PLOS Computational Biology, doi:10.1371/journal.pcbi.1011050 (Table 2)

Negru et al., Virtual Screening of Substances Used in the Treatment of SARS-CoV-2 Infection and Analysis of Compounds With Known Action on Structurally Similar Proteins From Other Viruses, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.113432

Rani et al., Modern drug discovery applications for the identification of novel candidates for COVID-19 infections, Annals of Medicine and Surgery, doi:10.1016/j.amsu.2022.104125

Shahhamzehei et al., In Silico and In Vitro Identification of Pan-Coronaviral Main Protease Inhibitors from a Large Natural Product Library, Pharmaceuticals, doi:10.3390/ph15030308

Ali et al., Implication of in silico studies in the search for novel inhibitors against SARS‐CoV‐2, Archiv der Pharmazie, doi:10.1002/ardp.202100360

HELALİ et al., Natural substances and coronavirus: review and potential for the inhibition of SARS-CoV-2, Current Perspectives on Medicinal and Aromatic Plants (CUPMAP), doi:10.38093/cupmap.1029572

Mukherjee et al., Role of medicinal plants in inhibiting SARS-CoV-2 and in the management of post-COVID-19 complications, Phytomedicine, doi:10.1016/j.phymed.2022.153930

https://pubmed.ncbi.nlm.nih.gov/34236507/ (In Silico)

https://europepmc.org/article/PMC/PMC10143378

https://sites.google.com/view/coronabank/coronabank/natural-compounds

http://journal.unhas.ac.id/index.php/ijoab/article/view/25284

https://www.researchgate.net/publication/370491709_Y_Wang_A_E_Tan_O_Chew_A_Hsueh_and_D_E_J..

https://www.pnrjournal.com/index.php/home/article/view/4167 (In Silico)

https://www.sciencedirect.com/science/article/pii/S0223523421007066

https://www.mdpi.com/2304-8158/10/9/2084/htm

Hossain et al., Study of kaempferol in the treatment of COVID-19 combined with Chikungunya co-infection by network pharmacology and molecular docking technology, Informatics in Medicine Unlocked, doi:10.1016/j.imu.2023.101289

Gao et al., Kaempferol inhibits SARS-CoV-2 invasion by impairing heptad repeats-mediated viral fusion, Phytomedicine, doi:10.1016/j.phymed.2023.154942

He et al., Recent advances towards natural plants as potential inhibitors of SARS-Cov-2 targets, Pharmaceutical Biology, doi:10.1080/13880209.2023.2241518

Onyango, O., In Silico Models for Anti-COVID-19 Drug Discovery: A Systematic Review, Advances in Pharmacological and Pharmaceutical Sciences, doi:10.1155/2023/4562974

Akter et al., Plausibility of natural immunomodulators in the treatment of COVID-19–A comprehensive analysis and future recommendations, Heliyon, doi:10.1016/j.heliyon.2023.e17478

Rafiq et al., A Comprehensive Update of Various Attempts by Medicinal Chemists to Combat COVID-19 through Natural Products, Molecules, doi:10.3390/molecules28124860

Corbo et al., Inhibitory potential of phytochemicals on five SARS-CoV-2 proteins: in silico evaluation of endemic plants of Bosnia and Herzegovina, Biotechnology & Biotechnological Equipment, doi:10.1080/13102818.2023.2222196

Schake et al., An interaction-based drug discovery screen explains known SARS-CoV-2 inhibitors and predicts new compound scaffolds, Scientific Reports, doi:10.1038/s41598-023-35671-x

CHANDRA et al., Indian medicinal plants are effective in the treatment and management of COVID-19, BIOCELL, doi:10.32604/biocell.2023.026081

Alanzi et al., Structure-based virtual identification of natural inhibitors of SARS-CoV-2 and its Delta and Omicron variant proteins, Future Virology, doi:10.2217/fvl-2022-0184

Fan et al., Pharmaceutical approaches for COVID-19: An update on current therapeutic opportunities, Acta Pharmaceutica, doi:10.2478/acph-2023-0014

Yang et al., In silico evidence implicating novel mechanisms of Prunella vulgaris L. as a potential botanical drug against COVID-19-associated acute kidney injury, Frontiers in Pharmacology, doi:10.3389/fphar.2023.1188086

AKBABA et al., Phytochemicals of Hibiscus sabdariffa with Therapeutic Potential against SARS-CoV-2: A Molecular Docking Study, Journal of the Institute of Science and Technology, doi:10.21597/jist.1187616

Mehyar, N., Coronaviruses SARS-CoV, MERS-CoV, and SARS-CoV-2 helicase inhibitors: A systematic review of in vitro studies, Journal of Virus Eradication, doi:10.1016/j.jve.2023.100327

CHEN et al., Deciphering suppressive effects of Lianhua Qingwen Capsule on COVID-19 and synergistic effects of its major botanical drug pairs, Chinese Journal of Natural Medicines, doi:10.1016/S1875-5364(23)60455-8

Abou Baker et al., An overview on medicinal plants used for combating coronavirus: Current potentials and challenges, Journal of Agriculture and Food Research, doi:10.1016/j.jafr.2023.100632

Akanchise et al., Ginkgo Biloba and Long COVID: In Vivo and In Vitro Models for the Evaluation of Nanotherapeutic Efficacy, Pharmaceutics, doi:10.3390/pharmaceutics15051562

Toigo et al., Flavonoid as possible therapeutic targets against COVID-19: a scoping review of in silico studies, DARU Journal of Pharmaceutical Sciences, doi:10.1007/s40199-023-00461-3

Nguyen et al., The Potential of Ameliorating COVID-19 and Sequelae From Andrographis paniculata via Bioinformatics, Bioinformatics and Biology Insights, doi:10.1177/11779322221149622

Giordano et al., Food Plant Secondary Metabolites Antiviral Activity and Their Possible Roles in SARS-CoV-2 Treatment: An Overview, Molecules, doi:10.3390/molecules28062470

Fam et al., Channel activity of SARS-CoV-2 viroporin ORF3a inhibited by adamantanes and phenolic plant metabolites, Scientific Reports, doi:10.1038/s41598-023-31764-9

Yang et al., A Comprehensive Review of Natural Flavonoids with Anti-SARS-CoV-2 Activity, Molecules, doi:10.3390/molecules28062735

Tallei et al., Potential of Plant Bioactive Compounds as SARS-CoV-2 Main Protease (Mpro) and Spike (S) Glycoprotein Inhibitors: A Molecular Docking Study, Scientifica, doi:10.1155/2020/6307457

Khaerunnisa et al., Potential Inhibitor of COVID-19 Main Protease (Mpro) From Several Medicinal Plant Compounds by Molecular Docking Study, MDPI AG, doi:10.20944/preprints202003.0226.v1

Mardaneh et al., Inhibiting NF-κB During Cytokine Storm in COVID-19: Potential Role of Natural Products as a Promising Therapeutic Approach, MDPI AG, doi:10.20944/preprints202106.0130.v1

Bekheit et al., Potential RNA-dependent RNA polymerase inhibitors as prospective drug candidates for SARS-CoV-2, European Journal of Medicinal Chemistry, doi:10.1016/j.ejmech.2023.115292

Miraz et al., Nigelladine A among Selected Compounds from Nigella sativa Exhibits Propitious Interaction with Omicron Variant of SARS-CoV-2: An In Silico Study, International Journal of Clinical Practice, doi:10.1155/2023/9917306

Heleno et al., Plant Extracts and SARS-CoV-2: Research and Applications, Life, doi:10.3390/life13020386

Jiang et al., Exploration of Fuzheng Yugan Mixture on COVID-19 based on network pharmacology and molecular docking, Medicine, doi:10.1097/MD.0000000000032693

Azeem et al., Virtual screening of phytochemicals by targeting multiple proteins of severe acute respiratory syndrome coronavirus 2: Molecular docking and molecular dynamics simulation studies, International Journal of Immunopathology and Pharmacology, doi:10.1177/03946320221142793

Bijelić et al., Phytochemicals in the Prevention and Treatment of SARS-CoV-2—Clinical Evidence, Antibiotics, doi:10.3390/antibiotics11111614

Liu et al., Investigating the Potential Bioactive Components of Qing-Fei-Pai-Du Decoction Against COVID-19 in Diabetes/Diabetic Patients Based on Network Pharmacology and Molecular Docking, Natural Product Communications, doi:10.1177/1934578X221124769

BİLGİNER et al., Molecular Docking Study of Several Seconder Metabolites from Medicinal Plants as Potential Inhibitors of COVID-19 Main Protease, Turkish Journal of Pharmaceutical Sciences, doi:10.4274/tjps.galenos.2021.83548

Jamshidnia et al., An Update on Promising Agents against COVID-19: Secondary Metabolites and Mechanistic Aspects, Current Pharmaceutical Design, doi:10.2174/1381612828666220722124826

Liu et al., Network Pharmacology and Molecular Docking Elucidate the Underlying Pharmacological Mechanisms of the Herb Houttuynia cordata in Treating Pneumonia Caused by SARS-CoV-2, Viruses, doi:10.3390/v14071588

Negru et al., Virtual Screening of Substances Used in the Treatment of SARS-CoV-2 Infection and Analysis of Compounds With Known Action on Structurally Similar Proteins From Other Viruses, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.113432

Rani et al., Modern drug discovery applications for the identification of novel candidates for COVID-19 infections, Annals of Medicine and Surgery, doi:10.1016/j.amsu.2022.104125

Chaves et al., Commercially Available Flavonols Are Better SARS-CoV-2 Inhibitors Than Isoflavone and Flavones, Viruses, doi:10.3390/v14071458

Zhu et al., Flavonols and dihydroflavonols inhibit the main protease activity of SARS-CoV-2 and the replication of human coronavirus 229E, Virology, doi:10.1016/j.virol.2022.04.005

HELALİ et al., Natural substances and coronavirus: review and potential for the inhibition of SARS-CoV-2, Current Perspectives on Medicinal and Aromatic Plants (CUPMAP), doi:10.38093/cupmap.1029572

https://www.taylorfrancis.com/chapters/edit/10.1201/9781003323884-5/flavonoids-potential-t..

https://sites.google.com/view/coronabank/coronabank/natural-compounds

http://journal.unhas.ac.id/index.php/ijoab/article/view/25284

https://www.researchgate.net/publication/370491709_Y_Wang_A_E_Tan_O_Chew_A_Hsueh_and_D_E_J..

https://www.mdpi.com/2304-8158/10/9/2084/htm

Li et al., The TMPRSS2 Inhibitor Nafamostat Reduces SARS-CoV-2 Pulmonary Infection in Mouse Models of COVID-19, mBio, doi:10.1128/mBio.00970-21

Wu et al., Protease inhibitor Camostat Mesyalte blocks wild type SARS-CoV-2 and D614G viral entry in human engineered miniature lungs, Biomaterials, doi:10.1016/j.biomaterials.2022.121509

Choi et al., Foistar(Camostat mesylate) associated with the significant decrease in CRP levels compared to Kaletra(Lopinavir/Ritonavir) treatment in Korean mild COVID-19 pneumonic patients., medRxiv, doi:10.1101/2020.12.10.20240689

Chupp et al., A Phase 2 Randomized, Double-Blind, Placebo-controlled Trial of Oral Camostat Mesylate for Early Treatment of COVID-19 Outpatients Showed Shorter Illness Course and Attenuation of Loss of Smell and Taste, medRxiv, doi:10.1101/2022.01.28.22270035

Karolyi et al., Camostat Mesylate Versus Lopinavir/Ritonavir in Hospitalized Patients With COVID-19—Results From a Randomized, Controlled, Open Label, Platform Trial (ACOVACT), Frontiers in Pharmacology, doi:10.3389/fphar.2022.870493

Kinoshita et al., Phase 3, multicentre, double-blind, randomised, parallel-group, placebo-controlled study of camostat mesilate (FOY-305) for the treatment of COVID-19 (CANDLE study), medRxiv, doi:10.1101/2022.03.27.22271988

Khan et al., Possible therapeutic targets for SARS-CoV-2 infection and COVID-19, Journal of Allergy & Infectious Diseases, doi:10.46439/allergy.2.028

Kushwaha et al., A comprehensive review on the global efforts on vaccines and repurposed drugs for combating COVID-19, European Journal of Medicinal Chemistry, doi:10.1016/j.ejmech.2023.115719

Yadav et al., Role of Structural and Non-Structural Proteins and Therapeutic Targets of SARS-CoV-2 for COVID-19, Cells, doi:10.3390/cells10040821

Mushebenge et al., Assessing the Potential Contribution of in Silico Studies in Discovering Drug Candidates that Interact with Various SARS-CoV-2 Receptors, MDPI AG, doi:10.20944/preprints202308.0434.v1

Pandit et al., e-Pharmacophore modeling and in silico study of CD147 receptor against SARS-CoV-2 drugs, Genomics & Informatics, doi:10.5808/gi.23005

Farkaš et al., A Tale of Two Proteases: MPro and TMPRSS2 as Targets for COVID-19 Therapies, Pharmaceuticals, doi:10.3390/ph16060834

Lundstrom et al., COVID-19 signalome: Potential therapeutic interventions, Cellular Signalling, doi:10.1016/j.cellsig.2022.110559

Guo et al., Multi-omics in COVID-19: Driving development of therapeutics and vaccines, National Science Review, doi:10.1093/nsr/nwad161

Oliver et al., Different drug approaches to COVID-19 treatment worldwide: an update of new drugs and drugs repositioning to fight against the novel coronavirus, Therapeutic Advances in Vaccines and Immunotherapy, doi:10.1177/25151355221144845

Wang et al., Repurposing Drugs for the Treatment of COVID-19 and Its Cardiovascular Manifestations, Circulation Research, doi:10.1161/circresaha.122.321879

Xue et al., Repurposing clinically available drugs and therapies for pathogenic targets to combat SARS‐CoV‐2, MedComm, doi:10.1002/mco2.254

Pati et al., Drug discovery through Covid-19 genome sequencing with siamese graph convolutional neural network, Multimedia Tools and Applications, doi:10.1007/s11042-023-15270-8

Ceja-Gálvez et al., Severe COVID-19: Drugs and Clinical Trials, Journal of Clinical Medicine, doi:10.3390/jcm12082893

Esam et al., In silico investigation of the therapeutic and prophylactic potential of medicinal substances bearing guanidine moieties against COVID-19, Chemical Papers, doi:10.1007/s11696-022-02528-y

Nayak et al., Prospects of Novel and Repurposed Immunomodulatory Drugs against Acute Respiratory Distress Syndrome (ARDS) Associated with COVID-19 Disease, Journal of Personalized Medicine, doi:10.3390/jpm13040664

Kumar et al., COVID-19 therapeutics: Clinical application of repurposed drugs and futuristic strategies for target-based drug discovery, Genes & Diseases, doi:10.1016/j.gendis.2022.12.019

Astasio-Picado et al., Therapeutic Targets in the Virological Mechanism and in the Hyperinflammatory Response of Severe Acute Respiratory Syndrome Coronavirus Type 2 (SARS-CoV-2), Applied Sciences, doi:10.3390/app13074471

Săndulescu et al., Therapeutic developments for SARS-CoV-2 infection—Molecular mechanisms of action of antivirals and strategies for mitigating resistance in emerging variants in clinical practice, Frontiers in Microbiology, doi:10.3389/fmicb.2023.1132501

Campos-Gomez et al., Mucociliary Clearance Augmenting Drugs Block SARS-Cov-2 Replication in Human Airway Epithelial Cells, bioRxiv, doi:10.1101/2023.01.30.526308

Gautam et al., Promising Repurposed Antiviral Molecules to Combat SARS-CoV-2: A Review, Current Pharmaceutical Biotechnology, doi:10.2174/1389201024666230302113110

Raghav et al., Potential treatments of COVID-19: Drug repurposing and therapeutic interventions, Journal of Pharmacological Sciences, doi:10.1016/j.jphs.2023.02.004

Supianto et al., Cluster-based text mining for extracting drug candidates for the prevention of COVID-19 from the biomedical literature, Journal of Taibah University Medical Sciences, doi:10.1016/j.jtumed.2022.12.015

Wagoner et al., Combinations of Host- and Virus-Targeting Antiviral Drugs Confer Synergistic Suppression of SARS-CoV-2, Microbiology Spectrum, doi:10.1128/spectrum.03331-22

Zhong et al., Recent advances in small-molecular therapeutics for COVID-19, Precision Clinical Medicine, doi:10.1093/pcmedi/pbac024

Saloni et al., A computational study of potential therapeutics for COVID-19 invoking conceptual density functional theory, Structural Chemistry, doi:10.1007/s11224-022-02048-1

Jamalipour Soufi et al., Potential inhibitors of SARS-CoV-2: recent advances, Journal of Drug Targeting, doi:10.1080/1061186X.2020.1853736

Sarkar et al., Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives, Frontiers in Pharmacology, doi:10.3389/fphar.2020.572870

Frediansyah et al., Antivirals for COVID-19: A critical review, Clinical Epidemiology and Global Health, doi:10.1016/j.cegh.2020.07.006

https://www.sciencedirect.com/science/article/pii/S2352396421000487 (In Vitro)

https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(21)00048-7/fulltext

https://www.europeanpharmaceuticalreview.com/news/159375/camostat-cuts-recovery-time-in-ha..

https://clinicaltrials.gov/ct2/show/NCT04530617

https://sites.google.com/view/coronabank/coronabank/binding-and-internalisation-inhibitors

Srus et al., In Silico study of Wheatgrass constituents against Coronavirus COVID-19 Proteins., Research Square, doi:10.21203/rs.3.rs-1167417/v1

He et al., Recent advances towards natural plants as potential inhibitors of SARS-Cov-2 targets, Pharmaceutical Biology, doi:10.1080/13880209.2023.2241518

Badhe, A., In Silico study of Wheatgrass constituents against Coronavirus COVID-19 Proteins., Center for Open Science, doi:10.31219/osf.io/kg7yx

Onyango, O., In Silico Models for Anti-COVID-19 Drug Discovery: A Systematic Review, Advances in Pharmacological and Pharmaceutical Sciences, doi:10.1155/2023/4562974

Akter et al., Plausibility of natural immunomodulators in the treatment of COVID-19–A comprehensive analysis and future recommendations, Heliyon, doi:10.1016/j.heliyon.2023.e17478

Rafiq et al., A Comprehensive Update of Various Attempts by Medicinal Chemists to Combat COVID-19 through Natural Products, Molecules, doi:10.3390/molecules28124860

Alanzi et al., Structure-based virtual identification of natural inhibitors of SARS-CoV-2 and its Delta and Omicron variant proteins, Future Virology, doi:10.2217/fvl-2022-0184

CHEN et al., Deciphering suppressive effects of Lianhua Qingwen Capsule on COVID-19 and synergistic effects of its major botanical drug pairs, Chinese Journal of Natural Medicines, doi:10.1016/S1875-5364(23)60455-8

Xu et al., Screening compounds for treating the diabetes and COVID-19 from Miao medicine by molecular docking and bioinformatics, Arabian Journal of Chemistry, doi:10.1016/j.arabjc.2023.105001

Abou Baker et al., An overview on medicinal plants used for combating coronavirus: Current potentials and challenges, Journal of Agriculture and Food Research, doi:10.1016/j.jafr.2023.100632

Toigo et al., Flavonoid as possible therapeutic targets against COVID-19: a scoping review of in silico studies, DARU Journal of Pharmaceutical Sciences, doi:10.1007/s40199-023-00461-3

unknown, u., Trainee Poster Honorable Mention Poster Abstracts Presented at the 123^rdAnnual Meeting of the American Association of Colleges of Pharmacy, July 23-27, 2022, American Journal of Pharmaceutical Education, doi:10.5688/ajpe9169

Giordano et al., Food Plant Secondary Metabolites Antiviral Activity and Their Possible Roles in SARS-CoV-2 Treatment: An Overview, Molecules, doi:10.3390/molecules28062470

Bekheit et al., Potential RNA-dependent RNA polymerase inhibitors as prospective drug candidates for SARS-CoV-2, European Journal of Medicinal Chemistry, doi:10.1016/j.ejmech.2023.115292

Wu et al., In silico identification of drug candidates against COVID-19, Informatics in Medicine Unlocked, doi:10.1016/j.imu.2020.100461

Adedayo et al., In-silico studies of Momordica charantia extracts as potential candidates against SARS-CoV-2 targeting human main protease enzyme (MPRO), Informatics in Medicine Unlocked, doi:10.1016/j.imu.2023.101216

Hossain et al., Identification of medicinal plant-based phytochemicals as a potential inhibitor for SARS-CoV-2 main protease (Mpro) using molecular docking and deep learning methods, Computers in Biology and Medicine, doi:10.1016/j.compbiomed.2023.106785

Kawall et al., Inhibitory effect of phytochemicals towards SARS-CoV-2 papain like protease (PLpro) proteolytic and deubiquitinase activity, Frontiers in Chemistry, doi:10.3389/fchem.2022.1100460

Guerra et al., Critical Review of Plant-Derived Compounds as Possible Inhibitors of SARS-CoV-2 Proteases: A Comparison with Experimentally Validated Molecules, ACS Omega, doi:10.1021/acsomega.2c05766

Bajrai et al., In vitro screening of anti-viral and virucidal effects against SARS-CoV-2 by Hypericum perforatum and Echinacea, Scientific Reports, doi:10.1038/s41598-022-26157-3

Chen et al., The exploration of phytocompounds theoretically combats SARS-CoV-2 pandemic against virus entry, viral replication and immune evasion, Journal of Infection and Public Health, doi:10.1016/j.jiph.2022.11.022

Moezzi, M., Comprehensive in silico screening of flavonoids against SARS-CoV-2 main protease, Journal of Biomolecular Structure and Dynamics, doi:10.1080/07391102.2022.2142297

Amalia et al., The Potential of Phyllanthus Niruri Plant Secondary Metabolites in Providing Antiviral Protection Against Sars-Cov-2: A Literature Review, KnE Medicine, doi:10.18502/kme.v2i3.11915

Jamalipour Soufi et al., Potential inhibitors of SARS-CoV-2: recent advances, Journal of Drug Targeting, doi:10.1080/1061186X.2020.1853736

Rieder et al., A Review of In Silico Research, SARS-CoV-2, and Neurodegeneration: Focus on Papain-Like Protease, Neurotoxicity Research, doi:10.1007/s12640-022-00542-2

Negru et al., Virtual Screening of Substances Used in the Treatment of SARS-CoV-2 Infection and Analysis of Compounds With Known Action on Structurally Similar Proteins From Other Viruses, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.113432

Rani et al., Modern drug discovery applications for the identification of novel candidates for COVID-19 infections, Annals of Medicine and Surgery, doi:10.1016/j.amsu.2022.104125

Zhu et al., Flavonols and dihydroflavonols inhibit the main protease activity of SARS-CoV-2 and the replication of human coronavirus 229E, Virology, doi:10.1016/j.virol.2022.04.005

Adem et al., Multidimensional in silico strategy for identification of natural polyphenols-based SARS-CoV-2 main protease (Mpro) inhibitors to unveil a hope against COVID-19, Computers in Biology and Medicine, doi:10.1016/j.compbiomed.2022.105452

HELALİ et al., Natural substances and coronavirus: review and potential for the inhibition of SARS-CoV-2, Current Perspectives on Medicinal and Aromatic Plants (CUPMAP), doi:10.38093/cupmap.1029572

https://kspublisher.com/media/articles/MERJPS_34_51-65.pdf

https://www.taylorfrancis.com/chapters/edit/10.1201/9781003323884-5/flavonoids-potential-t..

https://sites.google.com/view/coronabank/coronabank/natural-compounds

https://digitalcommons.pcom.edu/research_day/research_day_GA_2022/researchGA2022/20/

https://www.sciencedirect.com/science/article/pii/S0223523421007066

https://www.mdpi.com/1424-8247/14/9/892

https://www.mdpi.com/2304-8158/10/9/2084/htm

He et al., Recent advances towards natural plants as potential inhibitors of SARS-Cov-2 targets, Pharmaceutical Biology, doi:10.1080/13880209.2023.2241518

Onyango, O., In Silico Models for Anti-COVID-19 Drug Discovery: A Systematic Review, Advances in Pharmacological and Pharmaceutical Sciences, doi:10.1155/2023/4562974

Akter et al., Plausibility of natural immunomodulators in the treatment of COVID-19–A comprehensive analysis and future recommendations, Heliyon, doi:10.1016/j.heliyon.2023.e17478

Rafiq et al., A Comprehensive Update of Various Attempts by Medicinal Chemists to Combat COVID-19 through Natural Products, Molecules, doi:10.3390/molecules28124860

Corbo et al., Inhibitory potential of phytochemicals on five SARS-CoV-2 proteins: in silico evaluation of endemic plants of Bosnia and Herzegovina, Biotechnology & Biotechnological Equipment, doi:10.1080/13102818.2023.2222196

Schake et al., An interaction-based drug discovery screen explains known SARS-CoV-2 inhibitors and predicts new compound scaffolds, Scientific Reports, doi:10.1038/s41598-023-35671-x

Lundstrom et al., COVID-19 signalome: Potential therapeutic interventions, Cellular Signalling, doi:10.1016/j.cellsig.2022.110559

Wang et al., Inflammasomes: a rising star on the horizon of COVID-19 pathophysiology, Frontiers in Immunology, doi:10.3389/fimmu.2023.1185233

Oliver et al., Different drug approaches to COVID-19 treatment worldwide: an update of new drugs and drugs repositioning to fight against the novel coronavirus, Therapeutic Advances in Vaccines and Immunotherapy, doi:10.1177/25151355221144845

Abou Baker et al., An overview on medicinal plants used for combating coronavirus: Current potentials and challenges, Journal of Agriculture and Food Research, doi:10.1016/j.jafr.2023.100632

Toigo et al., Flavonoid as possible therapeutic targets against COVID-19: a scoping review of in silico studies, DARU Journal of Pharmaceutical Sciences, doi:10.1007/s40199-023-00461-3

Srivastava et al., A Brief Review on Medicinal Plants-At-Arms against COVID-19, Interdisciplinary Perspectives on Infectious Diseases, doi:10.1155/2023/7598307

Bogoyavlenskiy et al., Computer Analysis of the Inhibition of ACE2 by Flavonoids and Identification of Their Potential Antiviral Pharmacophore Site, Molecules, doi:10.3390/molecules28093766

Giordano et al., Food Plant Secondary Metabolites Antiviral Activity and Their Possible Roles in SARS-CoV-2 Treatment: An Overview, Molecules, doi:10.3390/molecules28062470

Wu et al., Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods, Acta Pharmaceutica Sinica B, doi:10.1016/j.apsb.2020.02.008

England et al., Plants as Biofactories for Therapeutic Proteins and Antiviral Compounds to Combat COVID-19, Life, doi:10.3390/life13030617

Yang et al., A Comprehensive Review of Natural Flavonoids with Anti-SARS-CoV-2 Activity, Molecules, doi:10.3390/molecules28062735

Tallei et al., Potential of Plant Bioactive Compounds as SARS-CoV-2 Main Protease (Mpro) and Spike (S) Glycoprotein Inhibitors: A Molecular Docking Study, Scientifica, doi:10.1155/2020/6307457

Utomo et al., Revealing the Potency of Citrus and Galangal Constituents to Halt SARS-CoV-2 Infection, MDPI AG, doi:10.20944/preprints202003.0214.v1

Heleno et al., Plant Extracts and SARS-CoV-2: Research and Applications, Life, doi:10.3390/life13020386

Supianto et al., Cluster-based text mining for extracting drug candidates for the prevention of COVID-19 from the biomedical literature, Journal of Taibah University Medical Sciences, doi:10.1016/j.jtumed.2022.12.015

de Matos et al., Bioactive compounds as potential angiotensin-converting enzyme II inhibitors against COVID-19: a scoping review, Inflammation Research, doi:10.1007/s00011-022-01642-7

Jamalipour Soufi et al., Potential inhibitors of SARS-CoV-2: recent advances, Journal of Drug Targeting, doi:10.1080/1061186X.2020.1853736

Babu et al., Identification of differentially expressed genes and their major pathways among the patient with COVID-19, cystic fibrosis, and chronic kidney disease, Informatics in Medicine Unlocked, doi:10.1016/j.imu.2022.101038

Negru et al., Virtual Screening of Substances Used in the Treatment of SARS-CoV-2 Infection and Analysis of Compounds With Known Action on Structurally Similar Proteins From Other Viruses, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.113432

Qi et al., Discovery of TCMs and Derivatives Against the Main Protease of SARS-CoV-2 via High Throughput Screening, ADMET Analysis, and Inhibition Assay in Vitro, Journal of Molecular Structure, doi:10.1016/j.molstruc.2022.133709

Adem et al., Multidimensional in silico strategy for identification of natural polyphenols-based SARS-CoV-2 main protease (Mpro) inhibitors to unveil a hope against COVID-19, Computers in Biology and Medicine, doi:10.1016/j.compbiomed.2022.105452

Ali et al., Implication of in silico studies in the search for novel inhibitors against SARS‐CoV‐2, Archiv der Pharmazie, doi:10.1002/ardp.202100360

HELALİ et al., Natural substances and coronavirus: review and potential for the inhibition of SARS-CoV-2, Current Perspectives on Medicinal and Aromatic Plants (CUPMAP), doi:10.38093/cupmap.1029572

Mukherjee et al., Role of medicinal plants in inhibiting SARS-CoV-2 and in the management of post-COVID-19 complications, Phytomedicine, doi:10.1016/j.phymed.2022.153930

https://www.mdpi.com/2072-6643/13/8/2800

https://sites.google.com/view/coronabank/coronabank/natural-compounds

http://journal.unhas.ac.id/index.php/ijoab/article/view/25284

https://www.sciencedirect.com/science/article/pii/S0223523421007066

https://www.mdpi.com/2304-8158/10/9/2084/htm

Pan et al., Myricetin possesses the potency against SARS-CoV-2 infection through blocking viral-entry facilitators and suppressing inflammation in rats and mice, Phytomedicine, doi:10.1016/j.phymed.2023.154858

Singh et al., Medicinal plants, phytoconstituents and traditional formulation as potential therapies for SARS-CoV-2: a review update, Vegetos, doi:10.1007/s42535-023-00706-1

Lin et al., Plant flavonoid inhibition of SARS-CoV-2 main protease and viral replication, iScience, doi:10.1016/j.isci.2023.107602

He et al., Recent advances towards natural plants as potential inhibitors of SARS-Cov-2 targets, Pharmaceutical Biology, doi:10.1080/13880209.2023.2241518

Akter et al., Plausibility of natural immunomodulators in the treatment of COVID-19–A comprehensive analysis and future recommendations, Heliyon, doi:10.1016/j.heliyon.2023.e17478

Rafiq et al., A Comprehensive Update of Various Attempts by Medicinal Chemists to Combat COVID-19 through Natural Products, Molecules, doi:10.3390/molecules28124860

Krüger et al., Discovery of Polyphenolic Natural Products as SARS-CoV-2 Mpro Inhibitors for COVID-19, Pharmaceuticals, doi:10.3390/ph16020190

CHANDRA et al., Indian medicinal plants are effective in the treatment and management of COVID-19, BIOCELL, doi:10.32604/biocell.2023.026081

Tiwari et al., Virtual Screening of Phytochemicals in Search of a Potential Drug Candidate for COVID-19: DFT Study and Molecular Docking, COVID-19: Origin, Impact and Management (Part 2), doi:10.2174/9789815165944123010012

Farkaš et al., A Tale of Two Proteases: MPro and TMPRSS2 as Targets for COVID-19 Therapies, Pharmaceuticals, doi:10.3390/ph16060834

Lundstrom et al., COVID-19 signalome: Potential therapeutic interventions, Cellular Signalling, doi:10.1016/j.cellsig.2022.110559

Mehyar, N., Coronaviruses SARS-CoV, MERS-CoV, and SARS-CoV-2 helicase inhibitors: A systematic review of in vitro studies, Journal of Virus Eradication, doi:10.1016/j.jve.2023.100327

Priyandoko et al., Inflammation Inhibitory Activity of Green Tea, Soybean, and Guava Extracts During Sars-Cov-2 Infection Through TNF Protein in Cytokine Storm, Computational Biology and Chemistry, doi:10.1016/j.compbiolchem.2023.107898

Pang et al., The research progress of SARS-CoV-2 main protease inhibitors from 2020 to 2022, European Journal of Medicinal Chemistry, doi:10.1016/j.ejmech.2023.115491

Abou Baker et al., An overview on medicinal plants used for combating coronavirus: Current potentials and challenges, Journal of Agriculture and Food Research, doi:10.1016/j.jafr.2023.100632

unknown, u., Trainee Poster Honorable Mention Poster Abstracts Presented at the 123^rdAnnual Meeting of the American Association of Colleges of Pharmacy, July 23-27, 2022, American Journal of Pharmaceutical Education, doi:10.5688/ajpe9169

Zhang et al., Discovery and characterization of the covalent SARS-CoV-2 3CLpro inhibitors from Ginkgo biloba extract via integrating chemoproteomic and biochemical approaches, Phytomedicine, doi:10.1016/j.phymed.2023.154796

Kronenberger et al., COVID-19 therapeutics: Small-molecule drug development targeting SARS-CoV-2 main protease, Drug Discovery Today, doi:10.1016/j.drudis.2023.103579

Giordano et al., Food Plant Secondary Metabolites Antiviral Activity and Their Possible Roles in SARS-CoV-2 Treatment: An Overview, Molecules, doi:10.3390/molecules28062470

England et al., Plants as Biofactories for Therapeutic Proteins and Antiviral Compounds to Combat COVID-19, Life, doi:10.3390/life13030617

Rahman et al., In silico investigation and potential therapeutic approaches of natural products for COVID-19: Computer-aided drug design perspective, Frontiers in Cellular and Infection Microbiology, doi:10.3389/fcimb.2022.929430

Heleno et al., Plant Extracts and SARS-CoV-2: Research and Applications, Life, doi:10.3390/life13020386

Kawall et al., Inhibitory effect of phytochemicals towards SARS-CoV-2 papain like protease (PLpro) proteolytic and deubiquitinase activity, Frontiers in Chemistry, doi:10.3389/fchem.2022.1100460

Guerra et al., Critical Review of Plant-Derived Compounds as Possible Inhibitors of SARS-CoV-2 Proteases: A Comparison with Experimentally Validated Molecules, ACS Omega, doi:10.1021/acsomega.2c05766

Haritha et al., Quantum chemical studies on the binding domain of SARS-CoV-2 S-protein: human ACE2 interface complex, Journal of Biomolecular Structure and Dynamics, doi:10.1080/07391102.2022.2120537

Negru et al., Virtual Screening of Substances Used in the Treatment of SARS-CoV-2 Infection and Analysis of Compounds With Known Action on Structurally Similar Proteins From Other Viruses, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.113432

Chaves et al., Commercially Available Flavonols Are Better SARS-CoV-2 Inhibitors Than Isoflavone and Flavones, Viruses, doi:10.3390/v14071458

Uma Reddy et al., Multifaceted role of plant derived small molecule inhibitors on replication cycle of sars-cov-2, Microbial Pathogenesis, doi:10.1016/j.micpath.2022.105512

HELALİ et al., Natural substances and coronavirus: review and potential for the inhibition of SARS-CoV-2, Current Perspectives on Medicinal and Aromatic Plants (CUPMAP), doi:10.38093/cupmap.1029572

https://www.taylorfrancis.com/chapters/edit/10.1201/9781003323884-5/flavonoids-potential-t..

https://sites.google.com/view/coronabank/coronabank/natural-compounds

http://journal.unhas.ac.id/index.php/ijoab/article/view/25284

https://digitalcommons.pcom.edu/research_day/research_day_GA_2022/researchGA2022/20/

https://www.mdpi.com/1424-8247/14/9/892

https://www.mdpi.com/2304-8158/10/9/2084/htm

Bronte et al., Baricitinib restrains the immune dysregulation in patients with severe COVID-19, Journal of Clinical Investigation, doi:10.1172/JCI141772

Stebbing et al., JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality, Science Advances, doi:10.1126/sciadv.abe4724

Goletti et al., Baricitinib Therapy in Covid-19 Pneumonia — An Unmet Need Fulfilled, New England Journal of Medicine, doi:10.1056/NEJMe2034982

Melikhov et al., Use of Janus kinase inhibitors in COVID-19: a prospective observational series in 522 individuals, Annals of the Rheumatic Diseases, doi:10.1136/annrheumdis-2021-220049

Manoharan et al., Does baricitinib reduce mortality and disease progression in SARS-CoV-2 virus infected patients? A systematic review and meta analysis, Respiratory Medicine, doi:10.1016/j.rmed.2022.106986

Sampath et al., Use of Baricitinib in Treatment of COVID-19: A Systematic Review, medRxiv, doi:10.1101/2021.12.26.21268434

Tanaka et al., Propensity-Score Matched Analysis of the Effectiveness of Baricitinib in Patients with COVID-19 Using Nationwide Real-World Data: An Observational Matched Cohort Study from The Japan COVID-19 Task Force, Open Forum Infectious Diseases, doi:10.1093/ofid/ofad311

Tam et al., Targeting SARS-CoV-2 Non-Structural Proteins, International Journal of Molecular Sciences, doi:10.3390/ijms241613002

Kushwaha et al., A comprehensive review on the global efforts on vaccines and repurposed drugs for combating COVID-19, European Journal of Medicinal Chemistry, doi:10.1016/j.ejmech.2023.115719

Mushebenge et al., Assessing the Potential Contribution of in Silico Studies in Discovering Drug Candidates that Interact with Various SARS-CoV-2 Receptors, MDPI AG, doi:10.20944/preprints202308.0434.v1

Guo et al., Multi-omics in COVID-19: Driving development of therapeutics and vaccines, National Science Review, doi:10.1093/nsr/nwad161

Oliver et al., Different drug approaches to COVID-19 treatment worldwide: an update of new drugs and drugs repositioning to fight against the novel coronavirus, Therapeutic Advances in Vaccines and Immunotherapy, doi:10.1177/25151355221144845

Wang et al., Repurposing Drugs for the Treatment of COVID-19 and Its Cardiovascular Manifestations, Circulation Research, doi:10.1161/circresaha.122.321879

Xue et al., Repurposing clinically available drugs and therapies for pathogenic targets to combat SARS‐CoV‐2, MedComm, doi:10.1002/mco2.254

Ceja-Gálvez et al., Severe COVID-19: Drugs and Clinical Trials, Journal of Clinical Medicine, doi:10.3390/jcm12082893

Islam et al., Molecular-evaluated and explainable drug repurposing for COVID-19 using ensemble knowledge graph embedding, Scientific Reports, doi:10.1038/s41598-023-30095-z

Nayak et al., Prospects of Novel and Repurposed Immunomodulatory Drugs against Acute Respiratory Distress Syndrome (ARDS) Associated with COVID-19 Disease, Journal of Personalized Medicine, doi:10.3390/jpm13040664

Kumar et al., COVID-19 therapeutics: Clinical application of repurposed drugs and futuristic strategies for target-based drug discovery, Genes & Diseases, doi:10.1016/j.gendis.2022.12.019

Astasio-Picado et al., Therapeutic Targets in the Virological Mechanism and in the Hyperinflammatory Response of Severe Acute Respiratory Syndrome Coronavirus Type 2 (SARS-CoV-2), Applied Sciences, doi:10.3390/app13074471

Talukdar et al., Potential Drugs for COVID -19 Treatment Management With Their Contraindications and Drug- Drug Interaction, MDPI AG, doi:10.20944/preprints202105.0690.v1

Rudramurthy et al., In-Vitro Screening of Repurposed Drug Library against Severe Acute Respiratory Syndrome Coronavirus-2, Medical Research Archives, doi:10.18103/mra.v11i2.3595

Atoum et al., Paving New Roads Using Allium sativum as a Repurposed Drug and Analyzing its Antiviral Action Using Artificial Intelligence Technology, Iranian Journal of Pharmaceutical Research, doi:10.5812/ijpr-131577

Gautam et al., Promising Repurposed Antiviral Molecules to Combat SARS-CoV-2: A Review, Current Pharmaceutical Biotechnology, doi:10.2174/1389201024666230302113110

Raghav et al., Potential treatments of COVID-19: Drug repurposing and therapeutic interventions, Journal of Pharmacological Sciences, doi:10.1016/j.jphs.2023.02.004

Mavlankar et al., Interaction of surface glycoprotein of SARS-CoV-2 variants of concern with potential drug candidates: A molecular docking study, F1000Research, doi:10.12688/f1000research.109586.1

Jamalipour Soufi et al., Potential inhibitors of SARS-CoV-2: recent advances, Journal of Drug Targeting, doi:10.1080/1061186X.2020.1853736

Pillaiyar et al., Kinases as Potential Therapeutic Targets for Anti-coronaviral Therapy, Journal of Medicinal Chemistry, doi:10.1021/acs.jmedchem.1c00335

Frediansyah et al., Antivirals for COVID-19: A critical review, Clinical Epidemiology and Global Health, doi:10.1016/j.cegh.2020.07.006

Heimfarth et al., Drug repurposing and cytokine management in response to COVID-19: A review, International Immunopharmacology, doi:10.1016/j.intimp.2020.106947

https://www.sciencedirect.com/science/article/abs/pii/S2213260021003313

https://www.mdpi.com/2571-841X/6/4/45

https://sites.google.com/view/coronabank/coronabank/immunomodulatory-agents

Mittra et al., Resveratrol and Copper for treatment of severe COVID-19: an observational study (RESCU 002), medRxiv, doi:10.1101/2020.07.21.20151423

de Ligt et al., Resveratrol supplementation reduces ACE2 expression in human adipose tissue, Adipocyte, doi:10.1080/21623945.2021.1965315

He et al., Recent advances towards natural plants as potential inhibitors of SARS-Cov-2 targets, Pharmaceutical Biology, doi:10.1080/13880209.2023.2241518

Khan et al., Possible therapeutic targets for SARS-CoV-2 infection and COVID-19, Journal of Allergy & Infectious Diseases, doi:10.46439/allergy.2.028

Akter et al., Plausibility of natural immunomodulators in the treatment of COVID-19–A comprehensive analysis and future recommendations, Heliyon, doi:10.1016/j.heliyon.2023.e17478

Low et al., COVID-19 Therapeutic Potential of Natural Products, International Journal of Molecular Sciences, doi:10.3390/ijms24119589

Corbo et al., Inhibitory potential of phytochemicals on five SARS-CoV-2 proteins: in silico evaluation of endemic plants of Bosnia and Herzegovina, Biotechnology & Biotechnological Equipment, doi:10.1080/13102818.2023.2222196

Fan et al., Pharmaceutical approaches for COVID-19: An update on current therapeutic opportunities, Acta Pharmaceutica, doi:10.2478/acph-2023-0014

Abou Baker et al., An overview on medicinal plants used for combating coronavirus: Current potentials and challenges, Journal of Agriculture and Food Research, doi:10.1016/j.jafr.2023.100632

Srivastava et al., A Brief Review on Medicinal Plants-At-Arms against COVID-19, Interdisciplinary Perspectives on Infectious Diseases, doi:10.1155/2023/7598307

Giordano et al., Food Plant Secondary Metabolites Antiviral Activity and Their Possible Roles in SARS-CoV-2 Treatment: An Overview, Molecules, doi:10.3390/molecules28062470

Fam et al., Channel activity of SARS-CoV-2 viroporin ORF3a inhibited by adamantanes and phenolic plant metabolites, Scientific Reports, doi:10.1038/s41598-023-31764-9

Trivedi et al., Antiviral and Anti-Inflammatory Plant-Derived Bioactive Compounds and Their Potential Use in the Treatment of COVID-19-Related Pathologies, Journal of Xenobiotics, doi:10.3390/jox12040020

Mardaneh et al., Inhibiting NF-κB During Cytokine Storm in COVID-19: Potential Role of Natural Products as a Promising Therapeutic Approach, MDPI AG, doi:10.20944/preprints202106.0130.v1

Heleno et al., Plant Extracts and SARS-CoV-2: Research and Applications, Life, doi:10.3390/life13020386

Guo et al., Enhanced compound-protein binding affinity prediction by representing protein multimodal information via a coevolutionary strategy, Briefings in Bioinformatics, doi:10.1093/bib/bbac628

Bojkova et al., Identification of novel antiviral drug candidates using an optimized SARS-CoV-2 phenotypic screening platform, iScience, doi:10.1016/j.isci.2023.105944

Supianto et al., Cluster-based text mining for extracting drug candidates for the prevention of COVID-19 from the biomedical literature, Journal of Taibah University Medical Sciences, doi:10.1016/j.jtumed.2022.12.015

Bijelić et al., Phytochemicals in the Prevention and Treatment of SARS-CoV-2—Clinical Evidence, Antibiotics, doi:10.3390/antibiotics11111614

Milton-Laskibar et al., Potential usefulness of Mediterranean diet polyphenols against COVID-19-induced inflammation: a review of the current knowledge, Journal of Physiology and Biochemistry, doi:10.1007/s13105-022-00926-0

de Matos et al., Bioactive compounds as potential angiotensin-converting enzyme II inhibitors against COVID-19: a scoping review, Inflammation Research, doi:10.1007/s00011-022-01642-7

Sperry et al., Target-agnostic drug prediction integrated with medical record analysis uncovers differential associations of statins with increased survival in COVID-19 patients, PLOS Computational Biology, doi:10.1371/journal.pcbi.1011050 (Table 2)

Qi et al., Discovery of TCMs and Derivatives Against the Main Protease of SARS-CoV-2 via High Throughput Screening, ADMET Analysis, and Inhibition Assay in Vitro, Journal of Molecular Structure, doi:10.1016/j.molstruc.2022.133709

Mortezaei et al., Variations of SARS-CoV-2 in the Iranian Population and Candidate Putative Drug-like Compounds to Inhibit the Mutated Proteins, Heliyon, doi:10.1016/j.heliyon.2022.e09910

Ali et al., Implication of in silico studies in the search for novel inhibitors against SARS‐CoV‐2, Archiv der Pharmazie, doi:10.1002/ardp.202100360

https://www.nature.com/articles/s41598-022-13920-9 (RCT)

https://www.mdpi.com/2076-3921/10/9/1440 (Review)

https://sites.google.com/view/coronabank/coronabank/natural-compounds

http://journal.unhas.ac.id/index.php/ijoab/article/view/25284

https://www.sciencedirect.com/science/article/pii/S0223523421007066

https://www.mdpi.com/2304-8158/10/9/2084/htm

https://www.sciencedirect.com/science/article/pii/S0308814621026005

Bisht et al., Revisiting liquorice (Glycyrrhiza glabra L.) as anti-inflammatory, antivirals and immunomodulators: potential pharmacological applications with mechanistic insight., Phytomedicine Plus, doi:10.1016/j.phyplu.2021.100206

Khorshiddoust et al., Efficacy of a multiple-indication antiviral herbal drug (Saliravira®) for COVID-19 outpatients: A pre-clinical and randomized clinical trial study, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.112729

Zheng et al., Glycyrrhizic Acid for COVID-19: Findings of Targeting Pivotal Inflammatory Pathways Triggered by SARS-CoV-2, Frontiers in Pharmacology, doi:10.3389/fphar.2021.631206

Tam et al., Targeting SARS-CoV-2 Non-Structural Proteins, International Journal of Molecular Sciences, doi:10.3390/ijms241613002

Ullah et al., AVPCD: a plant-derived medicine database of antiviral phytochemicals for cancer, Covid-19, malaria and HIV, Database, doi:10.1093/database/baad056

Sekaran et al., In-silico network pharmacology study on Glycyrrhiza glabra: Analyzing the immune-boosting phytochemical properties of Siddha medicinal plant against COVID-19, Advances in Protein Chemistry and Structural Biology, doi:10.1016/bs.apcsb.2023.04.003

Jeong et al., Evaluation of the Antiviral Efficacy of Subcutaneous Nafamostat Formulated with Glycyrrhizic Acid against SARS-CoV-2 in a Murine Model, International Journal of Molecular Sciences, doi:10.3390/ijms24119579

Fan et al., Pharmaceutical approaches for COVID-19: An update on current therapeutic opportunities, Acta Pharmaceutica, doi:10.2478/acph-2023-0014

Xu et al., Screening compounds for treating the diabetes and COVID-19 from Miao medicine by molecular docking and bioinformatics, Arabian Journal of Chemistry, doi:10.1016/j.arabjc.2023.105001

Abou Baker et al., An overview on medicinal plants used for combating coronavirus: Current potentials and challenges, Journal of Agriculture and Food Research, doi:10.1016/j.jafr.2023.100632

Xue et al., Repurposing clinically available drugs and therapies for pathogenic targets to combat SARS‐CoV‐2, MedComm, doi:10.1002/mco2.254

Abhyankar et al., The Efficacy and Safety of Imusil® Tablets in the Treatment of Adult Patients With Mild COVID-19: A Prospective, Randomized, Multicenter, Open-Label Study, Cureus, doi:10.7759/cureus.35881

Kumar et al., COVID-19 therapeutics: Clinical application of repurposed drugs and futuristic strategies for target-based drug discovery, Genes & Diseases, doi:10.1016/j.gendis.2022.12.019

Zhang et al., Herbal medicines exhibit a high affinity for ACE2 in treating COVID-19, BioScience Trends, doi:10.5582/bst.2022.01534

de Matos et al., Bioactive compounds as potential angiotensin-converting enzyme II inhibitors against COVID-19: a scoping review, Inflammation Research, doi:10.1007/s00011-022-01642-7

Mousavi et al., Novel Drug Design for Treatment of COVID-19: A Systematic Review of Preclinical Studies, Canadian Journal of Infectious Diseases and Medical Microbiology, doi:10.1155/2022/2044282

Rieder et al., A Review of In Silico Research, SARS-CoV-2, and Neurodegeneration: Focus on Papain-Like Protease, Neurotoxicity Research, doi:10.1007/s12640-022-00542-2

Negru et al., Virtual Screening of Substances Used in the Treatment of SARS-CoV-2 Infection and Analysis of Compounds With Known Action on Structurally Similar Proteins From Other Viruses, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.113432

Rani et al., Modern drug discovery applications for the identification of novel candidates for COVID-19 infections, Annals of Medicine and Surgery, doi:10.1016/j.amsu.2022.104125

https://www.mdpi.com/1999-4915/13/4/609/pdf

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8227143/

https://pubmed.ncbi.nlm.nih.gov/33918301/

https://www.sciencedirect.com/science/article/pii/S2667031321000257

https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-020-04706-3

https://dergipark.org.tr/en/pub/jcm/issue/71238/1165597

https://www.sciencedirect.com/science/article/abs/pii/S0022286022022876

https://www.mdpi.com/2223-7747/10/12/2600

https://sites.google.com/view/coronabank/coronabank/natural-compounds

http://journal.unhas.ac.id/index.php/ijoab/article/view/25284

https://www.jcchems.com/index.php/JCCHEMS/article/download/1802/561

https://www.sciencedirect.com/science/article/pii/S0223523421007066

Xu et al., Current understanding of nucleoside analogs inhibiting the SARS-CoV-2 RNA-dependent RNA polymerase, Computational and Structural Biotechnology Journal, doi:10.1016/j.csbj.2023.09.001

Wei et al., Total network controllability analysis discovers explainable drugs for Covid-19 treatment, Biology Direct, doi:10.1186/s13062-023-00410-9

Kushwaha et al., A comprehensive review on the global efforts on vaccines and repurposed drugs for combating COVID-19, European Journal of Medicinal Chemistry, doi:10.1016/j.ejmech.2023.115719

Mushebenge et al., Assessing the Potential Contribution of in Silico Studies in Discovering Drug Candidates that Interact with Various SARS-CoV-2 Receptors, MDPI AG, doi:10.20944/preprints202308.0434.v1

Moura et al., Converging Paths: A Comprehensive Review of the Synergistic Approach between Complementary Medicines and Western Medicine in Addressing COVID-19 in 2020, BioMed, doi:10.3390/biomed3020025

Fan et al., Pharmaceutical approaches for COVID-19: An update on current therapeutic opportunities, Acta Pharmaceutica, doi:10.2478/acph-2023-0014

Li et al., Bioinformatics and system biology approach to identify the influences among COVID-19, ARDS and sepsis, Frontiers in Immunology, doi:10.3389/fimmu.2023.1152186

Gudima et al., Antiviral Therapy of COVID-19, International Journal of Molecular Sciences, doi:10.3390/ijms24108867

Oliver et al., Different drug approaches to COVID-19 treatment worldwide: an update of new drugs and drugs repositioning to fight against the novel coronavirus, Therapeutic Advances in Vaccines and Immunotherapy, doi:10.1177/25151355221144845

Xue et al., Repurposing clinically available drugs and therapies for pathogenic targets to combat SARS‐CoV‐2, MedComm, doi:10.1002/mco2.254

Clair et al., High-throughput SARS-CoV-2 antiviral testing method using the Celigo Image Cytometer, Research Square, doi:10.21203/rs.3.rs-2846848/v1

Ceja-Gálvez et al., Severe COVID-19: Drugs and Clinical Trials, Journal of Clinical Medicine, doi:10.3390/jcm12082893

Astasio-Picado et al., Therapeutic Targets in the Virological Mechanism and in the Hyperinflammatory Response of Severe Acute Respiratory Syndrome Coronavirus Type 2 (SARS-CoV-2), Applied Sciences, doi:10.3390/app13074471

Wu et al., Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods, Acta Pharmaceutica Sinica B, doi:10.1016/j.apsb.2020.02.008

Talukder et al., Drugs for COVID-19 Treatment: A New Challenge, Applied Biochemistry and Biotechnology, doi:10.1007/s12010-023-04439-4

Leonidou et al., New workflow predicts drug targets against SARS-CoV-2 via metabolic changes in infected cells, PLOS Computational Biology, doi:10.1371/journal.pcbi.1010903

Bekheit et al., Potential RNA-dependent RNA polymerase inhibitors as prospective drug candidates for SARS-CoV-2, European Journal of Medicinal Chemistry, doi:10.1016/j.ejmech.2023.115292

Gautam et al., Promising Repurposed Antiviral Molecules to Combat SARS-CoV-2: A Review, Current Pharmaceutical Biotechnology, doi:10.2174/1389201024666230302113110

Raghav et al., Potential treatments of COVID-19: Drug repurposing and therapeutic interventions, Journal of Pharmacological Sciences, doi:10.1016/j.jphs.2023.02.004

Supianto et al., Cluster-based text mining for extracting drug candidates for the prevention of COVID-19 from the biomedical literature, Journal of Taibah University Medical Sciences, doi:10.1016/j.jtumed.2022.12.015

Celik et al., In silico evaluation of potential inhibitory activity of remdesivir, favipiravir, ribavirin and galidesivir active forms on SARS-CoV-2 RNA polymerase, Molecular Diversity, doi:10.1007/s11030-021-10215-5

Kapoor et al., In silico evaluation of potential intervention against SARS-CoV-2 RNA-dependent RNA polymerase, Physics and Chemistry of the Earth, Parts A/B/C, doi:10.1016/j.pce.2022.103350

Zeng et al., Repurpose Open Data to Discover Therapeutics for COVID-19 Using Deep Learning, Journal of Proteome Research, doi:10.1021/acs.jproteome.0c00316

Xu et al., An update on inhibitors targeting RNA-dependent RNA polymerase for COVID-19 treatment: Promises and challenges, Biochemical Pharmacology, doi:10.1016/j.bcp.2022.115279

Zhong et al., Recent advances in small-molecular therapeutics for COVID-19, Precision Clinical Medicine, doi:10.1093/pcmedi/pbac024

Wang et al., Screening Potential Drugs for COVID-19 Based on Bound Nuclear Norm Regularization, Frontiers in Genetics, doi:10.3389/fgene.2021.749256

Jamalipour Soufi et al., Potential inhibitors of SARS-CoV-2: recent advances, Journal of Drug Targeting, doi:10.1080/1061186X.2020.1853736

Negru et al., Virtual Screening of Substances Used in the Treatment of SARS-CoV-2 Infection and Analysis of Compounds With Known Action on Structurally Similar Proteins From Other Viruses, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.113432

Frediansyah et al., Antivirals for COVID-19: A critical review, Clinical Epidemiology and Global Health, doi:10.1016/j.cegh.2020.07.006

https://sites.google.com/view/coronabank/coronabank/classical-and-potential-antivirals

Kushwaha et al., A comprehensive review on the global efforts on vaccines and repurposed drugs for combating COVID-19, European Journal of Medicinal Chemistry, doi:10.1016/j.ejmech.2023.115719

Mushebenge et al., Assessing the Potential Contribution of in Silico Studies in Discovering Drug Candidates that Interact with Various SARS-CoV-2 Receptors, MDPI AG, doi:10.20944/preprints202308.0434.v1

Oner et al., Investigation of antiviral substances in Covid 19 by Molecular Docking: In Silico Study, African Health Sciences, doi:10.4314/ahs.v23i1.4

Pandit et al., e-Pharmacophore modeling and in silico study of CD147 receptor against SARS-CoV-2 drugs, Genomics & Informatics, doi:10.5808/gi.23005

Onyango, O., In Silico Models for Anti-COVID-19 Drug Discovery: A Systematic Review, Advances in Pharmacological and Pharmaceutical Sciences, doi:10.1155/2023/4562974

Huang et al., DeepCoVDR: deep transfer learning with graph transformer and cross-attention for predicting COVID-19 drug response, Bioinformatics, doi:10.1093/bioinformatics/btad244

Oliver et al., Different drug approaches to COVID-19 treatment worldwide: an update of new drugs and drugs repositioning to fight against the novel coronavirus, Therapeutic Advances in Vaccines and Immunotherapy, doi:10.1177/25151355221144845

Xue et al., Repurposing clinically available drugs and therapies for pathogenic targets to combat SARS‐CoV‐2, MedComm, doi:10.1002/mco2.254

Nayak et al., Prospects of Novel and Repurposed Immunomodulatory Drugs against Acute Respiratory Distress Syndrome (ARDS) Associated with COVID-19 Disease, Journal of Personalized Medicine, doi:10.3390/jpm13040664

Kumar et al., COVID-19 therapeutics: Clinical application of repurposed drugs and futuristic strategies for target-based drug discovery, Genes & Diseases, doi:10.1016/j.gendis.2022.12.019

Astasio-Picado et al., Therapeutic Targets in the Virological Mechanism and in the Hyperinflammatory Response of Severe Acute Respiratory Syndrome Coronavirus Type 2 (SARS-CoV-2), Applied Sciences, doi:10.3390/app13074471

Khaerunnisa et al., Potential Inhibitor of COVID-19 Main Protease (Mpro) From Several Medicinal Plant Compounds by Molecular Docking Study, MDPI AG, doi:10.20944/preprints202003.0226.v1

Talukdar et al., Potential Drugs for COVID -19 Treatment Management With Their Contraindications and Drug- Drug Interaction, MDPI AG, doi:10.20944/preprints202105.0690.v1

Raghav et al., Potential treatments of COVID-19: Drug repurposing and therapeutic interventions, Journal of Pharmacological Sciences, doi:10.1016/j.jphs.2023.02.004

Guo et al., Enhanced compound-protein binding affinity prediction by representing protein multimodal information via a coevolutionary strategy, Briefings in Bioinformatics, doi:10.1093/bib/bbac628

Supianto et al., Cluster-based text mining for extracting drug candidates for the prevention of COVID-19 from the biomedical literature, Journal of Taibah University Medical Sciences, doi:10.1016/j.jtumed.2022.12.015

Zeng et al., Repurpose Open Data to Discover Therapeutics for COVID-19 Using Deep Learning, Journal of Proteome Research, doi:10.1021/acs.jproteome.0c00316

Shah et al., In silico studies on therapeutic agents for COVID-19: Drug repurposing approach, Life Sciences, doi:10.1016/j.lfs.2020.117652

Mousavi et al., Novel Drug Design for Treatment of COVID-19: A Systematic Review of Preclinical Studies, Canadian Journal of Infectious Diseases and Medical Microbiology, doi:10.1155/2022/2044282

Zhong et al., Recent advances in small-molecular therapeutics for COVID-19, Precision Clinical Medicine, doi:10.1093/pcmedi/pbac024

Mavlankar et al., Interaction of surface glycoprotein of SARS-CoV-2 variants of concern with potential drug candidates: A molecular docking study, F1000Research, doi:10.12688/f1000research.109586.1

Arshad et al., Prioritization of Anti‐SARS‐Cov‐2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics, Clinical Pharmacology & Therapeutics, doi:10.1002/cpt.1909

Loucera et al., Real-world evidence with a retrospective cohort of 15,968 Andalusian COVID-19 hospitalized patients suggests 21 new effective treatments and one drug that increases death risk., medRxiv, doi:10.1101/2022.08.14.22278751

Jamalipour Soufi et al., Potential inhibitors of SARS-CoV-2: recent advances, Journal of Drug Targeting, doi:10.1080/1061186X.2020.1853736

Rani et al., Modern drug discovery applications for the identification of novel candidates for COVID-19 infections, Annals of Medicine and Surgery, doi:10.1016/j.amsu.2022.104125

Davarpanah et al., Combination of Spironolactone and Sitagliptin Improves Clinical Outcomes of Outpatients with COVID-19: An Observational Study, medRxiv, doi:10.1101/2022.01.21.22269322

Sarkar et al., Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives, Frontiers in Pharmacology, doi:10.3389/fphar.2020.572870

Frediansyah et al., Antivirals for COVID-19: A critical review, Clinical Epidemiology and Global Health, doi:10.1016/j.cegh.2020.07.006

https://sites.google.com/view/coronabank/coronabank/classical-and-potential-antivirals

Agrawal et al., Artemisia Extracts and Artemisinin-Based Antimalarials for COVID-19 Management: Could These Be Effective Antivirals for COVID-19 Treatment?, Molecules, doi:10.3390/molecules27123828

Badraoui et al., Antiviral Effects of Artemisinin and Its Derivatives against SARS-CoV-2 Main Protease: Computational Evidences and Interactions with ACE2 Allelic Variants, Pharmaceuticals, doi:10.3390/ph15020129

Ahmad et al., Artemisia annua L. and Its Derivatives: Their Antiviral Effects on COVID-19 and Possible Mechanisms, Journal of Exploratory Research in Pharmacology, doi:10.14218/JERP.2021.00034

Tang et al., Network pharmacology-based predictions of active components and pharmacological mechanisms of Artemisia annua L. for the treatment of the novel Corona virus disease 2019 (COVID-19), BMC Complementary Medicine and Therapies, doi:10.1186/s12906-022-03523-2

Nair et al., Artemisia annuahot-water extracts show potent activityin vitroagainst Covid-19 variants including delta, bioRxiv, doi:10.1101/2021.09.08.459260

Si et al., Human organ chip-enabled pipeline to rapidly repurpose therapeutics during viral pandemics, bioRxiv, doi:10.1101/2020.04.13.039917

Gurung et al., Artesunate induces substantial topological alterations in the SARS-CoV-2 Nsp1 protein structure, Journal of King Saud University - Science, doi:10.1016/j.jksus.2021.101810

Nair et al., SARS-CoV-2 omicron variants are susceptible in vitro to Artemisia annua hot water extracts, Journal of Ethnopharmacology, doi:10.1016/j.jep.2023.116291

Ullah et al., AVPCD: a plant-derived medicine database of antiviral phytochemicals for cancer, Covid-19, malaria and HIV, Database, doi:10.1093/database/baad056

Rafiq et al., A Comprehensive Update of Various Attempts by Medicinal Chemists to Combat COVID-19 through Natural Products, Molecules, doi:10.3390/molecules28124860

Low et al., COVID-19 Therapeutic Potential of Natural Products, International Journal of Molecular Sciences, doi:10.3390/ijms24119589

Schake et al., An interaction-based drug discovery screen explains known SARS-CoV-2 inhibitors and predicts new compound scaffolds, Scientific Reports, doi:10.1038/s41598-023-35671-x

Moura et al., Converging Paths: A Comprehensive Review of the Synergistic Approach between Complementary Medicines and Western Medicine in Addressing COVID-19 in 2020, BioMed, doi:10.3390/biomed3020025

Oliver et al., Different drug approaches to COVID-19 treatment worldwide: an update of new drugs and drugs repositioning to fight against the novel coronavirus, Therapeutic Advances in Vaccines and Immunotherapy, doi:10.1177/25151355221144845

Abou Baker et al., An overview on medicinal plants used for combating coronavirus: Current potentials and challenges, Journal of Agriculture and Food Research, doi:10.1016/j.jafr.2023.100632

Srivastava et al., A Brief Review on Medicinal Plants-At-Arms against COVID-19, Interdisciplinary Perspectives on Infectious Diseases, doi:10.1155/2023/7598307

England et al., Plants as Biofactories for Therapeutic Proteins and Antiviral Compounds to Combat COVID-19, Life, doi:10.3390/life13030617

Atoum et al., Paving New Roads Using Allium sativum as a Repurposed Drug and Analyzing its Antiviral Action Using Artificial Intelligence Technology, Iranian Journal of Pharmaceutical Research, doi:10.5812/ijpr-131577

Anju et al., Virtual screening of quinoline derived library for SARS-COV-2 targeting viral entry and replication, Journal of Biomolecular Structure and Dynamics, doi:10.1080/07391102.2021.1913228

de Matos et al., Bioactive compounds as potential angiotensin-converting enzyme II inhibitors against COVID-19: a scoping review, Inflammation Research, doi:10.1007/s00011-022-01642-7

https://www.sciencedirect.com/science/article/abs/pii/S0378874121002439

https://chemrxiv.org/engage/chemrxiv/article-details/60c74a53469df45440f43d21

https://www.openaccessjournals.com/articles/targeting-tgf-pathway-with-covid19-drug-candid..

https://linkinghub.elsevier.com/retrieve/pii/S0378874121002439

https://pubmed.ncbi.nlm.nih.gov/34306988/

https://clinicaltrials.gov/ct2/show/NCT04530617

https://sites.google.com/view/coronabank/coronabank/antimicrobials

http://journal.unhas.ac.id/index.php/ijoab/article/view/25284

Park et al., Epigallocatechin Gallate (EGCG), a Green Tea Polyphenol, Reduces Coronavirus Replication in a Mouse Model, Viruses, doi:10.3390/v13122533

Tam et al., Targeting SARS-CoV-2 Non-Structural Proteins, International Journal of Molecular Sciences, doi:10.3390/ijms241613002

He et al., Recent advances towards natural plants as potential inhibitors of SARS-Cov-2 targets, Pharmaceutical Biology, doi:10.1080/13880209.2023.2241518

Mushebenge et al., Assessing the Potential Contribution of in Silico Studies in Discovering Drug Candidates that Interact with Various SARS-CoV-2 Receptors, MDPI AG, doi:10.20944/preprints202308.0434.v1

Rafiq et al., A Comprehensive Update of Various Attempts by Medicinal Chemists to Combat COVID-19 through Natural Products, Molecules, doi:10.3390/molecules28124860

Low et al., COVID-19 Therapeutic Potential of Natural Products, International Journal of Molecular Sciences, doi:10.3390/ijms24119589

AKBABA et al., Phytochemicals of Hibiscus sabdariffa with Therapeutic Potential against SARS-CoV-2: A Molecular Docking Study, Journal of the Institute of Science and Technology, doi:10.21597/jist.1187616

Abou Baker et al., An overview on medicinal plants used for combating coronavirus: Current potentials and challenges, Journal of Agriculture and Food Research, doi:10.1016/j.jafr.2023.100632

Toigo et al., Flavonoid as possible therapeutic targets against COVID-19: a scoping review of in silico studies, DARU Journal of Pharmaceutical Sciences, doi:10.1007/s40199-023-00461-3

Srivastava et al., A Brief Review on Medicinal Plants-At-Arms against COVID-19, Interdisciplinary Perspectives on Infectious Diseases, doi:10.1155/2023/7598307

DIABATE et al., Identification of promising high-affinity inhibitors of SARS-CoV-2 main protease from African Natural Products Databases by Virtual Screening, Research Square, doi:10.21203/rs.3.rs-2673755/v1

Fam et al., Channel activity of SARS-CoV-2 viroporin ORF3a inhibited by adamantanes and phenolic plant metabolites, Scientific Reports, doi:10.1038/s41598-023-31764-9

Maiti et al., Epigallocatechin-Gallate and Theaflavin-Gallate Interaction in SARS CoV-2 Spike-Protein Central-Channel with Reference to the Hydroxychloroquine Interaction: Bioinformatics and Molecular Docking Study, MDPI AG, doi:10.20944/preprints202004.0247.v1

Tallei et al., Potential of Plant Bioactive Compounds as SARS-CoV-2 Main Protease (Mpro) and Spike (S) Glycoprotein Inhibitors: A Molecular Docking Study, Scientifica, doi:10.1155/2020/6307457

Wu et al., Polyphenols as alternative treatments of COVID-19, Computational and Structural Biotechnology Journal, doi:10.1016/j.csbj.2021.09.022

Heleno et al., Plant Extracts and SARS-CoV-2: Research and Applications, Life, doi:10.3390/life13020386

Kawall et al., Inhibitory effect of phytochemicals towards SARS-CoV-2 papain like protease (PLpro) proteolytic and deubiquitinase activity, Frontiers in Chemistry, doi:10.3389/fchem.2022.1100460

Chen et al., The exploration of phytocompounds theoretically combats SARS-CoV-2 pandemic against virus entry, viral replication and immune evasion, Journal of Infection and Public Health, doi:10.1016/j.jiph.2022.11.022

Azeem et al., Virtual screening of phytochemicals by targeting multiple proteins of severe acute respiratory syndrome coronavirus 2: Molecular docking and molecular dynamics simulation studies, International Journal of Immunopathology and Pharmacology, doi:10.1177/03946320221142793

Rieder et al., A Review of In Silico Research, SARS-CoV-2, and Neurodegeneration: Focus on Papain-Like Protease, Neurotoxicity Research, doi:10.1007/s12640-022-00542-2

Ali et al., Implication of in silico studies in the search for novel inhibitors against SARS‐CoV‐2, Archiv der Pharmazie, doi:10.1002/ardp.202100360

https://www.researchgate.net/publication/373256147_A_Critical_Review_on_the_Potency_of_Phy..

https://sites.google.com/view/coronabank/coronabank/natural-compounds

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10013230/pdf/42535_2023_Article_601.pdf/?tool..

https://www.sciencedirect.com/science/article/pii/S0223523421007066

https://www.mdpi.com/1424-8247/14/9/892

https://www.mdpi.com/2304-8158/10/9/2084/htm

https://www.sciencedirect.com/science/article/pii/S0308814621026005

Amani et al., Efficacy and safety of arbidol (umifenovir) in patients with COVID‐19: A systematic review and meta‐analysis, Immunity, Inflammation and Disease, doi:10.1002/iid3.502

Girgis et al., Indole-Based Compounds as Potential Drug Candidates for SARS-CoV-2, Molecules, doi:10.3390/molecules28186603

Kushwaha et al., A comprehensive review on the global efforts on vaccines and repurposed drugs for combating COVID-19, European Journal of Medicinal Chemistry, doi:10.1016/j.ejmech.2023.115719

Pandit et al., e-Pharmacophore modeling and in silico study of CD147 receptor against SARS-CoV-2 drugs, Genomics & Informatics, doi:10.5808/gi.23005

Moura et al., Converging Paths: A Comprehensive Review of the Synergistic Approach between Complementary Medicines and Western Medicine in Addressing COVID-19 in 2020, BioMed, doi:10.3390/biomed3020025

Fan et al., Pharmaceutical approaches for COVID-19: An update on current therapeutic opportunities, Acta Pharmaceutica, doi:10.2478/acph-2023-0014

Gudima et al., Antiviral Therapy of COVID-19, International Journal of Molecular Sciences, doi:10.3390/ijms24108867

Oliver et al., Different drug approaches to COVID-19 treatment worldwide: an update of new drugs and drugs repositioning to fight against the novel coronavirus, Therapeutic Advances in Vaccines and Immunotherapy, doi:10.1177/25151355221144845

Pati et al., Drug discovery through Covid-19 genome sequencing with siamese graph convolutional neural network, Multimedia Tools and Applications, doi:10.1007/s11042-023-15270-8

Ali et al., Computational Prediction of Nigella sativa Compounds as Potential Drug Agents for Targeting Spike Protein of SARS-CoV-2, Pakistan BioMedical Journal, doi:10.54393/pbmj.v6i3.853

Kumar et al., COVID-19 therapeutics: Clinical application of repurposed drugs and futuristic strategies for target-based drug discovery, Genes & Diseases, doi:10.1016/j.gendis.2022.12.019

Astasio-Picado et al., Therapeutic Targets in the Virological Mechanism and in the Hyperinflammatory Response of Severe Acute Respiratory Syndrome Coronavirus Type 2 (SARS-CoV-2), Applied Sciences, doi:10.3390/app13074471

Talukder et al., Drugs for COVID-19 Treatment: A New Challenge, Applied Biochemistry and Biotechnology, doi:10.1007/s12010-023-04439-4

Gautam et al., Promising Repurposed Antiviral Molecules to Combat SARS-CoV-2: A Review, Current Pharmaceutical Biotechnology, doi:10.2174/1389201024666230302113110

Raghav et al., Potential treatments of COVID-19: Drug repurposing and therapeutic interventions, Journal of Pharmacological Sciences, doi:10.1016/j.jphs.2023.02.004

Zeng et al., Repurpose Open Data to Discover Therapeutics for COVID-19 Using Deep Learning, Journal of Proteome Research, doi:10.1021/acs.jproteome.0c00316

Gangadharan et al., Repurposing of Potential Antiviral Drugs against RNA-dependent RNA Polymerase of SARS-CoV-2 by Computational Approach, Journal of Infection and Public Health, doi:10.1016/j.jiph.2022.09.007

Zhong et al., Recent advances in small-molecular therapeutics for COVID-19, Precision Clinical Medicine, doi:10.1093/pcmedi/pbac024

Tsuji, M., Virtual Screening and Quantum Chemistry Analysis for SARS-CoV-2 RNA-Dependent RNA Polymerase Using the ChEMBL Database: Reproduction of the Remdesivir-RTP and Favipiravir-RTP Binding Modes Obtained from Cryo-EM Experiments with High Binding Affinity, International Journal of Molecular Sciences, doi:10.3390/ijms231911009

Jamalipour Soufi et al., Potential inhibitors of SARS-CoV-2: recent advances, Journal of Drug Targeting, doi:10.1080/1061186X.2020.1853736

Sarkar et al., Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives, Frontiers in Pharmacology, doi:10.3389/fphar.2020.572870

Frediansyah et al., Antivirals for COVID-19: A critical review, Clinical Epidemiology and Global Health, doi:10.1016/j.cegh.2020.07.006

Heimfarth et al., Drug repurposing and cytokine management in response to COVID-19: A review, International Immunopharmacology, doi:10.1016/j.intimp.2020.106947

https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-020-05698-w

https://www.mdpi.com/1999-4915/13/8/1665

https://www.newindianexpress.com/nation/2021/sep/15/clinical-trial-of-anti-viral-drug-umif..

https://sites.google.com/view/coronabank/coronabank/binding-and-internalisation-inhibitors

Tam et al., Targeting SARS-CoV-2 Non-Structural Proteins, International Journal of Molecular Sciences, doi:10.3390/ijms241613002

Kushwaha et al., A comprehensive review on the global efforts on vaccines and repurposed drugs for combating COVID-19, European Journal of Medicinal Chemistry, doi:10.1016/j.ejmech.2023.115719

Mushebenge et al., Assessing the Potential Contribution of in Silico Studies in Discovering Drug Candidates that Interact with Various SARS-CoV-2 Receptors, MDPI AG, doi:10.20944/preprints202308.0434.v1

Pandit et al., e-Pharmacophore modeling and in silico study of CD147 receptor against SARS-CoV-2 drugs, Genomics & Informatics, doi:10.5808/gi.23005

Onyango, O., In Silico Models for Anti-COVID-19 Drug Discovery: A Systematic Review, Advances in Pharmacological and Pharmaceutical Sciences, doi:10.1155/2023/4562974

Huang et al., DeepCoVDR: deep transfer learning with graph transformer and cross-attention for predicting COVID-19 drug response, Bioinformatics, doi:10.1093/bioinformatics/btad244

Mittal et al., Identification of potential molecules against COVID-19 main protease through structure-guided virtual screening approach, Journal of Biomolecular Structure and Dynamics, doi:10.1080/07391102.2020.1768151

Oliver et al., Different drug approaches to COVID-19 treatment worldwide: an update of new drugs and drugs repositioning to fight against the novel coronavirus, Therapeutic Advances in Vaccines and Immunotherapy, doi:10.1177/25151355221144845

Xue et al., Repurposing clinically available drugs and therapies for pathogenic targets to combat SARS‐CoV‐2, MedComm, doi:10.1002/mco2.254

Nayak et al., Prospects of Novel and Repurposed Immunomodulatory Drugs against Acute Respiratory Distress Syndrome (ARDS) Associated with COVID-19 Disease, Journal of Personalized Medicine, doi:10.3390/jpm13040664

Kumar et al., COVID-19 therapeutics: Clinical application of repurposed drugs and futuristic strategies for target-based drug discovery, Genes & Diseases, doi:10.1016/j.gendis.2022.12.019

Talukdar et al., Potential Drugs for COVID -19 Treatment Management With Their Contraindications and Drug- Drug Interaction, MDPI AG, doi:10.20944/preprints202105.0690.v1

Kanhed et al., Identification of potential Mpro inhibitors for the treatment of COVID-19 by using systematic virtual screening approach, Molecular Diversity, doi:10.1007/s11030-020-10130-1

Raghav et al., Potential treatments of COVID-19: Drug repurposing and therapeutic interventions, Journal of Pharmacological Sciences, doi:10.1016/j.jphs.2023.02.004

Guo et al., Enhanced compound-protein binding affinity prediction by representing protein multimodal information via a coevolutionary strategy, Briefings in Bioinformatics, doi:10.1093/bib/bbac628

Supianto et al., Cluster-based text mining for extracting drug candidates for the prevention of COVID-19 from the biomedical literature, Journal of Taibah University Medical Sciences, doi:10.1016/j.jtumed.2022.12.015

Shah et al., In silico studies on therapeutic agents for COVID-19: Drug repurposing approach, Life Sciences, doi:10.1016/j.lfs.2020.117652

Mousavi et al., Novel Drug Design for Treatment of COVID-19: A Systematic Review of Preclinical Studies, Canadian Journal of Infectious Diseases and Medical Microbiology, doi:10.1155/2022/2044282

Zhong et al., Recent advances in small-molecular therapeutics for COVID-19, Precision Clinical Medicine, doi:10.1093/pcmedi/pbac024

Arshad et al., Prioritization of Anti‐SARS‐Cov‐2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics, Clinical Pharmacology & Therapeutics, doi:10.1002/cpt.1909

Loucera et al., Real-world evidence with a retrospective cohort of 15,968 Andalusian COVID-19 hospitalized patients suggests 21 new effective treatments and one drug that increases death risk., medRxiv, doi:10.1101/2022.08.14.22278751

Jamalipour Soufi et al., Potential inhibitors of SARS-CoV-2: recent advances, Journal of Drug Targeting, doi:10.1080/1061186X.2020.1853736

Rieder et al., A Review of In Silico Research, SARS-CoV-2, and Neurodegeneration: Focus on Papain-Like Protease, Neurotoxicity Research, doi:10.1007/s12640-022-00542-2

Sperry et al., Target-agnostic drug prediction integrated with medical record analysis uncovers differential associations of statins with increased survival in COVID-19 patients, PLOS Computational Biology, doi:10.1371/journal.pcbi.1011050 (Table 2)

Davarpanah et al., Combination of Spironolactone and Sitagliptin Improves Clinical Outcomes of Outpatients with COVID-19: An Observational Study, medRxiv, doi:10.1101/2022.01.21.22269322

Sarkar et al., Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives, Frontiers in Pharmacology, doi:10.3389/fphar.2020.572870

https://sites.google.com/view/coronabank/coronabank/classical-and-potential-antivirals

Lin et al., Plant flavonoid inhibition of SARS-CoV-2 main protease and viral replication, iScience, doi:10.1016/j.isci.2023.107602

He et al., Recent advances towards natural plants as potential inhibitors of SARS-Cov-2 targets, Pharmaceutical Biology, doi:10.1080/13880209.2023.2241518

Khan et al., Possible therapeutic targets for SARS-CoV-2 infection and COVID-19, Journal of Allergy & Infectious Diseases, doi:10.46439/allergy.2.028

Soni et al., In Silico Evaluation of Promising Naturally Occurring Bioactive Ligands Against Molecular Targets of SARS-Cov-2, Proceedings of the National Academy of Sciences, India Section B: Biological Sciences, doi:10.1007/s40011-023-01496-x

Akter et al., Plausibility of natural immunomodulators in the treatment of COVID-19–A comprehensive analysis and future recommendations, Heliyon, doi:10.1016/j.heliyon.2023.e17478

Rafiq et al., A Comprehensive Update of Various Attempts by Medicinal Chemists to Combat COVID-19 through Natural Products, Molecules, doi:10.3390/molecules28124860

Tiwari et al., Virtual Screening of Phytochemicals in Search of a Potential Drug Candidate for COVID-19: DFT Study and Molecular Docking, COVID-19: Origin, Impact and Management (Part 2), doi:10.2174/9789815165944123010012

Abou Baker et al., An overview on medicinal plants used for combating coronavirus: Current potentials and challenges, Journal of Agriculture and Food Research, doi:10.1016/j.jafr.2023.100632

Srivastava et al., A Brief Review on Medicinal Plants-At-Arms against COVID-19, Interdisciplinary Perspectives on Infectious Diseases, doi:10.1155/2023/7598307

Patel et al., Bioprospecting phytochemicals of Rosmarinus officinalis L. for targeting SARS-CoV-2 main protease (Mpro): a computational study, Journal of Molecular Modeling, doi:10.1007/s00894-023-05569-6

Nguyen et al., The Potential of Ameliorating COVID-19 and Sequelae From Andrographis paniculata via Bioinformatics, Bioinformatics and Biology Insights, doi:10.1177/11779322221149622

Giordano et al., Food Plant Secondary Metabolites Antiviral Activity and Their Possible Roles in SARS-CoV-2 Treatment: An Overview, Molecules, doi:10.3390/molecules28062470

Ibeh et al., Computational studies of potential antiviral compounds from some selected Nigerian medicinal plants against SARS-CoV-2 proteins, Informatics in Medicine Unlocked, doi:10.1016/j.imu.2023.101230

Heleno et al., Plant Extracts and SARS-CoV-2: Research and Applications, Life, doi:10.3390/life13020386

Bojkova et al., Identification of novel antiviral drug candidates using an optimized SARS-CoV-2 phenotypic screening platform, iScience, doi:10.1016/j.isci.2023.105944

Guerra et al., Critical Review of Plant-Derived Compounds as Possible Inhibitors of SARS-CoV-2 Proteases: A Comparison with Experimentally Validated Molecules, ACS Omega, doi:10.1021/acsomega.2c05766

Moezzi, M., Comprehensive in silico screening of flavonoids against SARS-CoV-2 main protease, Journal of Biomolecular Structure and Dynamics, doi:10.1080/07391102.2022.2142297

Kushari et al., An integrated computational approach towards the screening of active plant metabolites as potential inhibitors of SARS-CoV-2: an overview, Structural Chemistry, doi:10.1007/s11224-022-02066-z

Liu et al., Network Pharmacology and Molecular Docking Elucidate the Underlying Pharmacological Mechanisms of the Herb Houttuynia cordata in Treating Pneumonia Caused by SARS-CoV-2, Viruses, doi:10.3390/v14071588

Sperry et al., Target-agnostic drug prediction integrated with medical record analysis uncovers differential associations of statins with increased survival in COVID-19 patients, PLOS Computational Biology, doi:10.1371/journal.pcbi.1011050 (Table 2)

Rani et al., Modern drug discovery applications for the identification of novel candidates for COVID-19 infections, Annals of Medicine and Surgery, doi:10.1016/j.amsu.2022.104125

HELALİ et al., Natural substances and coronavirus: review and potential for the inhibition of SARS-CoV-2, Current Perspectives on Medicinal and Aromatic Plants (CUPMAP), doi:10.38093/cupmap.1029572

https://sites.google.com/view/coronabank/coronabank/natural-compounds

http://journal.unhas.ac.id/index.php/ijoab/article/view/25284

https://www.mdpi.com/2304-8158/10/9/2084/htm

Sha et al., Current state-of-the-art and potential future therapeutic drugs against COVID-19, Frontiers in Cell and Developmental Biology, doi:10.3389/fcell.2023.1238027

Lin et al., Plant flavonoid inhibition of SARS-CoV-2 main protease and viral replication, iScience, doi:10.1016/j.isci.2023.107602

He et al., Recent advances towards natural plants as potential inhibitors of SARS-Cov-2 targets, Pharmaceutical Biology, doi:10.1080/13880209.2023.2241518

Low et al., COVID-19 Therapeutic Potential of Natural Products, International Journal of Molecular Sciences, doi:10.3390/ijms24119589

Mittal et al., Identification of potential molecules against COVID-19 main protease through structure-guided virtual screening approach, Journal of Biomolecular Structure and Dynamics, doi:10.1080/07391102.2020.1768151

CHANDRA et al., Indian medicinal plants are effective in the treatment and management of COVID-19, BIOCELL, doi:10.32604/biocell.2023.026081

Xie et al., Exploring the mechanism of Ge-Gen-Qin-Lian-Wan against Novel coronavirus pneumonia based on network pharmacology and molecular docking techniques, Medical Data Mining, doi:10.53388/MDM202306016

Mehyar, N., Coronaviruses SARS-CoV, MERS-CoV, and SARS-CoV-2 helicase inhibitors: A systematic review of in vitro studies, Journal of Virus Eradication, doi:10.1016/j.jve.2023.100327

Pang et al., The research progress of SARS-CoV-2 main protease inhibitors from 2020 to 2022, European Journal of Medicinal Chemistry, doi:10.1016/j.ejmech.2023.115491

Abou Baker et al., An overview on medicinal plants used for combating coronavirus: Current potentials and challenges, Journal of Agriculture and Food Research, doi:10.1016/j.jafr.2023.100632

Xue et al., Repurposing clinically available drugs and therapies for pathogenic targets to combat SARS‐CoV‐2, MedComm, doi:10.1002/mco2.254

Toigo et al., Flavonoid as possible therapeutic targets against COVID-19: a scoping review of in silico studies, DARU Journal of Pharmaceutical Sciences, doi:10.1007/s40199-023-00461-3

Bogoyavlenskiy et al., Computer Analysis of the Inhibition of ACE2 by Flavonoids and Identification of Their Potential Antiviral Pharmacophore Site, Molecules, doi:10.3390/molecules28093766

Kronenberger et al., COVID-19 therapeutics: Small-molecule drug development targeting SARS-CoV-2 main protease, Drug Discovery Today, doi:10.1016/j.drudis.2023.103579

Yang et al., A Comprehensive Review of Natural Flavonoids with Anti-SARS-CoV-2 Activity, Molecules, doi:10.3390/molecules28062735

Abdizadeh et al., Efficacy Evaluation of Quercetin and Its Analogues on the Main Protease Enzyme of the COVID-19 Using Molecular Docking Studies, journal of ilam university of medical sciences, doi:10.52547/sjimu.30.4.66

Heleno et al., Plant Extracts and SARS-CoV-2: Research and Applications, Life, doi:10.3390/life13020386

Glaab et al., Pharmacophore Model for SARS-CoV-2 3CLpro Small-Molecule Inhibitors and in Vitro Experimental Validation of Computationally Screened Inhibitors, Journal of Chemical Information and Modeling, doi:10.1021/acs.jcim.1c00258

Xu et al., An update on inhibitors targeting RNA-dependent RNA polymerase for COVID-19 treatment: Promises and challenges, Biochemical Pharmacology, doi:10.1016/j.bcp.2022.115279

Dinda et al., Some natural compounds and their analogues having potent anti- SARS-CoV-2 and anti-proteases activities as lead molecules in drug discovery for COVID-19, European Journal of Medicinal Chemistry Reports, doi:10.1016/j.ejmcr.2022.100079

Uma Reddy et al., Multifaceted role of plant derived small molecule inhibitors on replication cycle of sars-cov-2, Microbial Pathogenesis, doi:10.1016/j.micpath.2022.105512

Mukherjee et al., Role of medicinal plants in inhibiting SARS-CoV-2 and in the management of post-COVID-19 complications, Phytomedicine, doi:10.1016/j.phymed.2022.153930

https://sites.google.com/view/coronabank/coronabank/natural-compounds

https://www.mdpi.com/1424-8247/14/9/892

Li et al., The TMPRSS2 Inhibitor Nafamostat Reduces SARS-CoV-2 Pulmonary Infection in Mouse Models of COVID-19, mBio, doi:10.1128/mBio.00970-21

Neary et al., Evaluation of intranasal nafamostat or camostat for SARS-CoV-2 chemoprophylaxis in Syrian golden hamsters, bioRxiv, doi:10.1101/2021.07.08.451654

Kushwaha et al., A comprehensive review on the global efforts on vaccines and repurposed drugs for combating COVID-19, European Journal of Medicinal Chemistry, doi:10.1016/j.ejmech.2023.115719

Jeong et al., Evaluation of the Antiviral Efficacy of Subcutaneous Nafamostat Formulated with Glycyrrhizic Acid against SARS-CoV-2 in a Murine Model, International Journal of Molecular Sciences, doi:10.3390/ijms24119579

Farkaš et al., A Tale of Two Proteases: MPro and TMPRSS2 as Targets for COVID-19 Therapies, Pharmaceuticals, doi:10.3390/ph16060834

Guo et al., Multi-omics in COVID-19: Driving development of therapeutics and vaccines, National Science Review, doi:10.1093/nsr/nwad161

Oliver et al., Different drug approaches to COVID-19 treatment worldwide: an update of new drugs and drugs repositioning to fight against the novel coronavirus, Therapeutic Advances in Vaccines and Immunotherapy, doi:10.1177/25151355221144845

Wang et al., Repurposing Drugs for the Treatment of COVID-19 and Its Cardiovascular Manifestations, Circulation Research, doi:10.1161/circresaha.122.321879

Xue et al., Repurposing clinically available drugs and therapies for pathogenic targets to combat SARS‐CoV‐2, MedComm, doi:10.1002/mco2.254

Pati et al., Drug discovery through Covid-19 genome sequencing with siamese graph convolutional neural network, Multimedia Tools and Applications, doi:10.1007/s11042-023-15270-8

Kumar et al., COVID-19 therapeutics: Clinical application of repurposed drugs and futuristic strategies for target-based drug discovery, Genes & Diseases, doi:10.1016/j.gendis.2022.12.019

Astasio-Picado et al., Therapeutic Targets in the Virological Mechanism and in the Hyperinflammatory Response of Severe Acute Respiratory Syndrome Coronavirus Type 2 (SARS-CoV-2), Applied Sciences, doi:10.3390/app13074471

Săndulescu et al., Therapeutic developments for SARS-CoV-2 infection—Molecular mechanisms of action of antivirals and strategies for mitigating resistance in emerging variants in clinical practice, Frontiers in Microbiology, doi:10.3389/fmicb.2023.1132501

Gautam et al., Promising Repurposed Antiviral Molecules to Combat SARS-CoV-2: A Review, Current Pharmaceutical Biotechnology, doi:10.2174/1389201024666230302113110

Raghav et al., Potential treatments of COVID-19: Drug repurposing and therapeutic interventions, Journal of Pharmacological Sciences, doi:10.1016/j.jphs.2023.02.004

Supianto et al., Cluster-based text mining for extracting drug candidates for the prevention of COVID-19 from the biomedical literature, Journal of Taibah University Medical Sciences, doi:10.1016/j.jtumed.2022.12.015

Ravindran et al., Discovery of host-directed modulators of virus infection by probing the SARS-CoV-2–host protein–protein interaction network, Briefings in Bioinformatics, doi:10.1093/bib/bbac456

Wagoner et al., Combinations of Host- and Virus-Targeting Antiviral Drugs Confer Synergistic Suppression of SARS-CoV-2, Microbiology Spectrum, doi:10.1128/spectrum.03331-22

Zhong et al., Recent advances in small-molecular therapeutics for COVID-19, Precision Clinical Medicine, doi:10.1093/pcmedi/pbac024

Jamalipour Soufi et al., Potential inhibitors of SARS-CoV-2: recent advances, Journal of Drug Targeting, doi:10.1080/1061186X.2020.1853736

Sarkar et al., Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives, Frontiers in Pharmacology, doi:10.3389/fphar.2020.572870

https://www.mdpi.com/1999-4915/13/9/1768 (In Vitro)

https://www.sciencedirect.com/science/article/pii/S2589537021004491 (RCT)

https://sites.google.com/view/coronabank/coronabank/binding-and-internalisation-inhibitors

He et al., Recent advances towards natural plants as potential inhibitors of SARS-Cov-2 targets, Pharmaceutical Biology, doi:10.1080/13880209.2023.2241518

Khan et al., Possible therapeutic targets for SARS-CoV-2 infection and COVID-19, Journal of Allergy & Infectious Diseases, doi:10.46439/allergy.2.028

Low et al., COVID-19 Therapeutic Potential of Natural Products, International Journal of Molecular Sciences, doi:10.3390/ijms24119589

Miguel et al., Enhanced fatty acid oxidation through Metformin and Baicalin as therapy for COVID-19 and associated inflammatory states in lung and kidney, Free Radical Biology and Medicine, doi:10.1016/j.freeradbiomed.2023.03.245

Abou Baker et al., An overview on medicinal plants used for combating coronavirus: Current potentials and challenges, Journal of Agriculture and Food Research, doi:10.1016/j.jafr.2023.100632

Xue et al., Repurposing clinically available drugs and therapies for pathogenic targets to combat SARS‐CoV‐2, MedComm, doi:10.1002/mco2.254

Srivastava et al., A Brief Review on Medicinal Plants-At-Arms against COVID-19, Interdisciplinary Perspectives on Infectious Diseases, doi:10.1155/2023/7598307

Kronenberger et al., COVID-19 therapeutics: Small-molecule drug development targeting SARS-CoV-2 main protease, Drug Discovery Today, doi:10.1016/j.drudis.2023.103579

Xing, H., Current situation of COVID-19 treating with combination of traditional Chinese and Western medicine, TMR Integrative Medicine, doi:10.53388/TMRIM202307009

Wu et al., Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods, Acta Pharmaceutica Sinica B, doi:10.1016/j.apsb.2020.02.008

Yang et al., A Comprehensive Review of Natural Flavonoids with Anti-SARS-CoV-2 Activity, Molecules, doi:10.3390/molecules28062735

Bekheit et al., Potential RNA-dependent RNA polymerase inhibitors as prospective drug candidates for SARS-CoV-2, European Journal of Medicinal Chemistry, doi:10.1016/j.ejmech.2023.115292

Guerra et al., Critical Review of Plant-Derived Compounds as Possible Inhibitors of SARS-CoV-2 Proteases: A Comparison with Experimentally Validated Molecules, ACS Omega, doi:10.1021/acsomega.2c05766

Azeem et al., Virtual screening of phytochemicals by targeting multiple proteins of severe acute respiratory syndrome coronavirus 2: Molecular docking and molecular dynamics simulation studies, International Journal of Immunopathology and Pharmacology, doi:10.1177/03946320221142793

Bijelić et al., Phytochemicals in the Prevention and Treatment of SARS-CoV-2—Clinical Evidence, Antibiotics, doi:10.3390/antibiotics11111614

Xu et al., An update on inhibitors targeting RNA-dependent RNA polymerase for COVID-19 treatment: Promises and challenges, Biochemical Pharmacology, doi:10.1016/j.bcp.2022.115279

Negru et al., Virtual Screening of Substances Used in the Treatment of SARS-CoV-2 Infection and Analysis of Compounds With Known Action on Structurally Similar Proteins From Other Viruses, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.113432

Rani et al., Modern drug discovery applications for the identification of novel candidates for COVID-19 infections, Annals of Medicine and Surgery, doi:10.1016/j.amsu.2022.104125

Uma Reddy et al., Multifaceted role of plant derived small molecule inhibitors on replication cycle of sars-cov-2, Microbial Pathogenesis, doi:10.1016/j.micpath.2022.105512

https://www.karger.com/Article/Abstract/519564

https://sites.google.com/view/coronabank/coronabank/natural-compounds

http://journal.unhas.ac.id/index.php/ijoab/article/view/25284

https://www.mdpi.com/2304-8158/10/9/2084/htm

Sun et al., Unraveling the mechanism of action of cepharanthine for the treatment of novel coronavirus pneumonia (COVID-19) from the perspectives of systematic pharmacology, Arabian Journal of Chemistry, doi:10.1016/j.arabjc.2023.104722

Xia et al., The brief overview, antivirus and anti-SARS-CoV-2 activity, quantitative methods, and pharmacokinetics of cepharanthine: a potential small-molecule drug against COVID-19, Frontiers in Pharmacology, doi:10.3389/fphar.2023.1098972

Tam et al., Targeting SARS-CoV-2 Non-Structural Proteins, International Journal of Molecular Sciences, doi:10.3390/ijms241613002

He et al., Recent advances towards natural plants as potential inhibitors of SARS-Cov-2 targets, Pharmaceutical Biology, doi:10.1080/13880209.2023.2241518

Khan et al., Possible therapeutic targets for SARS-CoV-2 infection and COVID-19, Journal of Allergy & Infectious Diseases, doi:10.46439/allergy.2.028

Mehyar, N., Coronaviruses SARS-CoV, MERS-CoV, and SARS-CoV-2 helicase inhibitors: A systematic review of in vitro studies, Journal of Virus Eradication, doi:10.1016/j.jve.2023.100327

Abou Baker et al., An overview on medicinal plants used for combating coronavirus: Current potentials and challenges, Journal of Agriculture and Food Research, doi:10.1016/j.jafr.2023.100632

Xue et al., Repurposing clinically available drugs and therapies for pathogenic targets to combat SARS‐CoV‐2, MedComm, doi:10.1002/mco2.254

Yang et al., Bench-to-bedside: Innovation of small molecule anti-SARS-CoV-2 drugs in China, European Journal of Medicinal Chemistry, doi:10.1016/j.ejmech.2023.115503

Islam et al., Molecular-evaluated and explainable drug repurposing for COVID-19 using ensemble knowledge graph embedding, Scientific Reports, doi:10.1038/s41598-023-30095-z

Naz et al., Repurposing FIASMAs against Acid Sphingomyelinase for COVID-19: A Computational Molecular Docking and Dynamic Simulation Approach, Molecules, doi:10.3390/molecules28072989

Trivedi et al., Antiviral and Anti-Inflammatory Plant-Derived Bioactive Compounds and Their Potential Use in the Treatment of COVID-19-Related Pathologies, Journal of Xenobiotics, doi:10.3390/jox12040020

Rudramurthy et al., In-Vitro Screening of Repurposed Drug Library against Severe Acute Respiratory Syndrome Coronavirus-2, Medical Research Archives, doi:10.18103/mra.v11i2.3595

Raghav et al., Potential treatments of COVID-19: Drug repurposing and therapeutic interventions, Journal of Pharmacological Sciences, doi:10.1016/j.jphs.2023.02.004

Suet-May et al., COVID-19: How Effective Are the Repurposed Drugs and Novel Agents in Treating the Infection?, Sudan Journal of Medical Sciences, doi:10.18502/sjms.v17i4.12550

Dinda et al., Some natural compounds and their analogues having potent anti- SARS-CoV-2 and anti-proteases activities as lead molecules in drug discovery for COVID-19, European Journal of Medicinal Chemistry Reports, doi:10.1016/j.ejmcr.2022.100079

Jamalipour Soufi et al., Potential inhibitors of SARS-CoV-2: recent advances, Journal of Drug Targeting, doi:10.1080/1061186X.2020.1853736

Kumar et al., Identification of potential COVID-19 treatment compounds which inhibit SARS Cov2 prototypic, Delta and Omicron variant infection, Virology, doi:10.1016/j.virol.2022.05.004

Zhang et al., A cell-based large-scale screening of natural compounds for inhibitors of SARS-CoV-2, Signal Transduction and Targeted Therapy, doi:10.1038/s41392-020-00343-z

Uma Reddy et al., Multifaceted role of plant derived small molecule inhibitors on replication cycle of sars-cov-2, Microbial Pathogenesis, doi:10.1016/j.micpath.2022.105512

https://www.researchgate.net/publication/373256147_A_Critical_Review_on_the_Potency_of_Phy..

https://sites.google.com/view/coronabank/coronabank/natural-compounds

https://www.sciencedirect.com/science/article/pii/S2213422021000688

Akter et al., Plausibility of natural immunomodulators in the treatment of COVID-19–A comprehensive analysis and future recommendations, Heliyon, doi:10.1016/j.heliyon.2023.e17478

Rafiq et al., A Comprehensive Update of Various Attempts by Medicinal Chemists to Combat COVID-19 through Natural Products, Molecules, doi:10.3390/molecules28124860

Alanzi et al., Structure-based virtual identification of natural inhibitors of SARS-CoV-2 and its Delta and Omicron variant proteins, Future Virology, doi:10.2217/fvl-2022-0184

Abou Baker et al., An overview on medicinal plants used for combating coronavirus: Current potentials and challenges, Journal of Agriculture and Food Research, doi:10.1016/j.jafr.2023.100632

unknown, u., Trainee Poster Honorable Mention Poster Abstracts Presented at the 123^rdAnnual Meeting of the American Association of Colleges of Pharmacy, July 23-27, 2022, American Journal of Pharmaceutical Education, doi:10.5688/ajpe9169

Srivastava et al., A Brief Review on Medicinal Plants-At-Arms against COVID-19, Interdisciplinary Perspectives on Infectious Diseases, doi:10.1155/2023/7598307

Giordano et al., Food Plant Secondary Metabolites Antiviral Activity and Their Possible Roles in SARS-CoV-2 Treatment: An Overview, Molecules, doi:10.3390/molecules28062470

Khaerunnisa et al., Potential Inhibitor of COVID-19 Main Protease (Mpro) From Several Medicinal Plant Compounds by Molecular Docking Study, MDPI AG, doi:10.20944/preprints202003.0226.v1

Kawall et al., Inhibitory effect of phytochemicals towards SARS-CoV-2 papain like protease (PLpro) proteolytic and deubiquitinase activity, Frontiers in Chemistry, doi:10.3389/fchem.2022.1100460

Milton-Laskibar et al., Potential usefulness of Mediterranean diet polyphenols against COVID-19-induced inflammation: a review of the current knowledge, Journal of Physiology and Biochemistry, doi:10.1007/s13105-022-00926-0

Aati et al., Garcinia cambogia Phenolics as Potent Anti-COVID-19 Agents: Phytochemical Profiling, Biological Activities, and Molecular Docking, Plants, doi:10.3390/plants11192521

Sperry et al., Target-agnostic drug prediction integrated with medical record analysis uncovers differential associations of statins with increased survival in COVID-19 patients, PLOS Computational Biology, doi:10.1371/journal.pcbi.1011050 (Table 2)

Negru et al., Virtual Screening of Substances Used in the Treatment of SARS-CoV-2 Infection and Analysis of Compounds With Known Action on Structurally Similar Proteins From Other Viruses, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.113432

Qi et al., Discovery of TCMs and Derivatives Against the Main Protease of SARS-CoV-2 via High Throughput Screening, ADMET Analysis, and Inhibition Assay in Vitro, Journal of Molecular Structure, doi:10.1016/j.molstruc.2022.133709

BHARDWAJ et al., Molecular Docking Studies to Identify Promising Natural Inhibitors Targeting SARS-CoV-2 Nsp10-Nsp16 Protein Complex, Turkish Journal of Pharmaceutical Sciences, doi:10.4274/tjps.galenos.2021.56957

Ali et al., Implication of in silico studies in the search for novel inhibitors against SARS‐CoV‐2, Archiv der Pharmazie, doi:10.1002/ardp.202100360

HELALİ et al., Natural substances and coronavirus: review and potential for the inhibition of SARS-CoV-2, Current Perspectives on Medicinal and Aromatic Plants (CUPMAP), doi:10.38093/cupmap.1029572

https://www.researchgate.net/publication/373256147_A_Critical_Review_on_the_Potency_of_Phy..

https://sites.google.com/view/coronabank/coronabank/natural-compounds

https://journal.uinsgd.ac.id/index.php/biodjati/article/view/24521

https://digitalcommons.pcom.edu/research_day/research_day_GA_2022/researchGA2022/20/

https://www.mdpi.com/2304-8158/10/9/2084/htm

Khan et al., Possible therapeutic targets for SARS-CoV-2 infection and COVID-19, Journal of Allergy & Infectious Diseases, doi:10.46439/allergy.2.028

Lee, J., Treatment mechanism of immune triad from the repurposing drug against COVID-19, Translational Medicine of Aging, doi:10.1016/j.tma.2023.06.005

Oliver et al., Different drug approaches to COVID-19 treatment worldwide: an update of new drugs and drugs repositioning to fight against the novel coronavirus, Therapeutic Advances in Vaccines and Immunotherapy, doi:10.1177/25151355221144845

Wang et al., Repurposing Drugs for the Treatment of COVID-19 and Its Cardiovascular Manifestations, Circulation Research, doi:10.1161/circresaha.122.321879

Xue et al., Repurposing clinically available drugs and therapies for pathogenic targets to combat SARS‐CoV‐2, MedComm, doi:10.1002/mco2.254

Pati et al., Drug discovery through Covid-19 genome sequencing with siamese graph convolutional neural network, Multimedia Tools and Applications, doi:10.1007/s11042-023-15270-8

Ceja-Gálvez et al., Severe COVID-19: Drugs and Clinical Trials, Journal of Clinical Medicine, doi:10.3390/jcm12082893

Islam et al., Molecular-evaluated and explainable drug repurposing for COVID-19 using ensemble knowledge graph embedding, Scientific Reports, doi:10.1038/s41598-023-30095-z

Kumar et al., COVID-19 therapeutics: Clinical application of repurposed drugs and futuristic strategies for target-based drug discovery, Genes & Diseases, doi:10.1016/j.gendis.2022.12.019

Talukdar et al., Potential Drugs for COVID -19 Treatment Management With Their Contraindications and Drug- Drug Interaction, MDPI AG, doi:10.20944/preprints202105.0690.v1

Mostafa et al., FDA-Approved Drugs with Potent In Vitro Antiviral Activity against Severe Acute Respiratory Syndrome Coronavirus 2, Pharmaceuticals, doi:10.3390/ph13120443

Supianto et al., Cluster-based text mining for extracting drug candidates for the prevention of COVID-19 from the biomedical literature, Journal of Taibah University Medical Sciences, doi:10.1016/j.jtumed.2022.12.015

Zeng et al., Repurpose Open Data to Discover Therapeutics for COVID-19 Using Deep Learning, Journal of Proteome Research, doi:10.1021/acs.jproteome.0c00316

Tomazou et al., Multi-omics data integration and network-based analysis drives a multiplex drug repurposing approach to a shortlist of candidate drugs against COVID-19, Briefings in Bioinformatics, doi:10.1093/bib/bbab114

Mavlankar et al., Interaction of surface glycoprotein of SARS-CoV-2 variants of concern with potential drug candidates: A molecular docking study, F1000Research, doi:10.12688/f1000research.109586.1

Loucera et al., Real-world evidence with a retrospective cohort of 15,968 Andalusian COVID-19 hospitalized patients suggests 21 new effective treatments and one drug that increases death risk., medRxiv, doi:10.1101/2022.08.14.22278751

Chellasamy et al., Docking and molecular dynamics studies of human ezrin protein with a modelled SARS-CoV-2 endodomain and their interaction with potential invasion inhibitors, Journal of King Saud University - Science, doi:10.1016/j.jksus.2022.102277

Sperry et al., Target-agnostic drug prediction integrated with medical record analysis uncovers differential associations of statins with increased survival in COVID-19 patients, PLOS Computational Biology, doi:10.1371/journal.pcbi.1011050 (Table 2)

Nandi et al., Repurposing of Drugs and HTS to Combat SARS-CoV-2 Main Protease Utilizing Structure-Based Molecular Docking, Letters in Drug Design & Discovery, doi:10.2174/1570180818666211007111105

Issac et al., Improved And Optimized Drug Repurposing For The SARS-CoV-2 Pandemic, bioRxiv, doi:10.1101/2022.03.24.485618

https://sites.google.com/view/coronabank/coronabank/immunomodulatory-agents

Wu et al., Network pharmacology and bioinformatics analysis identifies potential therapeutic targets of Naringenin against COVID-19/LUSC, Frontiers in Endocrinology, doi:10.3389/fendo.2023.1187882

Elkaeed et al., Computer-assisted drug discovery of potential natural inhibitors of the SARS-CoV-2 RNA-dependent RNA polymerase through a multi-phase in silico approach, Antiviral Therapy, doi:10.1177/13596535231199838

He et al., Recent advances towards natural plants as potential inhibitors of SARS-Cov-2 targets, Pharmaceutical Biology, doi:10.1080/13880209.2023.2241518

Khan et al., Possible therapeutic targets for SARS-CoV-2 infection and COVID-19, Journal of Allergy & Infectious Diseases, doi:10.46439/allergy.2.028

Akter et al., Plausibility of natural immunomodulators in the treatment of COVID-19–A comprehensive analysis and future recommendations, Heliyon, doi:10.1016/j.heliyon.2023.e17478

Low et al., COVID-19 Therapeutic Potential of Natural Products, International Journal of Molecular Sciences, doi:10.3390/ijms24119589

Fan et al., Pharmaceutical approaches for COVID-19: An update on current therapeutic opportunities, Acta Pharmaceutica, doi:10.2478/acph-2023-0014

CHEN et al., Deciphering suppressive effects of Lianhua Qingwen Capsule on COVID-19 and synergistic effects of its major botanical drug pairs, Chinese Journal of Natural Medicines, doi:10.1016/S1875-5364(23)60455-8

Priyandoko et al., Inflammation Inhibitory Activity of Green Tea, Soybean, and Guava Extracts During Sars-Cov-2 Infection Through TNF Protein in Cytokine Storm, Computational Biology and Chemistry, doi:10.1016/j.compbiolchem.2023.107898

Abou Baker et al., An overview on medicinal plants used for combating coronavirus: Current potentials and challenges, Journal of Agriculture and Food Research, doi:10.1016/j.jafr.2023.100632

Aleebrahim-Dehkordi et al., Targeting the vital Non-Structural Proteins (NSP12, NSP7, NSP8 and NSP3) from SARS-CoV-2 and Inhibition of RNA Polymerase by Natural Bioactive Compound naringenin as a Promising Drug Candidate against COVID-19, Journal of Molecular Structure, doi:10.1016/j.molstruc.2023.135642

Giordano et al., Food Plant Secondary Metabolites Antiviral Activity and Their Possible Roles in SARS-CoV-2 Treatment: An Overview, Molecules, doi:10.3390/molecules28062470

Khaerunnisa et al., Potential Inhibitor of COVID-19 Main Protease (Mpro) From Several Medicinal Plant Compounds by Molecular Docking Study, MDPI AG, doi:10.20944/preprints202003.0226.v1

Ibeh et al., Computational studies of potential antiviral compounds from some selected Nigerian medicinal plants against SARS-CoV-2 proteins, Informatics in Medicine Unlocked, doi:10.1016/j.imu.2023.101230

Abdizadeh et al., Efficacy Evaluation of Quercetin and Its Analogues on the Main Protease Enzyme of the COVID-19 Using Molecular Docking Studies, journal of ilam university of medical sciences, doi:10.52547/sjimu.30.4.66

Milton-Laskibar et al., Potential usefulness of Mediterranean diet polyphenols against COVID-19-induced inflammation: a review of the current knowledge, Journal of Physiology and Biochemistry, doi:10.1007/s13105-022-00926-0

deAndrés-Galiana et al., Analysis of transcriptomic responses to SARS-CoV-2 reveals plausible defective pathways responsible for increased susceptibility to infection and complications and helps to develop fast-track repositioning of drugs against COVID-19, Computers in Biology and Medicine, doi:10.1016/j.compbiomed.2022.106029

Sperry et al., Target-agnostic drug prediction integrated with medical record analysis uncovers differential associations of statins with increased survival in COVID-19 patients, PLOS Computational Biology, doi:10.1371/journal.pcbi.1011050 (Table 2)

https://sites.google.com/view/coronabank/coronabank/natural-compounds

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10013230/pdf/42535_2023_Article_601.pdf/?tool..

https://www.mdpi.com/2304-8158/10/9/2084/htm

Yuan et al., The role of cell death in SARS-CoV-2 infection, Signal Transduction and Targeted Therapy, doi:10.1038/s41392-023-01580-8

Tam et al., Targeting SARS-CoV-2 Non-Structural Proteins, International Journal of Molecular Sciences, doi:10.3390/ijms241613002

Yadav et al., Role of Structural and Non-Structural Proteins and Therapeutic Targets of SARS-CoV-2 for COVID-19, Cells, doi:10.3390/cells10040821

Mushebenge et al., Assessing the Potential Contribution of in Silico Studies in Discovering Drug Candidates that Interact with Various SARS-CoV-2 Receptors, MDPI AG, doi:10.20944/preprints202308.0434.v1

Carabineiro et al., CuFe2O4 Magnetic Nanoparticles as Heterogeneous Catalysts for Synthesis of Dihydropyrimidinones as Inhibitors of SARS-CoV-2 Surface Proteins—Insights from Molecular Docking Studies, Processes, doi:10.3390/pr11082294

Zmudzinski et al., Ebselen derivatives inhibit SARS-CoV-2 replication by inhibition of its essential proteins: PLpro and Mpro proteases, and nsp14 guanine N7-methyltransferase, Scientific Reports, doi:10.1038/s41598-023-35907-w

Farkaš et al., A Tale of Two Proteases: MPro and TMPRSS2 as Targets for COVID-19 Therapies, Pharmaceuticals, doi:10.3390/ph16060834

Mehyar, N., Coronaviruses SARS-CoV, MERS-CoV, and SARS-CoV-2 helicase inhibitors: A systematic review of in vitro studies, Journal of Virus Eradication, doi:10.1016/j.jve.2023.100327

Oliver et al., Different drug approaches to COVID-19 treatment worldwide: an update of new drugs and drugs repositioning to fight against the novel coronavirus, Therapeutic Advances in Vaccines and Immunotherapy, doi:10.1177/25151355221144845

Pang et al., The research progress of SARS-CoV-2 main protease inhibitors from 2020 to 2022, European Journal of Medicinal Chemistry, doi:10.1016/j.ejmech.2023.115491

Xue et al., Repurposing clinically available drugs and therapies for pathogenic targets to combat SARS‐CoV‐2, MedComm, doi:10.1002/mco2.254

Graf et al., Ferrocenoyl-substituted quinolinone and coumarin as organometallic inhibitors of SARS-CoV-2 3CLpro main protease, Metallomics, doi:10.1093/mtomcs/mfad023

Kronenberger et al., COVID-19 therapeutics: Small-molecule drug development targeting SARS-CoV-2 main protease, Drug Discovery Today, doi:10.1016/j.drudis.2023.103579

Kumar et al., COVID-19 therapeutics: Clinical application of repurposed drugs and futuristic strategies for target-based drug discovery, Genes & Diseases, doi:10.1016/j.gendis.2022.12.019

Rudramurthy et al., In-Vitro Screening of Repurposed Drug Library against Severe Acute Respiratory Syndrome Coronavirus-2, Medical Research Archives, doi:10.18103/mra.v11i2.3595

Wu et al., In silico identification of drug candidates against COVID-19, Informatics in Medicine Unlocked, doi:10.1016/j.imu.2020.100461

Zhong et al., Recent advances in small-molecular therapeutics for COVID-19, Precision Clinical Medicine, doi:10.1093/pcmedi/pbac024

Jamalipour Soufi et al., Potential inhibitors of SARS-CoV-2: recent advances, Journal of Drug Targeting, doi:10.1080/1061186X.2020.1853736

Ali et al., Implication of in silico studies in the search for novel inhibitors against SARS‐CoV‐2, Archiv der Pharmazie, doi:10.1002/ardp.202100360

https://sites.google.com/view/coronabank/coronabank/classical-and-potential-antivirals

Qu et al., A new integrated framework for the identification of potential virus–drug associations, Frontiers in Microbiology, doi:10.3389/fmicb.2023.1179414

He et al., Recent advances towards natural plants as potential inhibitors of SARS-Cov-2 targets, Pharmaceutical Biology, doi:10.1080/13880209.2023.2241518

Mushebenge et al., Assessing the Potential Contribution of in Silico Studies in Discovering Drug Candidates that Interact with Various SARS-CoV-2 Receptors, MDPI AG, doi:10.20944/preprints202308.0434.v1

CHEN et al., Deciphering suppressive effects of Lianhua Qingwen Capsule on COVID-19 and synergistic effects of its major botanical drug pairs, Chinese Journal of Natural Medicines, doi:10.1016/S1875-5364(23)60455-8

Abou Baker et al., An overview on medicinal plants used for combating coronavirus: Current potentials and challenges, Journal of Agriculture and Food Research, doi:10.1016/j.jafr.2023.100632

Xu et al., Bioactive compounds from Huashi Baidu decoction possess both antiviral and anti-inflammatory effects against COVID-19, Proceedings of the National Academy of Sciences, doi:10.1073/pnas.2301775120

Xing, H., Current situation of COVID-19 treating with combination of traditional Chinese and Western medicine, TMR Integrative Medicine, doi:10.53388/TMRIM202307009

Trivedi et al., Antiviral and Anti-Inflammatory Plant-Derived Bioactive Compounds and Their Potential Use in the Treatment of COVID-19-Related Pathologies, Journal of Xenobiotics, doi:10.3390/jox12040020

Ibeh et al., Computational studies of potential antiviral compounds from some selected Nigerian medicinal plants against SARS-CoV-2 proteins, Informatics in Medicine Unlocked, doi:10.1016/j.imu.2023.101230

Rahman et al., In silico investigation and potential therapeutic approaches of natural products for COVID-19: Computer-aided drug design perspective, Frontiers in Cellular and Infection Microbiology, doi:10.3389/fcimb.2022.929430

Bojkova et al., Identification of novel antiviral drug candidates using an optimized SARS-CoV-2 phenotypic screening platform, iScience, doi:10.1016/j.isci.2023.105944

Guerra et al., Critical Review of Plant-Derived Compounds as Possible Inhibitors of SARS-CoV-2 Proteases: A Comparison with Experimentally Validated Molecules, ACS Omega, doi:10.1021/acsomega.2c05766

Zhou et al., Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2, Cell Discovery, doi:10.1038/s41421-020-0153-3

Sperry et al., Target-agnostic drug prediction integrated with medical record analysis uncovers differential associations of statins with increased survival in COVID-19 patients, PLOS Computational Biology, doi:10.1371/journal.pcbi.1011050 (Table 2)

Qi et al., Discovery of TCMs and Derivatives Against the Main Protease of SARS-CoV-2 via High Throughput Screening, ADMET Analysis, and Inhibition Assay in Vitro, Journal of Molecular Structure, doi:10.1016/j.molstruc.2022.133709

Jang et al., Drugs repurposed for COVID-19 by virtual screening of 6,218 drugs and cell-based assay, Proceedings of the National Academy of Sciences, doi:10.1073/pnas.2024302118

https://sites.google.com/view/coronabank/coronabank/natural-compounds

http://journal.unhas.ac.id/index.php/ijoab/article/view/25284

https://www.sciencedirect.com/science/article/pii/S0223523421007066

https://www.sciencedirect.com/science/article/pii/S2213422021000688

Hsu et al., The effect of sofosbuvir-based treatment on the clinical outcomes of patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials, International Journal of Antimicrobial Agents, doi:10.1016/j.ijantimicag.2022.106545

Sokhela et al., Randomized clinical trial of nitazoxanide or sofosbuvir/daclatasvir for the prevention of SARS-CoV-2 infection, Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkac266

Xu et al., Current understanding of nucleoside analogs inhibiting the SARS-CoV-2 RNA-dependent RNA polymerase, Computational and Structural Biotechnology Journal, doi:10.1016/j.csbj.2023.09.001

Mushebenge et al., Assessing the Potential Contribution of in Silico Studies in Discovering Drug Candidates that Interact with Various SARS-CoV-2 Receptors, MDPI AG, doi:10.20944/preprints202308.0434.v1

Onyango, O., In Silico Models for Anti-COVID-19 Drug Discovery: A Systematic Review, Advances in Pharmacological and Pharmaceutical Sciences, doi:10.1155/2023/4562974

Moura et al., Converging Paths: A Comprehensive Review of the Synergistic Approach between Complementary Medicines and Western Medicine in Addressing COVID-19 in 2020, BioMed, doi:10.3390/biomed3020025

Lundstrom et al., COVID-19 signalome: Potential therapeutic interventions, Cellular Signalling, doi:10.1016/j.cellsig.2022.110559

Oliver et al., Different drug approaches to COVID-19 treatment worldwide: an update of new drugs and drugs repositioning to fight against the novel coronavirus, Therapeutic Advances in Vaccines and Immunotherapy, doi:10.1177/25151355221144845

Xue et al., Repurposing clinically available drugs and therapies for pathogenic targets to combat SARS‐CoV‐2, MedComm, doi:10.1002/mco2.254

Ceja-Gálvez et al., Severe COVID-19: Drugs and Clinical Trials, Journal of Clinical Medicine, doi:10.3390/jcm12082893

Kumar et al., COVID-19 therapeutics: Clinical application of repurposed drugs and futuristic strategies for target-based drug discovery, Genes & Diseases, doi:10.1016/j.gendis.2022.12.019

Astasio-Picado et al., Therapeutic Targets in the Virological Mechanism and in the Hyperinflammatory Response of Severe Acute Respiratory Syndrome Coronavirus Type 2 (SARS-CoV-2), Applied Sciences, doi:10.3390/app13074471

Bekheit et al., Potential RNA-dependent RNA polymerase inhibitors as prospective drug candidates for SARS-CoV-2, European Journal of Medicinal Chemistry, doi:10.1016/j.ejmech.2023.115292

Rudramurthy et al., In-Vitro Screening of Repurposed Drug Library against Severe Acute Respiratory Syndrome Coronavirus-2, Medical Research Archives, doi:10.18103/mra.v11i2.3595

Xu et al., An update on inhibitors targeting RNA-dependent RNA polymerase for COVID-19 treatment: Promises and challenges, Biochemical Pharmacology, doi:10.1016/j.bcp.2022.115279

Yakoot et al., Clinical utility of repurposing a short course of hepatitis C drugs for COVID19. A randomized controlled study, medRxiv, doi:10.1101/2022.07.18.22277477

Rani et al., Modern drug discovery applications for the identification of novel candidates for COVID-19 infections, Annals of Medicine and Surgery, doi:10.1016/j.amsu.2022.104125

Medhat et al., Sofosbuvir/Ledipasvir in Combination or Nitazoxanide Alone are Safe and Efficient Treatments for COVID-19 Infection: A Randomized Controlled Trial for Repurposing antivirals, Arab Journal of Gastroenterology, doi:10.1016/j.ajg.2022.04.005

Frediansyah et al., Antivirals for COVID-19: A critical review, Clinical Epidemiology and Global Health, doi:10.1016/j.cegh.2020.07.006

https://sites.google.com/view/coronabank/coronabank/classical-and-potential-antivirals

Cortés-Borra et al., Amantadine in the prevention of clinical symptoms caused by SARS-CoV-2, Pharmacological Reports, doi:10.1007/s43440-021-00231-5

Butterworth, R., Potential for the Repurposing of Adamantane Antivirals for COVID-19, Drugs in R&D, doi:10.1007/s40268-021-00351-6

Chober et al., Improved survival in intensive care unit in severe COVID-19 associated with amantadine use - retrospective study, International Journal of Infectious Diseases, doi:10.1016/j.ijid.2022.09.026

Fani et al., Targeting host calcium channels and viroporins: a promising strategy for SARS-CoV-2 therapy, Future Virology, doi:10.2217/fvl-2022-0203

Qu et al., A new integrated framework for the identification of potential virus–drug associations, Frontiers in Microbiology, doi:10.3389/fmicb.2023.1179414

Breitinger et al., Patch-clamp studies and cell viability assays suggest a distinct site for viroporin inhibitors on the E protein of SARS-CoV-2, Virology Journal, doi:10.1186/s12985-023-02095-y

Lundstrom et al., COVID-19 signalome: Potential therapeutic interventions, Cellular Signalling, doi:10.1016/j.cellsig.2022.110559

Fam et al., Channel activity of SARS-CoV-2 viroporin ORF3a inhibited by adamantanes and phenolic plant metabolites, Scientific Reports, doi:10.1038/s41598-023-31764-9

Frediansyah et al., Antivirals for COVID-19: A critical review, Clinical Epidemiology and Global Health, doi:10.1016/j.cegh.2020.07.006

https://www.nature.com/articles/s42003-021-02866-9

https://www.nature.com/articles/s41594-020-00536-8

https://www.researchsquare.com/article/rs-121743/v1

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8063946/

https://www.nature.com/articles/s41392-021-00558-8

https://pubmed.ncbi.nlm.nih.gov/33344913/

https://www.sciencedirect.com/science/article/pii/S092485792030162X

https://www.eurekaselect.com/183729/article

https://www.researchsquare.com/article/rs-493154/v1

https://sites.google.com/view/coronabank/coronabank/classical-and-potential-antivirals

Sa-ngiamsuntorn et al., Anti-SARS-CoV-2 Activity of Andrographis paniculata Extract and Its Major Component Andrographolide in Human Lung Epithelial Cells and Cytotoxicity Evaluation in Major Organ Cell Representatives, Journal of Natural Products, doi:10.1021/acs.jnatprod.0c01324

Wanaratna et al., Efficacy and safety of Andrographis paniculata extract in patients with mild COVID-19: A randomized controlled trial, medRxiv, doi:10.1101/2021.07.08.21259912

He et al., Recent advances towards natural plants as potential inhibitors of SARS-Cov-2 targets, Pharmaceutical Biology, doi:10.1080/13880209.2023.2241518

Akter et al., Plausibility of natural immunomodulators in the treatment of COVID-19–A comprehensive analysis and future recommendations, Heliyon, doi:10.1016/j.heliyon.2023.e17478

Rafiq et al., A Comprehensive Update of Various Attempts by Medicinal Chemists to Combat COVID-19 through Natural Products, Molecules, doi:10.3390/molecules28124860

Low et al., COVID-19 Therapeutic Potential of Natural Products, International Journal of Molecular Sciences, doi:10.3390/ijms24119589

Abou Baker et al., An overview on medicinal plants used for combating coronavirus: Current potentials and challenges, Journal of Agriculture and Food Research, doi:10.1016/j.jafr.2023.100632

Xue et al., Repurposing clinically available drugs and therapies for pathogenic targets to combat SARS‐CoV‐2, MedComm, doi:10.1002/mco2.254

Srivastava et al., A Brief Review on Medicinal Plants-At-Arms against COVID-19, Interdisciplinary Perspectives on Infectious Diseases, doi:10.1155/2023/7598307

Nguyen et al., The Potential of Ameliorating COVID-19 and Sequelae From Andrographis paniculata via Bioinformatics, Bioinformatics and Biology Insights, doi:10.1177/11779322221149622

Nasirzadeh et al., Inhibiting IL-6 During Cytokine Storm in COVID-19: Potential Role of Natural Products, MDPI AG, doi:10.20944/preprints202106.0131.v1

Guerra et al., Critical Review of Plant-Derived Compounds as Possible Inhibitors of SARS-CoV-2 Proteases: A Comparison with Experimentally Validated Molecules, ACS Omega, doi:10.1021/acsomega.2c05766

Jamalipour Soufi et al., Potential inhibitors of SARS-CoV-2: recent advances, Journal of Drug Targeting, doi:10.1080/1061186X.2020.1853736

Uma Reddy et al., Multifaceted role of plant derived small molecule inhibitors on replication cycle of sars-cov-2, Microbial Pathogenesis, doi:10.1016/j.micpath.2022.105512

Mukherjee et al., Role of medicinal plants in inhibiting SARS-CoV-2 and in the management of post-COVID-19 complications, Phytomedicine, doi:10.1016/j.phymed.2022.153930

https://www.researchgate.net/publication/373256147_A_Critical_Review_on_the_Potency_of_Phy..

https://sites.google.com/view/coronabank/coronabank/natural-compounds

http://journal.unhas.ac.id/index.php/ijoab/article/view/25284

https://www.sciencedirect.com/science/article/pii/S0223523421007066

Wang et al., Stand Up to Stand Out: Natural Dietary Polyphenols Curcumin, Resveratrol, and Gossypol as Potential Therapeutic Candidates against Severe Acute Respiratory Syndrome Coronavirus 2 Infection, Nutrients, doi:10.3390/nu15183885

Rafiq et al., A Comprehensive Update of Various Attempts by Medicinal Chemists to Combat COVID-19 through Natural Products, Molecules, doi:10.3390/molecules28124860

Mehyar, N., Coronaviruses SARS-CoV, MERS-CoV, and SARS-CoV-2 helicase inhibitors: A systematic review of in vitro studies, Journal of Virus Eradication, doi:10.1016/j.jve.2023.100327

Fu et al., The mechanism of TCM prevention and treatment of heavy COVID-19 based on data mining and network pharmacology, Drug Combination Therapy, doi:10.53388/DCT20230010

Alexova et al., Anti-COVID-19 Potential of Ellagic Acid and Polyphenols of Punica granatum L., Molecules, doi:10.3390/molecules28093772

Giordano et al., Food Plant Secondary Metabolites Antiviral Activity and Their Possible Roles in SARS-CoV-2 Treatment: An Overview, Molecules, doi:10.3390/molecules28062470

Bekheit et al., Potential RNA-dependent RNA polymerase inhibitors as prospective drug candidates for SARS-CoV-2, European Journal of Medicinal Chemistry, doi:10.1016/j.ejmech.2023.115292

Guo et al., Enhanced compound-protein binding affinity prediction by representing protein multimodal information via a coevolutionary strategy, Briefings in Bioinformatics, doi:10.1093/bib/bbac628

Guerra et al., Critical Review of Plant-Derived Compounds as Possible Inhibitors of SARS-CoV-2 Proteases: A Comparison with Experimentally Validated Molecules, ACS Omega, doi:10.1021/acsomega.2c05766

Sperry et al., Target-agnostic drug prediction integrated with medical record analysis uncovers differential associations of statins with increased survival in COVID-19 patients, PLOS Computational Biology, doi:10.1371/journal.pcbi.1011050 (Table 2)

Negru et al., Virtual Screening of Substances Used in the Treatment of SARS-CoV-2 Infection and Analysis of Compounds With Known Action on Structurally Similar Proteins From Other Viruses, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.113432

Qi et al., Discovery of TCMs and Derivatives Against the Main Protease of SARS-CoV-2 via High Throughput Screening, ADMET Analysis, and Inhibition Assay in Vitro, Journal of Molecular Structure, doi:10.1016/j.molstruc.2022.133709

Rani et al., Modern drug discovery applications for the identification of novel candidates for COVID-19 infections, Annals of Medicine and Surgery, doi:10.1016/j.amsu.2022.104125

https://pharmacia.pensoft.net/article/106534/download/pdf

https://sites.google.com/view/coronabank/coronabank/natural-compounds

https://pub.qu.edu.sa/index.php/journal/article/view/7719

https://themedicon.com/pdf/medicalsciences/MCMS-04-107.pdfandrographolide

https://www.mdpi.com/2304-8158/10/9/2084/htm

https://www.sciencedirect.com/science/article/pii/S0308814621026005

Hinks et al., Azithromycin versus standard care in patients with mild-to-moderate COVID-19 (ATOMIC2): an open-label, randomised trial, The Lancet Respiratory Medicine, doi:10.1016/S2213-2600(21)00263-0

Butler et al., Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial, The Lancet, doi:10.1016/S0140-6736(21)00461-X

Kushwaha et al., A comprehensive review on the global efforts on vaccines and repurposed drugs for combating COVID-19, European Journal of Medicinal Chemistry, doi:10.1016/j.ejmech.2023.115719

Oliver et al., Different drug approaches to COVID-19 treatment worldwide: an update of new drugs and drugs repositioning to fight against the novel coronavirus, Therapeutic Advances in Vaccines and Immunotherapy, doi:10.1177/25151355221144845

Xue et al., Repurposing clinically available drugs and therapies for pathogenic targets to combat SARS‐CoV‐2, MedComm, doi:10.1002/mco2.254

Islam et al., Molecular-evaluated and explainable drug repurposing for COVID-19 using ensemble knowledge graph embedding, Scientific Reports, doi:10.1038/s41598-023-30095-z

Kumar et al., COVID-19 therapeutics: Clinical application of repurposed drugs and futuristic strategies for target-based drug discovery, Genes & Diseases, doi:10.1016/j.gendis.2022.12.019

Homolak et al., Widely available lysosome targeting agents should be considered as potential therapy for COVID-19, International Journal of Antimicrobial Agents, doi:10.1016/j.ijantimicag.2020.106044

Mostafa et al., FDA-Approved Drugs with Potent In Vitro Antiviral Activity against Severe Acute Respiratory Syndrome Coronavirus 2, Pharmaceuticals, doi:10.3390/ph13120443

Raghav et al., Potential treatments of COVID-19: Drug repurposing and therapeutic interventions, Journal of Pharmacological Sciences, doi:10.1016/j.jphs.2023.02.004

Guo et al., Enhanced compound-protein binding affinity prediction by representing protein multimodal information via a coevolutionary strategy, Briefings in Bioinformatics, doi:10.1093/bib/bbac628

Supianto et al., Cluster-based text mining for extracting drug candidates for the prevention of COVID-19 from the biomedical literature, Journal of Taibah University Medical Sciences, doi:10.1016/j.jtumed.2022.12.015

Zeng et al., Repurpose Open Data to Discover Therapeutics for COVID-19 Using Deep Learning, Journal of Proteome Research, doi:10.1021/acs.jproteome.0c00316

Mousavi et al., Novel Drug Design for Treatment of COVID-19: A Systematic Review of Preclinical Studies, Canadian Journal of Infectious Diseases and Medical Microbiology, doi:10.1155/2022/2044282

Loucera et al., Real-world evidence with a retrospective cohort of 15,968 Andalusian COVID-19 hospitalized patients suggests 21 new effective treatments and one drug that increases death risk., medRxiv, doi:10.1101/2022.08.14.22278751

Monserrat Villatoro et al., A Case-Control of Patients with COVID-19 to Explore the Association of Previous Hospitalisation Use of Medication on the Mortality of COVID-19 Disease: A Propensity Score Matching Analysis, Pharmaceuticals, doi:10.3390/ph15010078

Sarkar et al., Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives, Frontiers in Pharmacology, doi:10.3389/fphar.2020.572870

https://sites.google.com/view/coronabank/coronabank/antimicrobials

Qu et al., A new integrated framework for the identification of potential virus–drug associations, Frontiers in Microbiology, doi:10.3389/fmicb.2023.1179414

Mushebenge et al., Assessing the Potential Contribution of in Silico Studies in Discovering Drug Candidates that Interact with Various SARS-CoV-2 Receptors, MDPI AG, doi:10.20944/preprints202308.0434.v1

Moura et al., Converging Paths: A Comprehensive Review of the Synergistic Approach between Complementary Medicines and Western Medicine in Addressing COVID-19 in 2020, BioMed, doi:10.3390/biomed3020025

Oliver et al., Different drug approaches to COVID-19 treatment worldwide: an update of new drugs and drugs repositioning to fight against the novel coronavirus, Therapeutic Advances in Vaccines and Immunotherapy, doi:10.1177/25151355221144845

Kumar et al., COVID-19 therapeutics: Clinical application of repurposed drugs and futuristic strategies for target-based drug discovery, Genes & Diseases, doi:10.1016/j.gendis.2022.12.019

Astasio-Picado et al., Therapeutic Targets in the Virological Mechanism and in the Hyperinflammatory Response of Severe Acute Respiratory Syndrome Coronavirus Type 2 (SARS-CoV-2), Applied Sciences, doi:10.3390/app13074471

Gautam et al., Promising Repurposed Antiviral Molecules to Combat SARS-CoV-2: A Review, Current Pharmaceutical Biotechnology, doi:10.2174/1389201024666230302113110

Raghav et al., Potential treatments of COVID-19: Drug repurposing and therapeutic interventions, Journal of Pharmacological Sciences, doi:10.1016/j.jphs.2023.02.004

Guo et al., Enhanced compound-protein binding affinity prediction by representing protein multimodal information via a coevolutionary strategy, Briefings in Bioinformatics, doi:10.1093/bib/bbac628

Chen et al., The exploration of phytocompounds theoretically combats SARS-CoV-2 pandemic against virus entry, viral replication and immune evasion, Journal of Infection and Public Health, doi:10.1016/j.jiph.2022.11.022

Zhong et al., Recent advances in small-molecular therapeutics for COVID-19, Precision Clinical Medicine, doi:10.1093/pcmedi/pbac024

Talluri, S., Molecular Docking and Virtual Screening Based Prediction of Drugs for COVID-19, Combinatorial Chemistry & High Throughput Screening, doi:10.2174/1386207323666200814132149

Jamalipour Soufi et al., Potential inhibitors of SARS-CoV-2: recent advances, Journal of Drug Targeting, doi:10.1080/1061186X.2020.1853736

Negru et al., Virtual Screening of Substances Used in the Treatment of SARS-CoV-2 Infection and Analysis of Compounds With Known Action on Structurally Similar Proteins From Other Viruses, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.113432

Rani et al., Modern drug discovery applications for the identification of novel candidates for COVID-19 infections, Annals of Medicine and Surgery, doi:10.1016/j.amsu.2022.104125

Sarkar et al., Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives, Frontiers in Pharmacology, doi:10.3389/fphar.2020.572870

Frediansyah et al., Antivirals for COVID-19: A critical review, Clinical Epidemiology and Global Health, doi:10.1016/j.cegh.2020.07.006

https://sites.google.com/view/coronabank/coronabank/classical-and-potential-antivirals

Wang et al., Stand Up to Stand Out: Natural Dietary Polyphenols Curcumin, Resveratrol, and Gossypol as Potential Therapeutic Candidates against Severe Acute Respiratory Syndrome Coronavirus 2 Infection, Nutrients, doi:10.3390/nu15183885

He et al., Recent advances towards natural plants as potential inhibitors of SARS-Cov-2 targets, Pharmaceutical Biology, doi:10.1080/13880209.2023.2241518

Mushebenge et al., Assessing the Potential Contribution of in Silico Studies in Discovering Drug Candidates that Interact with Various SARS-CoV-2 Receptors, MDPI AG, doi:10.20944/preprints202308.0434.v1

Abou Baker et al., An overview on medicinal plants used for combating coronavirus: Current potentials and challenges, Journal of Agriculture and Food Research, doi:10.1016/j.jafr.2023.100632

Toigo et al., Flavonoid as possible therapeutic targets against COVID-19: a scoping review of in silico studies, DARU Journal of Pharmaceutical Sciences, doi:10.1007/s40199-023-00461-3

unknown, u., Trainee Poster Honorable Mention Poster Abstracts Presented at the 123^rdAnnual Meeting of the American Association of Colleges of Pharmacy, July 23-27, 2022, American Journal of Pharmaceutical Education, doi:10.5688/ajpe9169

Srivastava et al., A Brief Review on Medicinal Plants-At-Arms against COVID-19, Interdisciplinary Perspectives on Infectious Diseases, doi:10.1155/2023/7598307

Giordano et al., Food Plant Secondary Metabolites Antiviral Activity and Their Possible Roles in SARS-CoV-2 Treatment: An Overview, Molecules, doi:10.3390/molecules28062470

Nasirzadeh et al., Inhibiting IL-6 During Cytokine Storm in COVID-19: Potential Role of Natural Products, MDPI AG, doi:10.20944/preprints202106.0131.v1

Bekheit et al., Potential RNA-dependent RNA polymerase inhibitors as prospective drug candidates for SARS-CoV-2, European Journal of Medicinal Chemistry, doi:10.1016/j.ejmech.2023.115292

Kawall et al., Inhibitory effect of phytochemicals towards SARS-CoV-2 papain like protease (PLpro) proteolytic and deubiquitinase activity, Frontiers in Chemistry, doi:10.3389/fchem.2022.1100460

Guerra et al., Critical Review of Plant-Derived Compounds as Possible Inhibitors of SARS-CoV-2 Proteases: A Comparison with Experimentally Validated Molecules, ACS Omega, doi:10.1021/acsomega.2c05766

Patel et al., Computational investigation of natural compounds as potential main protease (Mpro) inhibitors for SARS-CoV-2 virus, Computers in Biology and Medicine, doi:10.1016/j.compbiomed.2022.106318

BHARDWAJ et al., Molecular Docking Studies to Identify Promising Natural Inhibitors Targeting SARS-CoV-2 Nsp10-Nsp16 Protein Complex, Turkish Journal of Pharmaceutical Sciences, doi:10.4274/tjps.galenos.2021.56957

Uma Reddy et al., Multifaceted role of plant derived small molecule inhibitors on replication cycle of sars-cov-2, Microbial Pathogenesis, doi:10.1016/j.micpath.2022.105512

https://sites.google.com/view/coronabank/coronabank/natural-compounds

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10013230/pdf/42535_2023_Article_601.pdf/?tool..

https://digitalcommons.pcom.edu/research_day/research_day_GA_2022/researchGA2022/20/

Schloer et al., Targeting the endolysosomal host-SARS-CoV-2 interface by clinically licensed functional inhibitors of acid sphingomyelinase (FIASMA) including the antidepressant fluoxetine, Emerging Microbes & Infections, doi:10.1080/22221751.2020.1829082

Péricat et al., Antiviral and Anti-Inflammatory Activities of Fluoxetine in a SARS-CoV-2 Infection Mouse Model, International Journal of Molecular Sciences, doi:10.3390/ijms232113623

Sedighi et al., Efficacy and safety of adding fluoxetine to the treatment regimen of hospitalized patients with non‐critical COVID ‐19 pneumonia: A double‐blind randomized, placebo‐controlled clinical trial, Neuropsychopharmacology Reports, doi:10.1002/npr2.12327

Qu et al., A new integrated framework for the identification of potential virus–drug associations, Frontiers in Microbiology, doi:10.3389/fmicb.2023.1179414

Kushwaha et al., A comprehensive review on the global efforts on vaccines and repurposed drugs for combating COVID-19, European Journal of Medicinal Chemistry, doi:10.1016/j.ejmech.2023.115719

Chen et al., Metabolic alterations upon SARS-CoV-2 infection and potential therapeutic targets against coronavirus infection, Signal Transduction and Targeted Therapy, doi:10.1038/s41392-023-01510-8

Oliver et al., Different drug approaches to COVID-19 treatment worldwide: an update of new drugs and drugs repositioning to fight against the novel coronavirus, Therapeutic Advances in Vaccines and Immunotherapy, doi:10.1177/25151355221144845

Lenze et al., Beyond “Psychotropic”, The Journal of Clinical Psychiatry, doi:10.4088/jcp.22r14494

Homolak et al., Widely available lysosome targeting agents should be considered as potential therapy for COVID-19, International Journal of Antimicrobial Agents, doi:10.1016/j.ijantimicag.2020.106044

Sperry et al., Target-agnostic drug prediction integrated with medical record analysis uncovers differential associations of statins with increased survival in COVID-19 patients, PLOS Computational Biology, doi:10.1371/journal.pcbi.1011050 (Table 2)

Chen et al., Drug Repurposing Screen for Compounds Inhibiting the Cytopathic Effect of SARS-CoV-2, Frontiers in Pharmacology, doi:10.3389/fphar.2020.592737

MacFadden et al., Screening Large Population Health Databases for Potential COVID-19 Therapeutics: A Pharmacopeia-Wide Association Study (PWAS) of Commonly Prescribed Medications, Open Forum Infectious Diseases, doi:10.1093/ofid/ofac156

Issac et al., Improved And Optimized Drug Repurposing For The SARS-CoV-2 Pandemic, bioRxiv, doi:10.1101/2022.03.24.485618

https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3896539

https://www.nature.com/articles/s41598-021-85049-0

https://pubmed.ncbi.nlm.nih.gov/32975484/

https://sites.google.com/view/coronabank/coronabank/immunomodulatory-agents

Xu et al., Current understanding of nucleoside analogs inhibiting the SARS-CoV-2 RNA-dependent RNA polymerase, Computational and Structural Biotechnology Journal, doi:10.1016/j.csbj.2023.09.001

Kushwaha et al., A comprehensive review on the global efforts on vaccines and repurposed drugs for combating COVID-19, European Journal of Medicinal Chemistry, doi:10.1016/j.ejmech.2023.115719

Lundstrom et al., COVID-19 signalome: Potential therapeutic interventions, Cellular Signalling, doi:10.1016/j.cellsig.2022.110559

Oliver et al., Different drug approaches to COVID-19 treatment worldwide: an update of new drugs and drugs repositioning to fight against the novel coronavirus, Therapeutic Advances in Vaccines and Immunotherapy, doi:10.1177/25151355221144845

Xue et al., Repurposing clinically available drugs and therapies for pathogenic targets to combat SARS‐CoV‐2, MedComm, doi:10.1002/mco2.254

Astasio-Picado et al., Therapeutic Targets in the Virological Mechanism and in the Hyperinflammatory Response of Severe Acute Respiratory Syndrome Coronavirus Type 2 (SARS-CoV-2), Applied Sciences, doi:10.3390/app13074471

Bekheit et al., Potential RNA-dependent RNA polymerase inhibitors as prospective drug candidates for SARS-CoV-2, European Journal of Medicinal Chemistry, doi:10.1016/j.ejmech.2023.115292

Celik et al., In silico evaluation of potential inhibitory activity of remdesivir, favipiravir, ribavirin and galidesivir active forms on SARS-CoV-2 RNA polymerase, Molecular Diversity, doi:10.1007/s11030-021-10215-5

Shah et al., In silico studies on therapeutic agents for COVID-19: Drug repurposing approach, Life Sciences, doi:10.1016/j.lfs.2020.117652

Xu et al., An update on inhibitors targeting RNA-dependent RNA polymerase for COVID-19 treatment: Promises and challenges, Biochemical Pharmacology, doi:10.1016/j.bcp.2022.115279

Jamalipour Soufi et al., Potential inhibitors of SARS-CoV-2: recent advances, Journal of Drug Targeting, doi:10.1080/1061186X.2020.1853736

Rieder et al., A Review of In Silico Research, SARS-CoV-2, and Neurodegeneration: Focus on Papain-Like Protease, Neurotoxicity Research, doi:10.1007/s12640-022-00542-2

Negru et al., Virtual Screening of Substances Used in the Treatment of SARS-CoV-2 Infection and Analysis of Compounds With Known Action on Structurally Similar Proteins From Other Viruses, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.113432

Sarkar et al., Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives, Frontiers in Pharmacology, doi:10.3389/fphar.2020.572870

https://sites.google.com/view/coronabank/coronabank/classical-and-potential-antivirals

http://hdl.handle.net/10523/13405

Qu et al., A new integrated framework for the identification of potential virus–drug associations, Frontiers in Microbiology, doi:10.3389/fmicb.2023.1179414

He et al., Recent advances towards natural plants as potential inhibitors of SARS-Cov-2 targets, Pharmaceutical Biology, doi:10.1080/13880209.2023.2241518

Akter et al., Plausibility of natural immunomodulators in the treatment of COVID-19–A comprehensive analysis and future recommendations, Heliyon, doi:10.1016/j.heliyon.2023.e17478

Rafiq et al., A Comprehensive Update of Various Attempts by Medicinal Chemists to Combat COVID-19 through Natural Products, Molecules, doi:10.3390/molecules28124860

CHEN et al., Deciphering suppressive effects of Lianhua Qingwen Capsule on COVID-19 and synergistic effects of its major botanical drug pairs, Chinese Journal of Natural Medicines, doi:10.1016/S1875-5364(23)60455-8

Abou Baker et al., An overview on medicinal plants used for combating coronavirus: Current potentials and challenges, Journal of Agriculture and Food Research, doi:10.1016/j.jafr.2023.100632

Srivastava et al., A Brief Review on Medicinal Plants-At-Arms against COVID-19, Interdisciplinary Perspectives on Infectious Diseases, doi:10.1155/2023/7598307

Nayak et al., Prospects of Novel and Repurposed Immunomodulatory Drugs against Acute Respiratory Distress Syndrome (ARDS) Associated with COVID-19 Disease, Journal of Personalized Medicine, doi:10.3390/jpm13040664

Zhang et al., Herbal medicines exhibit a high affinity for ACE2 in treating COVID-19, BioScience Trends, doi:10.5582/bst.2022.01534

Guerra et al., Critical Review of Plant-Derived Compounds as Possible Inhibitors of SARS-CoV-2 Proteases: A Comparison with Experimentally Validated Molecules, ACS Omega, doi:10.1021/acsomega.2c05766

Bijelić et al., Phytochemicals in the Prevention and Treatment of SARS-CoV-2—Clinical Evidence, Antibiotics, doi:10.3390/antibiotics11111614

Choe et al., The Efficacy of Traditional Medicinal Plants in Modulating the Main Protease of SARS‐CoV‐2 and Cytokine Storm, Chemistry & Biodiversity, doi:10.1002/cbdv.202200655

Jamalipour Soufi et al., Potential inhibitors of SARS-CoV-2: recent advances, Journal of Drug Targeting, doi:10.1080/1061186X.2020.1853736

HELALİ et al., Natural substances and coronavirus: review and potential for the inhibition of SARS-CoV-2, Current Perspectives on Medicinal and Aromatic Plants (CUPMAP), doi:10.38093/cupmap.1029572

http://journal.unhas.ac.id/index.php/ijoab/article/view/25284

https://www.jcchems.com/index.php/JCCHEMS/article/download/1802/561

Jitobaom et al., Synergistic anti-SARS-CoV-2 activity of repurposed anti-parasitic drug combinations, BMC Pharmacology and Toxicology, doi:10.1186/s40360-022-00580-8

Mushebenge et al., Assessing the Potential Contribution of in Silico Studies in Discovering Drug Candidates that Interact with Various SARS-CoV-2 Receptors, MDPI AG, doi:10.20944/preprints202308.0434.v1

Low et al., COVID-19 Therapeutic Potential of Natural Products, International Journal of Molecular Sciences, doi:10.3390/ijms24119589

Wang et al., Inflammasomes: a rising star on the horizon of COVID-19 pathophysiology, Frontiers in Immunology, doi:10.3389/fimmu.2023.1185233

Oliver et al., Different drug approaches to COVID-19 treatment worldwide: an update of new drugs and drugs repositioning to fight against the novel coronavirus, Therapeutic Advances in Vaccines and Immunotherapy, doi:10.1177/25151355221144845

Wang et al., Repurposing Drugs for the Treatment of COVID-19 and Its Cardiovascular Manifestations, Circulation Research, doi:10.1161/circresaha.122.321879

Mostafa et al., FDA-Approved Drugs with Potent In Vitro Antiviral Activity against Severe Acute Respiratory Syndrome Coronavirus 2, Pharmaceuticals, doi:10.3390/ph13120443

Zeng et al., Repurpose Open Data to Discover Therapeutics for COVID-19 Using Deep Learning, Journal of Proteome Research, doi:10.1021/acs.jproteome.0c00316

Wang et al., Screening Potential Drugs for COVID-19 Based on Bound Nuclear Norm Regularization, Frontiers in Genetics, doi:10.3389/fgene.2021.749256

Arshad et al., Prioritization of Anti‐SARS‐Cov‐2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics, Clinical Pharmacology & Therapeutics, doi:10.1002/cpt.1909

Sperry et al., Target-agnostic drug prediction integrated with medical record analysis uncovers differential associations of statins with increased survival in COVID-19 patients, PLOS Computational Biology, doi:10.1371/journal.pcbi.1011050 (Table 2)

Gassen et al., SARS-CoV-2-mediated dysregulation of metabolism and autophagy uncovers host-targeting antivirals, Nature Communications, doi:10.1038/s41467-021-24007-w

Basu et al., Therapeutics for COVID-19 and post COVID-19 complications: An update, Current Research in Pharmacology and Drug Discovery, doi:10.1016/j.crphar.2022.100086

Mirabelli et al., Morphological cell profiling of SARS-CoV-2 infection identifies drug repurposing candidates for COVID-19, Proceedings of the National Academy of Sciences, doi:10.1073/pnas.2105815118

https://www.sciencedirect.com/science/article/pii/S2049080121007299doi:10.1111/bph.15843

https://sites.google.com/view/coronabank/coronabank/antimicrobials

Yuan et al., The role of cell death in SARS-CoV-2 infection, Signal Transduction and Targeted Therapy, doi:10.1038/s41392-023-01580-8

Khan et al., Possible therapeutic targets for SARS-CoV-2 infection and COVID-19, Journal of Allergy & Infectious Diseases, doi:10.46439/allergy.2.028

Mushebenge et al., Assessing the Potential Contribution of in Silico Studies in Discovering Drug Candidates that Interact with Various SARS-CoV-2 Receptors, MDPI AG, doi:10.20944/preprints202308.0434.v1

Gudima et al., Antiviral Therapy of COVID-19, International Journal of Molecular Sciences, doi:10.3390/ijms24108867

Wang et al., Inflammasomes: a rising star on the horizon of COVID-19 pathophysiology, Frontiers in Immunology, doi:10.3389/fimmu.2023.1185233

Oliver et al., Different drug approaches to COVID-19 treatment worldwide: an update of new drugs and drugs repositioning to fight against the novel coronavirus, Therapeutic Advances in Vaccines and Immunotherapy, doi:10.1177/25151355221144845

Xue et al., Repurposing clinically available drugs and therapies for pathogenic targets to combat SARS‐CoV‐2, MedComm, doi:10.1002/mco2.254

Pati et al., Drug discovery through Covid-19 genome sequencing with siamese graph convolutional neural network, Multimedia Tools and Applications, doi:10.1007/s11042-023-15270-8

Ceja-Gálvez et al., Severe COVID-19: Drugs and Clinical Trials, Journal of Clinical Medicine, doi:10.3390/jcm12082893

Nayak et al., Prospects of Novel and Repurposed Immunomodulatory Drugs against Acute Respiratory Distress Syndrome (ARDS) Associated with COVID-19 Disease, Journal of Personalized Medicine, doi:10.3390/jpm13040664

Kumar et al., COVID-19 therapeutics: Clinical application of repurposed drugs and futuristic strategies for target-based drug discovery, Genes & Diseases, doi:10.1016/j.gendis.2022.12.019

Astasio-Picado et al., Therapeutic Targets in the Virological Mechanism and in the Hyperinflammatory Response of Severe Acute Respiratory Syndrome Coronavirus Type 2 (SARS-CoV-2), Applied Sciences, doi:10.3390/app13074471

Raghav et al., Potential treatments of COVID-19: Drug repurposing and therapeutic interventions, Journal of Pharmacological Sciences, doi:10.1016/j.jphs.2023.02.004

Basu et al., Therapeutics for COVID-19 and post COVID-19 complications: An update, Current Research in Pharmacology and Drug Discovery, doi:10.1016/j.crphar.2022.100086

Heimfarth et al., Drug repurposing and cytokine management in response to COVID-19: A review, International Immunopharmacology, doi:10.1016/j.intimp.2020.106947

https://www.mdpi.com/2571-841X/6/4/45

Yu et al., The first Chinese oral anti-COVID-19 drug Azvudine launched, The Innovation, doi:10.1016/j.xinn.2022.100321

Shen et al., Real-world effectiveness of Azvudine in hospitalized patients with COVID-19: a retrospective cohort study, medRxiv, doi:10.1101/2023.01.23.23284899

da Silva et al., Serial viral load analysis by DDPCR to evaluate FNC efficacy and safety in the treatment of mild cases of COVID-19, Frontiers in Medicine, doi:10.3389/fmed.2023.1143485

Sun et al., Oral Azvudine for hospitalised patients with COVID-19 and pre-existing conditions: a retrospective cohort study, eClinicalMedicine, doi:10.1016/j.eclinm.2023.101981

Zhu, K., Efficacy and safety evaluation of Azvudine in the prospective treatment of COVID-19 based on four phase III clinical trials, Frontiers in Pharmacology, doi:10.3389/fphar.2023.1228548

Moura et al., Converging Paths: A Comprehensive Review of the Synergistic Approach between Complementary Medicines and Western Medicine in Addressing COVID-19 in 2020, BioMed, doi:10.3390/biomed3020025

Oliver et al., Different drug approaches to COVID-19 treatment worldwide: an update of new drugs and drugs repositioning to fight against the novel coronavirus, Therapeutic Advances in Vaccines and Immunotherapy, doi:10.1177/25151355221144845

Yang et al., Bench-to-bedside: Innovation of small molecule anti-SARS-CoV-2 drugs in China, European Journal of Medicinal Chemistry, doi:10.1016/j.ejmech.2023.115503

Xue et al., Repurposing clinically available drugs and therapies for pathogenic targets to combat SARS‐CoV‐2, MedComm, doi:10.1002/mco2.254

Săndulescu et al., Therapeutic developments for SARS-CoV-2 infection—Molecular mechanisms of action of antivirals and strategies for mitigating resistance in emerging variants in clinical practice, Frontiers in Microbiology, doi:10.3389/fmicb.2023.1132501

Zhong et al., Recent advances in small-molecular therapeutics for COVID-19, Precision Clinical Medicine, doi:10.1093/pcmedi/pbac024

Sarkar et al., Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives, Frontiers in Pharmacology, doi:10.3389/fphar.2020.572870

Frediansyah et al., Antivirals for COVID-19: A critical review, Clinical Epidemiology and Global Health, doi:10.1016/j.cegh.2020.07.006

https://www.trialsitenews.com/a/new-oral-drug-for-covid-19first-indigenous-chinese-drug-ap..

https://sites.google.com/view/coronabank/coronabank/classical-and-potential-antivirals

Farkaš et al., A Tale of Two Proteases: MPro and TMPRSS2 as Targets for COVID-19 Therapies, Pharmaceuticals, doi:10.3390/ph16060834

Pang et al., The research progress of SARS-CoV-2 main protease inhibitors from 2020 to 2022, European Journal of Medicinal Chemistry, doi:10.1016/j.ejmech.2023.115491

Wang et al., Repurposing Drugs for the Treatment of COVID-19 and Its Cardiovascular Manifestations, Circulation Research, doi:10.1161/circresaha.122.321879

Xue et al., Repurposing clinically available drugs and therapies for pathogenic targets to combat SARS‐CoV‐2, MedComm, doi:10.1002/mco2.254

Kronenberger et al., COVID-19 therapeutics: Small-molecule drug development targeting SARS-CoV-2 main protease, Drug Discovery Today, doi:10.1016/j.drudis.2023.103579

Wu et al., Polyphenols as alternative treatments of COVID-19, Computational and Structural Biotechnology Journal, doi:10.1016/j.csbj.2021.09.022

Guo et al., Enhanced compound-protein binding affinity prediction by representing protein multimodal information via a coevolutionary strategy, Briefings in Bioinformatics, doi:10.1093/bib/bbac628

Gantla et al., Repurposing of drugs for combined treatment of COVID-19 cytokine storm using machine learning, Medicine in Drug Discovery, doi:10.1016/j.medidd.2022.100148

Li et al., Potential clinical drugs as covalent inhibitors of the priming proteases of the spike protein of SARS-CoV-2, Computational and Structural Biotechnology Journal, doi:10.1016/j.csbj.2020.08.016

Ke et al., Artificial intelligence approach fighting COVID-19 with repurposing drugs, Biomedical Journal, doi:10.1016/j.bj.2020.05.001

Mody et al., Identification of 3-chymotrypsin like protease (3CLPro) inhibitors as potential anti-SARS-CoV-2 agents, Communications Biology, doi:10.1038/s42003-020-01577-x

Jamalipour Soufi et al., Potential inhibitors of SARS-CoV-2: recent advances, Journal of Drug Targeting, doi:10.1080/1061186X.2020.1853736

Negru et al., Virtual Screening of Substances Used in the Treatment of SARS-CoV-2 Infection and Analysis of Compounds With Known Action on Structurally Similar Proteins From Other Viruses, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.113432

Davarpanah et al., Combination of Spironolactone and Sitagliptin Improves Clinical Outcomes of Outpatients with COVID-19: An Observational Study, medRxiv, doi:10.1101/2022.01.21.22269322

https://sites.google.com/view/coronabank/coronabank/classical-and-potential-antivirals

He et al., Recent advances towards natural plants as potential inhibitors of SARS-Cov-2 targets, Pharmaceutical Biology, doi:10.1080/13880209.2023.2241518

Rafiq et al., A Comprehensive Update of Various Attempts by Medicinal Chemists to Combat COVID-19 through Natural Products, Molecules, doi:10.3390/molecules28124860

Abou Baker et al., An overview on medicinal plants used for combating coronavirus: Current potentials and challenges, Journal of Agriculture and Food Research, doi:10.1016/j.jafr.2023.100632

Toigo et al., Flavonoid as possible therapeutic targets against COVID-19: a scoping review of in silico studies, DARU Journal of Pharmaceutical Sciences, doi:10.1007/s40199-023-00461-3

Strodel et al., High Throughput Virtual Screening to Discover Inhibitors of the Main Protease of the Coronavirus SARS-CoV-2, MDPI AG, doi:10.20944/preprints202004.0161.v1

Rahman et al., In silico investigation and potential therapeutic approaches of natural products for COVID-19: Computer-aided drug design perspective, Frontiers in Cellular and Infection Microbiology, doi:10.3389/fcimb.2022.929430

Guerra et al., Critical Review of Plant-Derived Compounds as Possible Inhibitors of SARS-CoV-2 Proteases: A Comparison with Experimentally Validated Molecules, ACS Omega, doi:10.1021/acsomega.2c05766

Glaab et al., Pharmacophore Model for SARS-CoV-2 3CLpro Small-Molecule Inhibitors and in Vitro Experimental Validation of Computationally Screened Inhibitors, Journal of Chemical Information and Modeling, doi:10.1021/acs.jcim.1c00258

Chen et al., The exploration of phytocompounds theoretically combats SARS-CoV-2 pandemic against virus entry, viral replication and immune evasion, Journal of Infection and Public Health, doi:10.1016/j.jiph.2022.11.022

Yang et al., Potential medicinal plants involved in inhibiting 3CLpro activity: A practical alternate approach to combating COVID-19, Journal of Integrative Medicine, doi:10.1016/j.joim.2022.08.001

Negru et al., Virtual Screening of Substances Used in the Treatment of SARS-CoV-2 Infection and Analysis of Compounds With Known Action on Structurally Similar Proteins From Other Viruses, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.113432

Mukherjee et al., Role of medicinal plants in inhibiting SARS-CoV-2 and in the management of post-COVID-19 complications, Phytomedicine, doi:10.1016/j.phymed.2022.153930

https://www.researchgate.net/publication/373256147_A_Critical_Review_on_the_Potency_of_Phy..

https://sites.google.com/view/coronabank/coronabank/natural-compounds

Dhar et al., Doxycycline for the prevention of progression of COVID-19 to severe disease requiring intensive care unit (ICU) admission: A randomized, controlled, open-label, parallel group trial (DOXPREVENT.ICU), PLOS ONE, doi:10.1371/journal.pone.0280745

Al Sulaiman et al., Doxycycline’s Potential Role in Reducing Thrombosis and Mortality in Critically Ill Patients With COVID-19: A Multicenter Cohort Study, Clinical and Applied Thrombosis/Hemostasis, doi:10.1177/10760296231177017

Qu et al., A new integrated framework for the identification of potential virus–drug associations, Frontiers in Microbiology, doi:10.3389/fmicb.2023.1179414

Khan et al., Possible therapeutic targets for SARS-CoV-2 infection and COVID-19, Journal of Allergy & Infectious Diseases, doi:10.46439/allergy.2.028

Kushwaha et al., A comprehensive review on the global efforts on vaccines and repurposed drugs for combating COVID-19, European Journal of Medicinal Chemistry, doi:10.1016/j.ejmech.2023.115719

Oliver et al., Different drug approaches to COVID-19 treatment worldwide: an update of new drugs and drugs repositioning to fight against the novel coronavirus, Therapeutic Advances in Vaccines and Immunotherapy, doi:10.1177/25151355221144845

Wu et al., Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods, Acta Pharmaceutica Sinica B, doi:10.1016/j.apsb.2020.02.008

Taguchi et al., A new advanced in silico drug discovery method for novel coronavirus (SARS-CoV-2) with tensor decomposition-based unsupervised feature extraction, PLOS ONE, doi:10.1371/journal.pone.0238907

Mostafa et al., FDA-Approved Drugs with Potent In Vitro Antiviral Activity against Severe Acute Respiratory Syndrome Coronavirus 2, Pharmaceuticals, doi:10.3390/ph13120443

Rehman et al., In Silico molecular docking and dynamic analysis of natural compounds against major non-structural proteins of SARS-COV-2, Journal of Biomolecular Structure and Dynamics, doi:10.1080/07391102.2022.2139766

Mousavi et al., Novel Drug Design for Treatment of COVID-19: A Systematic Review of Preclinical Studies, Canadian Journal of Infectious Diseases and Medical Microbiology, doi:10.1155/2022/2044282

Tsuji, M., Virtual Screening and Quantum Chemistry Analysis for SARS-CoV-2 RNA-Dependent RNA Polymerase Using the ChEMBL Database: Reproduction of the Remdesivir-RTP and Favipiravir-RTP Binding Modes Obtained from Cryo-EM Experiments with High Binding Affinity, International Journal of Molecular Sciences, doi:10.3390/ijms231911009

Nandi et al., Repurposing of Drugs and HTS to Combat SARS-CoV-2 Main Protease Utilizing Structure-Based Molecular Docking, Letters in Drug Design & Discovery, doi:10.2174/1570180818666211007111105

Sarkar et al., Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives, Frontiers in Pharmacology, doi:10.3389/fphar.2020.572870

Spiegel et al., Computational investigation on the antioxidant activities and on the Mpro SARS-CoV-2 non-covalent inhibition of isorhamnetin, Frontiers in Chemistry, doi:10.3389/fchem.2023.1122880

Low et al., COVID-19 Therapeutic Potential of Natural Products, International Journal of Molecular Sciences, doi:10.3390/ijms24119589

Corbo et al., Inhibitory potential of phytochemicals on five SARS-CoV-2 proteins: in silico evaluation of endemic plants of Bosnia and Herzegovina, Biotechnology & Biotechnological Equipment, doi:10.1080/13102818.2023.2222196

Akanchise et al., Ginkgo Biloba and Long COVID: In Vivo and In Vitro Models for the Evaluation of Nanotherapeutic Efficacy, Pharmaceutics, doi:10.3390/pharmaceutics15051562

Bogoyavlenskiy et al., Computer Analysis of the Inhibition of ACE2 by Flavonoids and Identification of Their Potential Antiviral Pharmacophore Site, Molecules, doi:10.3390/molecules28093766

Giordano et al., Food Plant Secondary Metabolites Antiviral Activity and Their Possible Roles in SARS-CoV-2 Treatment: An Overview, Molecules, doi:10.3390/molecules28062470

Yang et al., A Comprehensive Review of Natural Flavonoids with Anti-SARS-CoV-2 Activity, Molecules, doi:10.3390/molecules28062735

Ibeh et al., Computational studies of potential antiviral compounds from some selected Nigerian medicinal plants against SARS-CoV-2 proteins, Informatics in Medicine Unlocked, doi:10.1016/j.imu.2023.101230

Heleno et al., Plant Extracts and SARS-CoV-2: Research and Applications, Life, doi:10.3390/life13020386

Guerra et al., Critical Review of Plant-Derived Compounds as Possible Inhibitors of SARS-CoV-2 Proteases: A Comparison with Experimentally Validated Molecules, ACS Omega, doi:10.1021/acsomega.2c05766

de Matos et al., Bioactive compounds as potential angiotensin-converting enzyme II inhibitors against COVID-19: a scoping review, Inflammation Research, doi:10.1007/s00011-022-01642-7

Shahhamzehei et al., In Silico and In Vitro Identification of Pan-Coronaviral Main Protease Inhibitors from a Large Natural Product Library, Pharmaceuticals, doi:10.3390/ph15030308

http://journal.unhas.ac.id/index.php/ijoab/article/view/25284

https://www.sciencedirect.com/science/article/pii/S0223523421007066

Foo et al., HIV protease inhibitors Nelfinavir and Lopinavir/Ritonavir markedly improve lung pathology in SARS-CoV-2-infected Syrian hamsters despite lack of an antiviral effect, Antiviral Research, doi:10.1016/j.antiviral.2022.105311

Xu et al., Preventive and therapeutic benefits of nelfinavir in rhesus macaques and human beings infected with SARS-CoV-2, Signal Transduction and Targeted Therapy, doi:10.1038/s41392-023-01429-0

Mushebenge et al., Assessing the Potential Contribution of in Silico Studies in Discovering Drug Candidates that Interact with Various SARS-CoV-2 Receptors, MDPI AG, doi:10.20944/preprints202308.0434.v1

Mittal et al., Identification of potential molecules against COVID-19 main protease through structure-guided virtual screening approach, Journal of Biomolecular Structure and Dynamics, doi:10.1080/07391102.2020.1768151

AKBABA et al., Phytochemicals of Hibiscus sabdariffa with Therapeutic Potential against SARS-CoV-2: A Molecular Docking Study, Journal of the Institute of Science and Technology, doi:10.21597/jist.1187616

Wang et al., Repurposing Drugs for the Treatment of COVID-19 and Its Cardiovascular Manifestations, Circulation Research, doi:10.1161/circresaha.122.321879

Xue et al., Repurposing clinically available drugs and therapies for pathogenic targets to combat SARS‐CoV‐2, MedComm, doi:10.1002/mco2.254

Ali et al., Computational Prediction of Nigella sativa Compounds as Potential Drug Agents for Targeting Spike Protein of SARS-CoV-2, Pakistan BioMedical Journal, doi:10.54393/pbmj.v6i3.853

Khaerunnisa et al., Potential Inhibitor of COVID-19 Main Protease (Mpro) From Several Medicinal Plant Compounds by Molecular Docking Study, MDPI AG, doi:10.20944/preprints202003.0226.v1

Kanhed et al., Identification of potential Mpro inhibitors for the treatment of COVID-19 by using systematic virtual screening approach, Molecular Diversity, doi:10.1007/s11030-020-10130-1

Gidari et al., Nelfinavir: An Old Ally in the COVID-19 Fight?, Microorganisms, doi:10.3390/microorganisms10122471

Arshad et al., Prioritization of Anti‐SARS‐Cov‐2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics, Clinical Pharmacology & Therapeutics, doi:10.1002/cpt.1909

Frediansyah et al., Antivirals for COVID-19: A critical review, Clinical Epidemiology and Global Health, doi:10.1016/j.cegh.2020.07.006

https://sites.google.com/view/coronabank/coronabank/classical-and-potential-antivirals

Ruan et al., Virtual high-throughput screening: Potential inhibitors targeting aminopeptidase N (CD13) and PIKfyve for SARS-CoV-2, Open Life Sciences, doi:10.1515/biol-2022-0637

Mittal et al., Identification of potential molecules against COVID-19 main protease through structure-guided virtual screening approach, Journal of Biomolecular Structure and Dynamics, doi:10.1080/07391102.2020.1768151

Moura et al., Converging Paths: A Comprehensive Review of the Synergistic Approach between Complementary Medicines and Western Medicine in Addressing COVID-19 in 2020, BioMed, doi:10.3390/biomed3020025

Ramírez Salinas et al., In Silico Screening of Drugs That Target Different Forms of E Protein for Potential Treatment of COVID-19, Pharmaceuticals, doi:10.3390/ph16020296

Wu et al., In silico identification of drug candidates against COVID-19, Informatics in Medicine Unlocked, doi:10.1016/j.imu.2020.100461

Wu et al., Polyphenols as alternative treatments of COVID-19, Computational and Structural Biotechnology Journal, doi:10.1016/j.csbj.2021.09.022

Kanhed et al., Identification of potential Mpro inhibitors for the treatment of COVID-19 by using systematic virtual screening approach, Molecular Diversity, doi:10.1007/s11030-020-10130-1

Anju et al., Virtual screening of quinoline derived library for SARS-COV-2 targeting viral entry and replication, Journal of Biomolecular Structure and Dynamics, doi:10.1080/07391102.2021.1913228

Mousavi et al., Novel Drug Design for Treatment of COVID-19: A Systematic Review of Preclinical Studies, Canadian Journal of Infectious Diseases and Medical Microbiology, doi:10.1155/2022/2044282

Talluri, S., Molecular Docking and Virtual Screening Based Prediction of Drugs for COVID-19, Combinatorial Chemistry & High Throughput Screening, doi:10.2174/1386207323666200814132149

Jamalipour Soufi et al., Potential inhibitors of SARS-CoV-2: recent advances, Journal of Drug Targeting, doi:10.1080/1061186X.2020.1853736

Negru et al., Virtual Screening of Substances Used in the Treatment of SARS-CoV-2 Infection and Analysis of Compounds With Known Action on Structurally Similar Proteins From Other Viruses, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.113432

Frediansyah et al., Antivirals for COVID-19: A critical review, Clinical Epidemiology and Global Health, doi:10.1016/j.cegh.2020.07.006

https://sites.google.com/view/coronabank/coronabank/classical-and-potential-antivirals

Chaves et al., Atazanavir is a competitive inhibitor of SARS-CoV-2 Mpro, impairing variants replication in vitro and in vivo, bioRxiv, doi:10.1101/2021.11.24.469775

Chaves et al., Atazanavir Is a Competitive Inhibitor of SARS-CoV-2 Mpro, Impairing Variants Replication In Vitro and In Vivo, Pharmaceuticals, doi:10.3390/ph15010021

Mushebenge et al., Assessing the Potential Contribution of in Silico Studies in Discovering Drug Candidates that Interact with Various SARS-CoV-2 Receptors, MDPI AG, doi:10.20944/preprints202308.0434.v1

Mittal et al., Identification of potential molecules against COVID-19 main protease through structure-guided virtual screening approach, Journal of Biomolecular Structure and Dynamics, doi:10.1080/07391102.2020.1768151

Oliver et al., Different drug approaches to COVID-19 treatment worldwide: an update of new drugs and drugs repositioning to fight against the novel coronavirus, Therapeutic Advances in Vaccines and Immunotherapy, doi:10.1177/25151355221144845

Kronenberger et al., COVID-19 therapeutics: Small-molecule drug development targeting SARS-CoV-2 main protease, Drug Discovery Today, doi:10.1016/j.drudis.2023.103579

Gautam et al., Promising Repurposed Antiviral Molecules to Combat SARS-CoV-2: A Review, Current Pharmaceutical Biotechnology, doi:10.2174/1389201024666230302113110

Beck et al., Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model, Computational and Structural Biotechnology Journal, doi:10.1016/j.csbj.2020.03.025

Zhong et al., Recent advances in small-molecular therapeutics for COVID-19, Precision Clinical Medicine, doi:10.1093/pcmedi/pbac024

Arshad et al., Prioritization of Anti‐SARS‐Cov‐2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics, Clinical Pharmacology & Therapeutics, doi:10.1002/cpt.1909

Frediansyah et al., Antivirals for COVID-19: A critical review, Clinical Epidemiology and Global Health, doi:10.1016/j.cegh.2020.07.006

Heimfarth et al., Drug repurposing and cytokine management in response to COVID-19: A review, International Immunopharmacology, doi:10.1016/j.intimp.2020.106947

https://sites.google.com/view/coronabank/coronabank/classical-and-potential-antivirals

Qu et al., A new integrated framework for the identification of potential virus–drug associations, Frontiers in Microbiology, doi:10.3389/fmicb.2023.1179414

He et al., Recent advances towards natural plants as potential inhibitors of SARS-Cov-2 targets, Pharmaceutical Biology, doi:10.1080/13880209.2023.2241518

Akter et al., Plausibility of natural immunomodulators in the treatment of COVID-19–A comprehensive analysis and future recommendations, Heliyon, doi:10.1016/j.heliyon.2023.e17478

Rafiq et al., A Comprehensive Update of Various Attempts by Medicinal Chemists to Combat COVID-19 through Natural Products, Molecules, doi:10.3390/molecules28124860

Xie et al., Exploring the mechanism of Ge-Gen-Qin-Lian-Wan against Novel coronavirus pneumonia based on network pharmacology and molecular docking techniques, Medical Data Mining, doi:10.53388/MDM202306016

Abou Baker et al., An overview on medicinal plants used for combating coronavirus: Current potentials and challenges, Journal of Agriculture and Food Research, doi:10.1016/j.jafr.2023.100632

Supianto et al., Cluster-based text mining for extracting drug candidates for the prevention of COVID-19 from the biomedical literature, Journal of Taibah University Medical Sciences, doi:10.1016/j.jtumed.2022.12.015

Qi et al., Discovery of TCMs and Derivatives Against the Main Protease of SARS-CoV-2 via High Throughput Screening, ADMET Analysis, and Inhibition Assay in Vitro, Journal of Molecular Structure, doi:10.1016/j.molstruc.2022.133709

Srivastava et al., The role of herbal plants in the inhibition of SARS-CoV-2 main protease: A computational approach, Journal of the Indian Chemical Society, doi:10.1016/j.jics.2022.100640

Ali et al., Implication of in silico studies in the search for novel inhibitors against SARS‐CoV‐2, Archiv der Pharmazie, doi:10.1002/ardp.202100360

Mukherjee et al., Role of medicinal plants in inhibiting SARS-CoV-2 and in the management of post-COVID-19 complications, Phytomedicine, doi:10.1016/j.phymed.2022.153930

https://sites.google.com/view/coronabank/coronabank/natural-compounds

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10013230/pdf/42535_2023_Article_601.pdf/?tool..

Yuan et al., The role of cell death in SARS-CoV-2 infection, Signal Transduction and Targeted Therapy, doi:10.1038/s41392-023-01580-8

Augustin et al., Drug repurposing for COVID-19: current evidence from randomized controlled adaptive platform trials and living systematic reviews, British Medical Bulletin, doi:10.1093/bmb/ldac037

Kushwaha et al., A comprehensive review on the global efforts on vaccines and repurposed drugs for combating COVID-19, European Journal of Medicinal Chemistry, doi:10.1016/j.ejmech.2023.115719

Oliver et al., Different drug approaches to COVID-19 treatment worldwide: an update of new drugs and drugs repositioning to fight against the novel coronavirus, Therapeutic Advances in Vaccines and Immunotherapy, doi:10.1177/25151355221144845

Wang et al., Repurposing Drugs for the Treatment of COVID-19 and Its Cardiovascular Manifestations, Circulation Research, doi:10.1161/circresaha.122.321879

Xue et al., Repurposing clinically available drugs and therapies for pathogenic targets to combat SARS‐CoV‐2, MedComm, doi:10.1002/mco2.254

Esam et al., In silico investigation of the therapeutic and prophylactic potential of medicinal substances bearing guanidine moieties against COVID-19, Chemical Papers, doi:10.1007/s11696-022-02528-y

Săndulescu et al., Therapeutic developments for SARS-CoV-2 infection—Molecular mechanisms of action of antivirals and strategies for mitigating resistance in emerging variants in clinical practice, Frontiers in Microbiology, doi:10.3389/fmicb.2023.1132501

Ravindran et al., Discovery of host-directed modulators of virus infection by probing the SARS-CoV-2–host protein–protein interaction network, Briefings in Bioinformatics, doi:10.1093/bib/bbac456

Tomazou et al., Multi-omics data integration and network-based analysis drives a multiplex drug repurposing approach to a shortlist of candidate drugs against COVID-19, Briefings in Bioinformatics, doi:10.1093/bib/bbab114

Chen et al., Drug Repurposing Screen for Compounds Inhibiting the Cytopathic Effect of SARS-CoV-2, Frontiers in Pharmacology, doi:10.3389/fphar.2020.592737

Sarkar et al., Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives, Frontiers in Pharmacology, doi:10.3389/fphar.2020.572870

https://sites.google.com/view/coronabank/coronabank/immunomodulatory-agents

He et al., Recent advances towards natural plants as potential inhibitors of SARS-Cov-2 targets, Pharmaceutical Biology, doi:10.1080/13880209.2023.2241518

Rafiq et al., A Comprehensive Update of Various Attempts by Medicinal Chemists to Combat COVID-19 through Natural Products, Molecules, doi:10.3390/molecules28124860

Low et al., COVID-19 Therapeutic Potential of Natural Products, International Journal of Molecular Sciences, doi:10.3390/ijms24119589

Fan et al., Pharmaceutical approaches for COVID-19: An update on current therapeutic opportunities, Acta Pharmaceutica, doi:10.2478/acph-2023-0014

Abou Baker et al., An overview on medicinal plants used for combating coronavirus: Current potentials and challenges, Journal of Agriculture and Food Research, doi:10.1016/j.jafr.2023.100632

Trivedi et al., Antiviral and Anti-Inflammatory Plant-Derived Bioactive Compounds and Their Potential Use in the Treatment of COVID-19-Related Pathologies, Journal of Xenobiotics, doi:10.3390/jox12040020

Chapola et al., A COMPARATIVE STUDY OF COVID-19 TRANSCRIPTIONAL SIGNATURES BETWEEN CLINICAL SAMPLES AND PRECLINICAL CELL MODELS IN THE SEARCH FOR DISEASE MASTER REGULATORS AND DRUG REPOSITIONING CANDIDATES, Virus Research, doi:10.1016/j.virusres.2023.199053

Bijelić et al., Phytochemicals in the Prevention and Treatment of SARS-CoV-2—Clinical Evidence, Antibiotics, doi:10.3390/antibiotics11111614

Xu et al., An update on inhibitors targeting RNA-dependent RNA polymerase for COVID-19 treatment: Promises and challenges, Biochemical Pharmacology, doi:10.1016/j.bcp.2022.115279

Zhang et al., A cell-based large-scale screening of natural compounds for inhibitors of SARS-CoV-2, Signal Transduction and Targeted Therapy, doi:10.1038/s41392-020-00343-z

https://www.researchgate.net/publication/373256147_A_Critical_Review_on_the_Potency_of_Phy..

https://sites.google.com/view/coronabank/coronabank/natural-compounds

https://www.sciencedirect.com/science/article/pii/S0924857923001723

Kushwaha et al., A comprehensive review on the global efforts on vaccines and repurposed drugs for combating COVID-19, European Journal of Medicinal Chemistry, doi:10.1016/j.ejmech.2023.115719

Oliver et al., Different drug approaches to COVID-19 treatment worldwide: an update of new drugs and drugs repositioning to fight against the novel coronavirus, Therapeutic Advances in Vaccines and Immunotherapy, doi:10.1177/25151355221144845

Ceja-Gálvez et al., Severe COVID-19: Drugs and Clinical Trials, Journal of Clinical Medicine, doi:10.3390/jcm12082893

Islam et al., Molecular-evaluated and explainable drug repurposing for COVID-19 using ensemble knowledge graph embedding, Scientific Reports, doi:10.1038/s41598-023-30095-z

Nayak et al., Prospects of Novel and Repurposed Immunomodulatory Drugs against Acute Respiratory Distress Syndrome (ARDS) Associated with COVID-19 Disease, Journal of Personalized Medicine, doi:10.3390/jpm13040664

Ghosh et al., Interactome-Based Machine Learning Predicts Potential Therapeutics for COVID-19, ACS Omega, doi:10.1021/acsomega.3c00030

Kumar et al., COVID-19 therapeutics: Clinical application of repurposed drugs and futuristic strategies for target-based drug discovery, Genes & Diseases, doi:10.1016/j.gendis.2022.12.019

Maria et al., Application of the PHENotype SIMulator for rapid identification of potential candidates in effective COVID-19 drug repurposing, Heliyon, doi:10.1016/j.heliyon.2023.e14115

Mostafa et al., FDA-Approved Drugs with Potent In Vitro Antiviral Activity against Severe Acute Respiratory Syndrome Coronavirus 2, Pharmaceuticals, doi:10.3390/ph13120443

Raghav et al., Potential treatments of COVID-19: Drug repurposing and therapeutic interventions, Journal of Pharmacological Sciences, doi:10.1016/j.jphs.2023.02.004

Zeng et al., Repurpose Open Data to Discover Therapeutics for COVID-19 Using Deep Learning, Journal of Proteome Research, doi:10.1021/acs.jproteome.0c00316

Issac et al., Improved And Optimized Drug Repurposing For The SARS-CoV-2 Pandemic, bioRxiv, doi:10.1101/2022.03.24.485618

https://sites.google.com/view/coronabank/coronabank/immunomodulatory-agents

He et al., Recent advances towards natural plants as potential inhibitors of SARS-Cov-2 targets, Pharmaceutical Biology, doi:10.1080/13880209.2023.2241518

Akter et al., Plausibility of natural immunomodulators in the treatment of COVID-19–A comprehensive analysis and future recommendations, Heliyon, doi:10.1016/j.heliyon.2023.e17478

Fan et al., Pharmaceutical approaches for COVID-19: An update on current therapeutic opportunities, Acta Pharmaceutica, doi:10.2478/acph-2023-0014

unknown, u., Trainee Poster Honorable Mention Poster Abstracts Presented at the 123^rdAnnual Meeting of the American Association of Colleges of Pharmacy, July 23-27, 2022, American Journal of Pharmaceutical Education, doi:10.5688/ajpe9169

Srivastava et al., A Brief Review on Medicinal Plants-At-Arms against COVID-19, Interdisciplinary Perspectives on Infectious Diseases, doi:10.1155/2023/7598307

Giordano et al., Food Plant Secondary Metabolites Antiviral Activity and Their Possible Roles in SARS-CoV-2 Treatment: An Overview, Molecules, doi:10.3390/molecules28062470

Khaerunnisa et al., Potential Inhibitor of COVID-19 Main Protease (Mpro) From Several Medicinal Plant Compounds by Molecular Docking Study, MDPI AG, doi:10.20944/preprints202003.0226.v1

Kawall et al., Inhibitory effect of phytochemicals towards SARS-CoV-2 papain like protease (PLpro) proteolytic and deubiquitinase activity, Frontiers in Chemistry, doi:10.3389/fchem.2022.1100460

BİLGİNER et al., Molecular Docking Study of Several Seconder Metabolites from Medicinal Plants as Potential Inhibitors of COVID-19 Main Protease, Turkish Journal of Pharmaceutical Sciences, doi:10.4274/tjps.galenos.2021.83548

Mukherjee et al., Role of medicinal plants in inhibiting SARS-CoV-2 and in the management of post-COVID-19 complications, Phytomedicine, doi:10.1016/j.phymed.2022.153930

https://sites.google.com/view/coronabank/coronabank/natural-compounds

https://digitalcommons.pcom.edu/research_day/research_day_GA_2022/researchGA2022/20/

https://www.mdpi.com/2304-8158/10/9/2084/htm

Molina et al., 556. Ruxolitinib for the Management of Severe Pneumonia Caused by SARS-CoV-2. Exploring the Combination with dexamethasone, Open Forum Infectious Diseases, doi:10.1093/ofid/ofab466.754

Rein et al., Randomized Phase 3 Trial of Ruxolitinib for COVID-19–Associated Acute Respiratory Distress Syndrome*, Critical Care Medicine, doi:10.1097/CCM.0000000000005682

Kushwaha et al., A comprehensive review on the global efforts on vaccines and repurposed drugs for combating COVID-19, European Journal of Medicinal Chemistry, doi:10.1016/j.ejmech.2023.115719

Mehyar, N., Coronaviruses SARS-CoV, MERS-CoV, and SARS-CoV-2 helicase inhibitors: A systematic review of in vitro studies, Journal of Virus Eradication, doi:10.1016/j.jve.2023.100327

Oliver et al., Different drug approaches to COVID-19 treatment worldwide: an update of new drugs and drugs repositioning to fight against the novel coronavirus, Therapeutic Advances in Vaccines and Immunotherapy, doi:10.1177/25151355221144845

Xue et al., Repurposing clinically available drugs and therapies for pathogenic targets to combat SARS‐CoV‐2, MedComm, doi:10.1002/mco2.254

Ceja-Gálvez et al., Severe COVID-19: Drugs and Clinical Trials, Journal of Clinical Medicine, doi:10.3390/jcm12082893

Islam et al., Molecular-evaluated and explainable drug repurposing for COVID-19 using ensemble knowledge graph embedding, Scientific Reports, doi:10.1038/s41598-023-30095-z

Kumar et al., COVID-19 therapeutics: Clinical application of repurposed drugs and futuristic strategies for target-based drug discovery, Genes & Diseases, doi:10.1016/j.gendis.2022.12.019

Pillaiyar et al., Kinases as Potential Therapeutic Targets for Anti-coronaviral Therapy, Journal of Medicinal Chemistry, doi:10.1021/acs.jmedchem.1c00335

Sarkar et al., Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives, Frontiers in Pharmacology, doi:10.3389/fphar.2020.572870

Heimfarth et al., Drug repurposing and cytokine management in response to COVID-19: A review, International Immunopharmacology, doi:10.1016/j.intimp.2020.106947

https://sites.google.com/view/coronabank/coronabank/immunomodulatory-agents

Yuan et al., The role of cell death in SARS-CoV-2 infection, Signal Transduction and Targeted Therapy, doi:10.1038/s41392-023-01580-8

Lundstrom et al., COVID-19 signalome: Potential therapeutic interventions, Cellular Signalling, doi:10.1016/j.cellsig.2022.110559

Wang et al., Inflammasomes: a rising star on the horizon of COVID-19 pathophysiology, Frontiers in Immunology, doi:10.3389/fimmu.2023.1185233

Oliver et al., Different drug approaches to COVID-19 treatment worldwide: an update of new drugs and drugs repositioning to fight against the novel coronavirus, Therapeutic Advances in Vaccines and Immunotherapy, doi:10.1177/25151355221144845

Xue et al., Repurposing clinically available drugs and therapies for pathogenic targets to combat SARS‐CoV‐2, MedComm, doi:10.1002/mco2.254

Ceja-Gálvez et al., Severe COVID-19: Drugs and Clinical Trials, Journal of Clinical Medicine, doi:10.3390/jcm12082893

Astasio-Picado et al., Therapeutic Targets in the Virological Mechanism and in the Hyperinflammatory Response of Severe Acute Respiratory Syndrome Coronavirus Type 2 (SARS-CoV-2), Applied Sciences, doi:10.3390/app13074471

Liu et al., Therapeutic Polypeptides and Peptidomimetics: Powerful Tools for COVID-19 Treatment, Clinical Drug Investigation, doi:10.1007/s40261-022-01231-w

Issac et al., Improved And Optimized Drug Repurposing For The SARS-CoV-2 Pandemic, bioRxiv, doi:10.1101/2022.03.24.485618

Heimfarth et al., Drug repurposing and cytokine management in response to COVID-19: A review, International Immunopharmacology, doi:10.1016/j.intimp.2020.106947

https://www.mdpi.com/2571-841X/6/4/45

https://sites.google.com/view/coronabank/coronabank/immunomodulatory-agents

Haji Aghajani et al., Promising effects of atorvastatin on mortality and need for mechanical ventilation in patients with severe COVID‐19; a retrospective cohort study, International Journal of Clinical Practice, doi:10.1111/ijcp.14434

Chen et al., Metabolic alterations upon SARS-CoV-2 infection and potential therapeutic targets against coronavirus infection, Signal Transduction and Targeted Therapy, doi:10.1038/s41392-023-01510-8

Oliver et al., Different drug approaches to COVID-19 treatment worldwide: an update of new drugs and drugs repositioning to fight against the novel coronavirus, Therapeutic Advances in Vaccines and Immunotherapy, doi:10.1177/25151355221144845

Taguchi et al., A new advanced in silico drug discovery method for novel coronavirus (SARS-CoV-2) with tensor decomposition-based unsupervised feature extraction, PLOS ONE, doi:10.1371/journal.pone.0238907

Risner et al., Maraviroc inhibits SARS-CoV-2 multiplication and s-protein mediated cell fusion in cell culture, bioRxiv, doi:10.1101/2020.08.12.246389

Tomazou et al., Multi-omics data integration and network-based analysis drives a multiplex drug repurposing approach to a shortlist of candidate drugs against COVID-19, Briefings in Bioinformatics, doi:10.1093/bib/bbab114

Sperry et al., Different HMGCR-inhibiting statins vary in their association with increased survival in patients with COVID-19, medRxiv, doi:10.1101/2022.04.12.22273802

MacFadden et al., Screening Large Population Health Databases for Potential COVID-19 Therapeutics: A Pharmacopeia-Wide Association Study (PWAS) of Commonly Prescribed Medications, Open Forum Infectious Diseases, doi:10.1093/ofid/ofac156

Issac et al., Improved And Optimized Drug Repurposing For The SARS-CoV-2 Pandemic, bioRxiv, doi:10.1101/2022.03.24.485618

https://www.sciencedirect.com/science/article/pii/S2352906721001639

https://www.mdpi.com/1999-4915/13/10/2084

https://sites.google.com/view/coronabank/coronabank/immunomodulatory-agents

Sokhela et al., Randomized clinical trial of nitazoxanide or sofosbuvir/daclatasvir for the prevention of SARS-CoV-2 infection, Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkac266

Oliver et al., Different drug approaches to COVID-19 treatment worldwide: an update of new drugs and drugs repositioning to fight against the novel coronavirus, Therapeutic Advances in Vaccines and Immunotherapy, doi:10.1177/25151355221144845

Xue et al., Repurposing clinically available drugs and therapies for pathogenic targets to combat SARS‐CoV‐2, MedComm, doi:10.1002/mco2.254

Ceja-Gálvez et al., Severe COVID-19: Drugs and Clinical Trials, Journal of Clinical Medicine, doi:10.3390/jcm12082893

Kumar et al., COVID-19 therapeutics: Clinical application of repurposed drugs and futuristic strategies for target-based drug discovery, Genes & Diseases, doi:10.1016/j.gendis.2022.12.019

Bekheit et al., Potential RNA-dependent RNA polymerase inhibitors as prospective drug candidates for SARS-CoV-2, European Journal of Medicinal Chemistry, doi:10.1016/j.ejmech.2023.115292

Xu et al., An update on inhibitors targeting RNA-dependent RNA polymerase for COVID-19 treatment: Promises and challenges, Biochemical Pharmacology, doi:10.1016/j.bcp.2022.115279

Yakoot et al., Clinical utility of repurposing a short course of hepatitis C drugs for COVID19. A randomized controlled study, medRxiv, doi:10.1101/2022.07.18.22277477

Negru et al., Virtual Screening of Substances Used in the Treatment of SARS-CoV-2 Infection and Analysis of Compounds With Known Action on Structurally Similar Proteins From Other Viruses, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.113432

Mosharaf et al., Computational identification of host genomic biomarkers highlighting their functions, pathways and regulators that influence SARS-CoV-2 infections and drug repurposing, Scientific Reports, doi:10.1038/s41598-022-08073-8

Wang et al., Combination of antiviral drugs inhibits SARS-CoV-2 polymerase and exonuclease and demonstrates COVID-19 therapeutic potential in viral cell culture, Communications Biology, doi:10.1038/s42003-022-03101-9

https://sites.google.com/view/coronabank/coronabank/classical-and-potential-antivirals

Mushebenge et al., Assessing the Potential Contribution of in Silico Studies in Discovering Drug Candidates that Interact with Various SARS-CoV-2 Receptors, MDPI AG, doi:10.20944/preprints202308.0434.v1

Mandal et al., In silico anti-viral assessment of phytoconstituents in a traditional (Siddha Medicine) polyherbal formulation – Targeting Mpro and pan-coronavirus post-fusion Spike protein, Journal of Traditional and Complementary Medicine, doi:10.1016/j.jtcme.2023.07.004

Akter et al., Plausibility of natural immunomodulators in the treatment of COVID-19–A comprehensive analysis and future recommendations, Heliyon, doi:10.1016/j.heliyon.2023.e17478

Giordano et al., Food Plant Secondary Metabolites Antiviral Activity and Their Possible Roles in SARS-CoV-2 Treatment: An Overview, Molecules, doi:10.3390/molecules28062470

Cerqueira et al., Edible alginate-based films with anti-SARS-CoV-2 activity, Food Microbiology, doi:10.1016/j.fm.2023.104251

Rahman et al., In silico investigation and potential therapeutic approaches of natural products for COVID-19: Computer-aided drug design perspective, Frontiers in Cellular and Infection Microbiology, doi:10.3389/fcimb.2022.929430

Azeem et al., Virtual screening of phytochemicals by targeting multiple proteins of severe acute respiratory syndrome coronavirus 2: Molecular docking and molecular dynamics simulation studies, International Journal of Immunopathology and Pharmacology, doi:10.1177/03946320221142793

Aati et al., Garcinia cambogia Phenolics as Potent Anti-COVID-19 Agents: Phytochemical Profiling, Biological Activities, and Molecular Docking, Plants, doi:10.3390/plants11192521

Youn et al., Robust therapeutic effects on COVID-19 of novel small molecules: Alleviation of SARS-CoV-2 S protein induction of ACE2/TMPRSS2, NOX2/ROS, and MCP-1, Frontiers in Cardiovascular Medicine, doi:10.3389/fcvm.2022.957340

https://www.pnrjournal.com/index.php/home/article/view/4167 (In Silico)

https://www.sciencedirect.com/science/article/pii/S0223523421007066

https://www.mdpi.com/2304-8158/10/9/2084/htm

Badrunanto et al., In-silico approaches potential compounds in ginger (Zingiber officinale) as inhibitors of membrane, envelope, nucleocapsid, Plpro, and Helicase proteins of the SARS-CoV-2, INTERNATIONAL CONFERENCE ON APPLIED COMPUTATIONAL INTELLIGENCE AND ANALYTICS (ACIA-2022), doi:10.1063/5.0127236

Corbo et al., Inhibitory potential of phytochemicals on five SARS-CoV-2 proteins: in silico evaluation of endemic plants of Bosnia and Herzegovina, Biotechnology & Biotechnological Equipment, doi:10.1080/13102818.2023.2222196

Abou Baker et al., An overview on medicinal plants used for combating coronavirus: Current potentials and challenges, Journal of Agriculture and Food Research, doi:10.1016/j.jafr.2023.100632

Ibeh et al., Computational studies of potential antiviral compounds from some selected Nigerian medicinal plants against SARS-CoV-2 proteins, Informatics in Medicine Unlocked, doi:10.1016/j.imu.2023.101230

Abdizadeh et al., Efficacy Evaluation of Quercetin and Its Analogues on the Main Protease Enzyme of the COVID-19 Using Molecular Docking Studies, journal of ilam university of medical sciences, doi:10.52547/sjimu.30.4.66

Heleno et al., Plant Extracts and SARS-CoV-2: Research and Applications, Life, doi:10.3390/life13020386

deAndrés-Galiana et al., Analysis of transcriptomic responses to SARS-CoV-2 reveals plausible defective pathways responsible for increased susceptibility to infection and complications and helps to develop fast-track repositioning of drugs against COVID-19, Computers in Biology and Medicine, doi:10.1016/j.compbiomed.2022.106029

Sperry et al., Target-agnostic drug prediction integrated with medical record analysis uncovers differential associations of statins with increased survival in COVID-19 patients, PLOS Computational Biology, doi:10.1371/journal.pcbi.1011050 (Table 2)

Rani et al., Modern drug discovery applications for the identification of novel candidates for COVID-19 infections, Annals of Medicine and Surgery, doi:10.1016/j.amsu.2022.104125

http://journal.unhas.ac.id/index.php/ijoab/article/view/25284

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10013230/pdf/42535_2023_Article_601.pdf/?tool..

https://www.mdpi.com/2304-8158/10/9/2084/htm

Khan et al., Possible therapeutic targets for SARS-CoV-2 infection and COVID-19, Journal of Allergy & Infectious Diseases, doi:10.46439/allergy.2.028

Kushwaha et al., A comprehensive review on the global efforts on vaccines and repurposed drugs for combating COVID-19, European Journal of Medicinal Chemistry, doi:10.1016/j.ejmech.2023.115719

Kiouri et al., Network-Based Prediction of Side Effects of Repurposed Antihypertensive Sartans against COVID-19 via Proteome and Drug-Target Interactomes, Proteomes, doi:10.3390/proteomes11020021

Oliver et al., Different drug approaches to COVID-19 treatment worldwide: an update of new drugs and drugs repositioning to fight against the novel coronavirus, Therapeutic Advances in Vaccines and Immunotherapy, doi:10.1177/25151355221144845

Kelaidonis et al., Computational and Enzymatic Studies of Sartans in SARS-CoV-2 Spike RBD-ACE2 Binding: The Role of Tetrazole and Perspectives as Antihypertensive and COVID-19 Therapeutics, International Journal of Molecular Sciences, doi:10.3390/ijms24098454

Islam et al., Molecular-evaluated and explainable drug repurposing for COVID-19 using ensemble knowledge graph embedding, Scientific Reports, doi:10.1038/s41598-023-30095-z

Khan et al., Repurposing of US-FDA approved drugs against SARS-CoV-2 main protease (Mpro) by using STD-NMR spectroscopy, in silico studies and antiviral assays, International Journal of Biological Macromolecules, doi:10.1016/j.ijbiomac.2023.123540

Supianto et al., Cluster-based text mining for extracting drug candidates for the prevention of COVID-19 from the biomedical literature, Journal of Taibah University Medical Sciences, doi:10.1016/j.jtumed.2022.12.015

Rieder et al., A Review of In Silico Research, SARS-CoV-2, and Neurodegeneration: Focus on Papain-Like Protease, Neurotoxicity Research, doi:10.1007/s12640-022-00542-2

Sperry et al., Target-agnostic drug prediction integrated with medical record analysis uncovers differential associations of statins with increased survival in COVID-19 patients, PLOS Computational Biology, doi:10.1371/journal.pcbi.1011050 (Table 2)

Sarkar et al., Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives, Frontiers in Pharmacology, doi:10.3389/fphar.2020.572870

Heimfarth et al., Drug repurposing and cytokine management in response to COVID-19: A review, International Immunopharmacology, doi:10.1016/j.intimp.2020.106947

Khan et al., Possible therapeutic targets for SARS-CoV-2 infection and COVID-19, Journal of Allergy & Infectious Diseases, doi:10.46439/allergy.2.028

Lundstrom et al., COVID-19 signalome: Potential therapeutic interventions, Cellular Signalling, doi:10.1016/j.cellsig.2022.110559

Wang et al., Repurposing Drugs for the Treatment of COVID-19 and Its Cardiovascular Manifestations, Circulation Research, doi:10.1161/circresaha.122.321879

Zhong et al., Recent advances in small-molecular therapeutics for COVID-19, Precision Clinical Medicine, doi:10.1093/pcmedi/pbac024

Patten et al., Identification of potent inhibitors of SARS-CoV-2 infection by combined pharmacological evaluation and cellular network prioritization., iScience, doi:10.1016/j.isci.2022.104925

Kumar et al., Identification of potential COVID-19 treatment compounds which inhibit SARS Cov2 prototypic, Delta and Omicron variant infection, Virology, doi:10.1016/j.virol.2022.05.004

Riva et al., A Large-scale Drug Repositioning Survey for SARS-CoV-2 Antivirals, bioRxiv, doi:10.1101/2020.04.16.044016

Chen et al., Drug Repurposing Screen for Compounds Inhibiting the Cytopathic Effect of SARS-CoV-2, Frontiers in Pharmacology, doi:10.3389/fphar.2020.592737

Basu et al., Therapeutics for COVID-19 and post COVID-19 complications: An update, Current Research in Pharmacology and Drug Discovery, doi:10.1016/j.crphar.2022.100086

Pillaiyar et al., Kinases as Potential Therapeutic Targets for Anti-coronaviral Therapy, Journal of Medicinal Chemistry, doi:10.1021/acs.jmedchem.1c00335

https://sites.google.com/view/coronabank/coronabank/binding-and-internalisation-inhibitors

Rafiq et al., A Comprehensive Update of Various Attempts by Medicinal Chemists to Combat COVID-19 through Natural Products, Molecules, doi:10.3390/molecules28124860

AKBABA et al., Phytochemicals of Hibiscus sabdariffa with Therapeutic Potential against SARS-CoV-2: A Molecular Docking Study, Journal of the Institute of Science and Technology, doi:10.21597/jist.1187616

Abou Baker et al., An overview on medicinal plants used for combating coronavirus: Current potentials and challenges, Journal of Agriculture and Food Research, doi:10.1016/j.jafr.2023.100632

Srivastava et al., A Brief Review on Medicinal Plants-At-Arms against COVID-19, Interdisciplinary Perspectives on Infectious Diseases, doi:10.1155/2023/7598307

Giordano et al., Food Plant Secondary Metabolites Antiviral Activity and Their Possible Roles in SARS-CoV-2 Treatment: An Overview, Molecules, doi:10.3390/molecules28062470

Rahman et al., In silico investigation and potential therapeutic approaches of natural products for COVID-19: Computer-aided drug design perspective, Frontiers in Cellular and Infection Microbiology, doi:10.3389/fcimb.2022.929430

Heleno et al., Plant Extracts and SARS-CoV-2: Research and Applications, Life, doi:10.3390/life13020386

Guerra et al., Critical Review of Plant-Derived Compounds as Possible Inhibitors of SARS-CoV-2 Proteases: A Comparison with Experimentally Validated Molecules, ACS Omega, doi:10.1021/acsomega.2c05766

de Matos et al., Bioactive compounds as potential angiotensin-converting enzyme II inhibitors against COVID-19: a scoping review, Inflammation Research, doi:10.1007/s00011-022-01642-7

https://www.sciencedirect.com/science/article/pii/S0223523421007066

https://www.mdpi.com/2304-8158/10/9/2084/htm

Abou Baker et al., An overview on medicinal plants used for combating coronavirus: Current potentials and challenges, Journal of Agriculture and Food Research, doi:10.1016/j.jafr.2023.100632

Pati et al., Drug discovery through Covid-19 genome sequencing with siamese graph convolutional neural network, Multimedia Tools and Applications, doi:10.1007/s11042-023-15270-8

England et al., Plants as Biofactories for Therapeutic Proteins and Antiviral Compounds to Combat COVID-19, Life, doi:10.3390/life13030617

Raghav et al., Potential treatments of COVID-19: Drug repurposing and therapeutic interventions, Journal of Pharmacological Sciences, doi:10.1016/j.jphs.2023.02.004

Chapola et al., A COMPARATIVE STUDY OF COVID-19 TRANSCRIPTIONAL SIGNATURES BETWEEN CLINICAL SAMPLES AND PRECLINICAL CELL MODELS IN THE SEARCH FOR DISEASE MASTER REGULATORS AND DRUG REPOSITIONING CANDIDATES, Virus Research, doi:10.1016/j.virusres.2023.199053

Zeng et al., Repurpose Open Data to Discover Therapeutics for COVID-19 Using Deep Learning, Journal of Proteome Research, doi:10.1021/acs.jproteome.0c00316

Dinda et al., Some natural compounds and their analogues having potent anti- SARS-CoV-2 and anti-proteases activities as lead molecules in drug discovery for COVID-19, European Journal of Medicinal Chemistry Reports, doi:10.1016/j.ejmcr.2022.100079

Patten et al., Identification of potent inhibitors of SARS-CoV-2 infection by combined pharmacological evaluation and cellular network prioritization., iScience, doi:10.1016/j.isci.2022.104925

Jamalipour Soufi et al., Potential inhibitors of SARS-CoV-2: recent advances, Journal of Drug Targeting, doi:10.1080/1061186X.2020.1853736

Uma Reddy et al., Multifaceted role of plant derived small molecule inhibitors on replication cycle of sars-cov-2, Microbial Pathogenesis, doi:10.1016/j.micpath.2022.105512

https://sites.google.com/view/coronabank/coronabank/natural-compounds

Wang et al., Stand Up to Stand Out: Natural Dietary Polyphenols Curcumin, Resveratrol, and Gossypol as Potential Therapeutic Candidates against Severe Acute Respiratory Syndrome Coronavirus 2 Infection, Nutrients, doi:10.3390/nu15183885

He et al., Recent advances towards natural plants as potential inhibitors of SARS-Cov-2 targets, Pharmaceutical Biology, doi:10.1080/13880209.2023.2241518

Srivastava et al., A Brief Review on Medicinal Plants-At-Arms against COVID-19, Interdisciplinary Perspectives on Infectious Diseases, doi:10.1155/2023/7598307

England et al., Plants as Biofactories for Therapeutic Proteins and Antiviral Compounds to Combat COVID-19, Life, doi:10.3390/life13030617

Rieder et al., A Review of In Silico Research, SARS-CoV-2, and Neurodegeneration: Focus on Papain-Like Protease, Neurotoxicity Research, doi:10.1007/s12640-022-00542-2

Qi et al., Discovery of TCMs and Derivatives Against the Main Protease of SARS-CoV-2 via High Throughput Screening, ADMET Analysis, and Inhibition Assay in Vitro, Journal of Molecular Structure, doi:10.1016/j.molstruc.2022.133709

Rani et al., Modern drug discovery applications for the identification of novel candidates for COVID-19 infections, Annals of Medicine and Surgery, doi:10.1016/j.amsu.2022.104125

Jang et al., Drugs repurposed for COVID-19 by virtual screening of 6,218 drugs and cell-based assay, Proceedings of the National Academy of Sciences, doi:10.1073/pnas.2024302118

Shahhamzehei et al., In Silico and In Vitro Identification of Pan-Coronaviral Main Protease Inhibitors from a Large Natural Product Library, Pharmaceuticals, doi:10.3390/ph15030308

https://sites.google.com/view/coronabank/coronabank/natural-compounds

https://www.mdpi.com/2304-8158/10/9/2084/htm

Drayman et al., Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2, Science, doi:10.1126/science.abg5827

Martínez‐Ortega et al., In Silico Characterization of Masitinib Interaction with SARS‐CoV‐2 Main Protease, ChemMedChem, doi:10.1002/cmdc.202100375

Drayman et al., Drug repurposing screen identifies masitinib as a 3CLpro inhibitor that blocks replication of SARS-CoV-2 in vitro, bioRxiv, doi:10.1101/2020.08.31.274639

Mehyar, N., Coronaviruses SARS-CoV, MERS-CoV, and SARS-CoV-2 helicase inhibitors: A systematic review of in vitro studies, Journal of Virus Eradication, doi:10.1016/j.jve.2023.100327

Pang et al., The research progress of SARS-CoV-2 main protease inhibitors from 2020 to 2022, European Journal of Medicinal Chemistry, doi:10.1016/j.ejmech.2023.115491

Xue et al., Repurposing clinically available drugs and therapies for pathogenic targets to combat SARS‐CoV‐2, MedComm, doi:10.1002/mco2.254

Kronenberger et al., COVID-19 therapeutics: Small-molecule drug development targeting SARS-CoV-2 main protease, Drug Discovery Today, doi:10.1016/j.drudis.2023.103579

Bojkova et al., Identification of novel antiviral drug candidates using an optimized SARS-CoV-2 phenotypic screening platform, iScience, doi:10.1016/j.isci.2023.105944

Ravindran et al., Discovery of host-directed modulators of virus infection by probing the SARS-CoV-2–host protein–protein interaction network, Briefings in Bioinformatics, doi:10.1093/bib/bbac456

Tsuji, M., Virtual Screening and Quantum Chemistry Analysis for SARS-CoV-2 RNA-Dependent RNA Polymerase Using the ChEMBL Database: Reproduction of the Remdesivir-RTP and Favipiravir-RTP Binding Modes Obtained from Cryo-EM Experiments with High Binding Affinity, International Journal of Molecular Sciences, doi:10.3390/ijms231911009

https://sites.google.com/view/coronabank/coronabank/classical-and-potential-antivirals

Xue et al., Repurposing clinically available drugs and therapies for pathogenic targets to combat SARS‐CoV‐2, MedComm, doi:10.1002/mco2.254

Pati et al., Drug discovery through Covid-19 genome sequencing with siamese graph convolutional neural network, Multimedia Tools and Applications, doi:10.1007/s11042-023-15270-8

Ceja-Gálvez et al., Severe COVID-19: Drugs and Clinical Trials, Journal of Clinical Medicine, doi:10.3390/jcm12082893

McAuley et al., Use of Human Lung Tissue Models for Screening of Drugs against SARS-CoV-2 Infection, Viruses, doi:10.3390/v14112417

Zeng et al., Repurpose Open Data to Discover Therapeutics for COVID-19 Using Deep Learning, Journal of Proteome Research, doi:10.1021/acs.jproteome.0c00316

Zhou et al., Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2, Cell Discovery, doi:10.1038/s41421-020-0153-3

Doshi et al., A computational approach to drug repurposing using graph neural networks, Computers in Biology and Medicine, doi:10.1016/j.compbiomed.2022.105992

deAndrés-Galiana et al., Analysis of transcriptomic responses to SARS-CoV-2 reveals plausible defective pathways responsible for increased susceptibility to infection and complications and helps to develop fast-track repositioning of drugs against COVID-19, Computers in Biology and Medicine, doi:10.1016/j.compbiomed.2022.106029

Sperry et al., Target-agnostic drug prediction integrated with medical record analysis uncovers differential associations of statins with increased survival in COVID-19 patients, PLOS Computational Biology, doi:10.1371/journal.pcbi.1011050 (Table 2)

Issac et al., Improved And Optimized Drug Repurposing For The SARS-CoV-2 Pandemic, bioRxiv, doi:10.1101/2022.03.24.485618

https://sites.google.com/view/coronabank/coronabank/immunomodulatory-agents

CHANDRA et al., Indian medicinal plants are effective in the treatment and management of COVID-19, BIOCELL, doi:10.32604/biocell.2023.026081

Fan et al., Pharmaceutical approaches for COVID-19: An update on current therapeutic opportunities, Acta Pharmaceutica, doi:10.2478/acph-2023-0014

CHEN et al., Deciphering suppressive effects of Lianhua Qingwen Capsule on COVID-19 and synergistic effects of its major botanical drug pairs, Chinese Journal of Natural Medicines, doi:10.1016/S1875-5364(23)60455-8

Xu et al., Screening compounds for treating the diabetes and COVID-19 from Miao medicine by molecular docking and bioinformatics, Arabian Journal of Chemistry, doi:10.1016/j.arabjc.2023.105001

Srivastava et al., A Brief Review on Medicinal Plants-At-Arms against COVID-19, Interdisciplinary Perspectives on Infectious Diseases, doi:10.1155/2023/7598307

Kumar et al., COVID-19 therapeutics: Clinical application of repurposed drugs and futuristic strategies for target-based drug discovery, Genes & Diseases, doi:10.1016/j.gendis.2022.12.019

Qi et al., Discovery of TCMs and Derivatives Against the Main Protease of SARS-CoV-2 via High Throughput Screening, ADMET Analysis, and Inhibition Assay in Vitro, Journal of Molecular Structure, doi:10.1016/j.molstruc.2022.133709

Rani et al., Modern drug discovery applications for the identification of novel candidates for COVID-19 infections, Annals of Medicine and Surgery, doi:10.1016/j.amsu.2022.104125

https://pharmacia.pensoft.net/article/106534/download/pdf

https://sites.google.com/view/coronabank/coronabank/natural-compounds

https://www.sciencedirect.com/science/article/pii/S0223523421007066

Mishra et al., Withaferin A for COVID-19: a Network Pharmacology Approach, Applied Biochemistry and Biotechnology, doi:10.1007/s12010-023-04525-7

Xu et al., Screening compounds for treating the diabetes and COVID-19 from Miao medicine by molecular docking and bioinformatics, Arabian Journal of Chemistry, doi:10.1016/j.arabjc.2023.105001

Abou Baker et al., An overview on medicinal plants used for combating coronavirus: Current potentials and challenges, Journal of Agriculture and Food Research, doi:10.1016/j.jafr.2023.100632

Srivastava et al., A Brief Review on Medicinal Plants-At-Arms against COVID-19, Interdisciplinary Perspectives on Infectious Diseases, doi:10.1155/2023/7598307

Ramli et al., Phytochemicals of Withania somnifera as a Future Promising Drug against SARS-CoV-2: Pharmacological Role, Molecular Mechanism, Molecular Docking Evaluation, and Efficient Delivery, Microorganisms, doi:10.3390/microorganisms11041000

England et al., Plants as Biofactories for Therapeutic Proteins and Antiviral Compounds to Combat COVID-19, Life, doi:10.3390/life13030617

Choe et al., The Efficacy of Traditional Medicinal Plants in Modulating the Main Protease of SARS‐CoV‐2 and Cytokine Storm, Chemistry & Biodiversity, doi:10.1002/cbdv.202200655

Tiwari et al., Molecular docking studies on the phytoconstituents as therapeutic leads against SARS-CoV-2, Polimery, doi:10.14314/polimery.2022.7.8

https://sites.google.com/view/coronabank/coronabank/natural-compounds

http://journal.unhas.ac.id/index.php/ijoab/article/view/25284

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10013230/pdf/42535_2023_Article_601.pdf/?tool..

Qu et al., A new integrated framework for the identification of potential virus–drug associations, Frontiers in Microbiology, doi:10.3389/fmicb.2023.1179414

Kushwaha et al., A comprehensive review on the global efforts on vaccines and repurposed drugs for combating COVID-19, European Journal of Medicinal Chemistry, doi:10.1016/j.ejmech.2023.115719

Oliver et al., Different drug approaches to COVID-19 treatment worldwide: an update of new drugs and drugs repositioning to fight against the novel coronavirus, Therapeutic Advances in Vaccines and Immunotherapy, doi:10.1177/25151355221144845

Rudramurthy et al., In-Vitro Screening of Repurposed Drug Library against Severe Acute Respiratory Syndrome Coronavirus-2, Medical Research Archives, doi:10.18103/mra.v11i2.3595

Jeong et al., Rapid discovery and classification of inhibitors of coronavirus infection by pseudovirus screen and amplified luminescence proximity homogeneous assay, Antiviral Research, doi:10.1016/j.antiviral.2022.105473

Sperry et al., Target-agnostic drug prediction integrated with medical record analysis uncovers differential associations of statins with increased survival in COVID-19 patients, PLOS Computational Biology, doi:10.1371/journal.pcbi.1011050 (Table 2)

Chen et al., Drug Repurposing Screen for Compounds Inhibiting the Cytopathic Effect of SARS-CoV-2, Frontiers in Pharmacology, doi:10.3389/fphar.2020.592737

Mirabelli et al., Morphological cell profiling of SARS-CoV-2 infection identifies drug repurposing candidates for COVID-19, Proceedings of the National Academy of Sciences, doi:10.1073/pnas.2105815118

Darquennes et al., Association between Functional Inhibitors of Acid Sphingomyelinase (FIASMAs) and Reduced Risk of Death in COVID-19 Patients: A Retrospective Cohort Study, Pharmaceuticals, doi:10.3390/ph14030226

https://sites.google.com/view/coronabank/coronabank/binding-and-internalisation-inhibitors

Pickard et al., Discovery of re-purposed drugs that slow SARS-CoV-2 replication in human cells, PLOS Pathogens, doi:10.1371/journal.ppat.1009840

Carter-Timofte et al., Antiviral Potential of the Antimicrobial Drug Atovaquone against SARS-CoV-2 and Emerging Variants of Concern, ACS Infectious Diseases, doi:10.1021/acsinfecdis.1c00278

Jain et al., Atovaquone for Treatment of COVID-19: A Prospective Randomized, Double-Blind, Placebo-Controlled Clinical Trial, medRxiv, doi:10.1101/2022.05.24.22275411

Kushwaha et al., A comprehensive review on the global efforts on vaccines and repurposed drugs for combating COVID-19, European Journal of Medicinal Chemistry, doi:10.1016/j.ejmech.2023.115719

Oliver et al., Different drug approaches to COVID-19 treatment worldwide: an update of new drugs and drugs repositioning to fight against the novel coronavirus, Therapeutic Advances in Vaccines and Immunotherapy, doi:10.1177/25151355221144845

Wu et al., Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods, Acta Pharmaceutica Sinica B, doi:10.1016/j.apsb.2020.02.008

Naz et al., Repurposing FIASMAs against Acid Sphingomyelinase for COVID-19: A Computational Molecular Docking and Dynamic Simulation Approach, Molecules, doi:10.3390/molecules28072989

Ahmed et al., Identification of FDA Approved Drugs with Antiviral Activity against SARS-CoV-2: A Tale from structure-based drug repurposing to host-cell mechanistic investigation, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2023.114614

Pasla et al., In silico Drug Repurposing for the Identification of Antimalarial Drugs as Candidate Inhibitors of SARS-CoV-2, Anti-Infective Agents, doi:10.2174/2211352519666211202141143

https://sites.google.com/view/coronabank/coronabank/antimicrobials

Priyandoko et al., Inflammation Inhibitory Activity of Green Tea, Soybean, and Guava Extracts During Sars-Cov-2 Infection Through TNF Protein in Cytokine Storm, Computational Biology and Chemistry, doi:10.1016/j.compbiolchem.2023.107898

Abou Baker et al., An overview on medicinal plants used for combating coronavirus: Current potentials and challenges, Journal of Agriculture and Food Research, doi:10.1016/j.jafr.2023.100632

Srivastava et al., A Brief Review on Medicinal Plants-At-Arms against COVID-19, Interdisciplinary Perspectives on Infectious Diseases, doi:10.1155/2023/7598307

Giordano et al., Food Plant Secondary Metabolites Antiviral Activity and Their Possible Roles in SARS-CoV-2 Treatment: An Overview, Molecules, doi:10.3390/molecules28062470

Rahman et al., In silico investigation and potential therapeutic approaches of natural products for COVID-19: Computer-aided drug design perspective, Frontiers in Cellular and Infection Microbiology, doi:10.3389/fcimb.2022.929430

Heleno et al., Plant Extracts and SARS-CoV-2: Research and Applications, Life, doi:10.3390/life13020386

Le-Trilling et al., Universally available herbal teas based on sage and perilla elicit potent antiviral activity against SARS-CoV-2 variants of concern by HMOX-1 upregulation in human cells, bioRxiv, doi:10.1101/2020.11.18.388710

https://pharmacia.pensoft.net/article/106534/download/pdf

https://www.sciencedirect.com/science/article/pii/S2213422021000688

https://www.mdpi.com/2304-8158/10/9/2084/htm

Xu et al., Copper(II) Gluconate Boosts the Anti-SARS-CoV-2 Effect of Disulfiram In Vitro, bioRxiv, doi:10.1101/2021.09.17.460613

Yuan et al., The role of cell death in SARS-CoV-2 infection, Signal Transduction and Targeted Therapy, doi:10.1038/s41392-023-01580-8

Tam et al., Targeting SARS-CoV-2 Non-Structural Proteins, International Journal of Molecular Sciences, doi:10.3390/ijms241613002

Mehyar, N., Coronaviruses SARS-CoV, MERS-CoV, and SARS-CoV-2 helicase inhibitors: A systematic review of in vitro studies, Journal of Virus Eradication, doi:10.1016/j.jve.2023.100327

Oliver et al., Different drug approaches to COVID-19 treatment worldwide: an update of new drugs and drugs repositioning to fight against the novel coronavirus, Therapeutic Advances in Vaccines and Immunotherapy, doi:10.1177/25151355221144845

Pang et al., The research progress of SARS-CoV-2 main protease inhibitors from 2020 to 2022, European Journal of Medicinal Chemistry, doi:10.1016/j.ejmech.2023.115491

Zhong et al., Recent advances in small-molecular therapeutics for COVID-19, Precision Clinical Medicine, doi:10.1093/pcmedi/pbac024

Jamalipour Soufi et al., Potential inhibitors of SARS-CoV-2: recent advances, Journal of Drug Targeting, doi:10.1080/1061186X.2020.1853736

Sperry et al., Target-agnostic drug prediction integrated with medical record analysis uncovers differential associations of statins with increased survival in COVID-19 patients, PLOS Computational Biology, doi:10.1371/journal.pcbi.1011050 (Table 2)

https://sites.google.com/view/coronabank/coronabank/classical-and-potential-antivirals

Stelzig et al., Estrogen regulates the expression of SARS-CoV-2 receptor ACE2 in differentiated airway epithelial cells, American Journal of Physiology-Lung Cellular and Molecular Physiology, doi:10.1152/ajplung.00153.2020

Tsegay et al., A repurposed drug screen identifies compounds that inhibit the binding of the COVID-19 spike protein to ACE2, bioRxiv, doi:10.1101/2021.04.08.439071

Lemes et al., 17β‐estradiol reduces SARS‐CoV‐2 infection in vitro, Physiological Reports, doi:10.14814/phy2.14707

Khan et al., Possible therapeutic targets for SARS-CoV-2 infection and COVID-19, Journal of Allergy & Infectious Diseases, doi:10.46439/allergy.2.028

Kushwaha et al., A comprehensive review on the global efforts on vaccines and repurposed drugs for combating COVID-19, European Journal of Medicinal Chemistry, doi:10.1016/j.ejmech.2023.115719

Xue et al., Repurposing clinically available drugs and therapies for pathogenic targets to combat SARS‐CoV‐2, MedComm, doi:10.1002/mco2.254

Zeng et al., Repurpose Open Data to Discover Therapeutics for COVID-19 Using Deep Learning, Journal of Proteome Research, doi:10.1021/acs.jproteome.0c00316

deAndrés-Galiana et al., Analysis of transcriptomic responses to SARS-CoV-2 reveals plausible defective pathways responsible for increased susceptibility to infection and complications and helps to develop fast-track repositioning of drugs against COVID-19, Computers in Biology and Medicine, doi:10.1016/j.compbiomed.2022.106029

Sperry et al., Target-agnostic drug prediction integrated with medical record analysis uncovers differential associations of statins with increased survival in COVID-19 patients, PLOS Computational Biology, doi:10.1371/journal.pcbi.1011050 (Table 2)

Issac et al., Improved And Optimized Drug Repurposing For The SARS-CoV-2 Pandemic, bioRxiv, doi:10.1101/2022.03.24.485618

Huang et al., DeepCoVDR: deep transfer learning with graph transformer and cross-attention for predicting COVID-19 drug response, Bioinformatics, doi:10.1093/bioinformatics/btad244

Srivastava et al., A Brief Review on Medicinal Plants-At-Arms against COVID-19, Interdisciplinary Perspectives on Infectious Diseases, doi:10.1155/2023/7598307

Eskandari, V., Repurposing the natural compounds as potential therapeutic agents for COVID-19 based on the molecular docking study of the main protease and the receptor-binding domain of spike protein, Journal of Molecular Modeling, doi:10.1007/s00894-022-05138-3

Ugurel et al., Evaluation of the potency of FDA-approved drugs on wild type and mutant SARS-CoV-2 helicase (Nsp13), International Journal of Biological Macromolecules, doi:10.1016/j.ijbiomac.2020.09.138

Hosseini et al., Computational molecular docking and virtual screening revealed promising SARS-CoV-2 drugs, Precision Clinical Medicine, doi:10.1093/pcmedi/pbab001

Bello et al., Innovative, rapid, high-throughput method for drug repurposing in a pandemic—A case study of SARS-CoV-2 and COVID-19, Frontiers in Pharmacology, doi:10.3389/fphar.2023.1130828

Bello et al., Erythromycin, Retapamulin, Pyridoxine, Folic acid and Ivermectin dose dependently inhibit cytopathic effect, Papain-like Protease and M^PROof SARS-CoV-2, bioRxiv, doi:10.1101/2022.12.28.522082

Sperry et al., Target-agnostic drug prediction integrated with medical record analysis uncovers differential associations of statins with increased survival in COVID-19 patients, PLOS Computational Biology, doi:10.1371/journal.pcbi.1011050 (Table 2)

Negru et al., Virtual Screening of Substances Used in the Treatment of SARS-CoV-2 Infection and Analysis of Compounds With Known Action on Structurally Similar Proteins From Other Viruses, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.113432

https://sites.google.com/view/coronabank/coronabank/natural-compounds

Wei et al., Total network controllability analysis discovers explainable drugs for Covid-19 treatment, Biology Direct, doi:10.1186/s13062-023-00410-9

Wei et al., Total controllability analysis discovers explainable drugs for Covid-19 treatment, arXiv, doi:10.48550/arXiv.2206.02970

Oliver et al., Different drug approaches to COVID-19 treatment worldwide: an update of new drugs and drugs repositioning to fight against the novel coronavirus, Therapeutic Advances in Vaccines and Immunotherapy, doi:10.1177/25151355221144845

Sameni et al., Deciphering molecular mechanisms of SARS-CoV-2 pathogenesis and drug repurposing through GRN motifs: a comprehensive systems biology study, 3 Biotech, doi:10.1007/s13205-023-03518-x

Liu et al., Potential covalent drugs targeting the main protease of the SARS-CoV-2 coronavirus, Bioinformatics, doi:10.1093/bioinformatics/btaa224

Tsuji, M., Virtual Screening and Quantum Chemistry Analysis for SARS-CoV-2 RNA-Dependent RNA Polymerase Using the ChEMBL Database: Reproduction of the Remdesivir-RTP and Favipiravir-RTP Binding Modes Obtained from Cryo-EM Experiments with High Binding Affinity, International Journal of Molecular Sciences, doi:10.3390/ijms231911009

Issac et al., Improved And Optimized Drug Repurposing For The SARS-CoV-2 Pandemic, bioRxiv, doi:10.1101/2022.03.24.485618

https://www.sciencedirect.com/science/article/abs/pii/S104620232100205X (In Silico)

https://www.atsjournals.org/doi/pdf/10.1164/ajrccm-conference.2022.205.1_MeetingAbstracts...

https://sites.google.com/view/coronabank/coronabank/immunomodulatory-agents

He et al., Recent advances towards natural plants as potential inhibitors of SARS-Cov-2 targets, Pharmaceutical Biology, doi:10.1080/13880209.2023.2241518

Akter et al., Plausibility of natural immunomodulators in the treatment of COVID-19–A comprehensive analysis and future recommendations, Heliyon, doi:10.1016/j.heliyon.2023.e17478

Sheikh et al., Promising roles of Zingiber officinale roscoe, Curcuma longa L., and Momordica charantia L. as immunity modulators against COVID-19: A bibliometric analysis, Journal of Agriculture and Food Research, doi:10.1016/j.jafr.2023.100680

Fan et al., Pharmaceutical approaches for COVID-19: An update on current therapeutic opportunities, Acta Pharmaceutica, doi:10.2478/acph-2023-0014

Abou Baker et al., An overview on medicinal plants used for combating coronavirus: Current potentials and challenges, Journal of Agriculture and Food Research, doi:10.1016/j.jafr.2023.100632

Kushari et al., An integrated computational approach towards the screening of active plant metabolites as potential inhibitors of SARS-CoV-2: an overview, Structural Chemistry, doi:10.1007/s11224-022-02066-z

Rajamanickam et al., Molecular insight of phytocompounds from Indian spices and its hyaluronic acid conjugates to block SARS-CoV-2 viral entry, Journal of Biomolecular Structure and Dynamics, doi:10.1080/07391102.2022.2121757

Srivastava et al., The role of herbal plants in the inhibition of SARS-CoV-2 main protease: A computational approach, Journal of the Indian Chemical Society, doi:10.1016/j.jics.2022.100640

Nag et al., Curcumin inhibits spike protein of new SARS-CoV-2 variant of concern (VOC) Omicron, an in silico study, Computers in Biology and Medicine, doi:10.1016/j.compbiomed.2022.105552

https://sites.google.com/view/coronabank/coronabank/natural-compounds

Onyango, O., In Silico Models for Anti-COVID-19 Drug Discovery: A Systematic Review, Advances in Pharmacological and Pharmaceutical Sciences, doi:10.1155/2023/4562974

Fan et al., Pharmaceutical approaches for COVID-19: An update on current therapeutic opportunities, Acta Pharmaceutica, doi:10.2478/acph-2023-0014

Xu et al., Screening compounds for treating the diabetes and COVID-19 from Miao medicine by molecular docking and bioinformatics, Arabian Journal of Chemistry, doi:10.1016/j.arabjc.2023.105001

Abou Baker et al., An overview on medicinal plants used for combating coronavirus: Current potentials and challenges, Journal of Agriculture and Food Research, doi:10.1016/j.jafr.2023.100632

Raghav et al., Potential treatments of COVID-19: Drug repurposing and therapeutic interventions, Journal of Pharmacological Sciences, doi:10.1016/j.jphs.2023.02.004

Ke et al., Artificial intelligence approach fighting COVID-19 with repurposing drugs, Biomedical Journal, doi:10.1016/j.bj.2020.05.001

Dinda et al., Some natural compounds and their analogues having potent anti- SARS-CoV-2 and anti-proteases activities as lead molecules in drug discovery for COVID-19, European Journal of Medicinal Chemistry Reports, doi:10.1016/j.ejmcr.2022.100079

Patten et al., Identification of potent inhibitors of SARS-CoV-2 infection by combined pharmacological evaluation and cellular network prioritization., iScience, doi:10.1016/j.isci.2022.104925

Rani et al., Modern drug discovery applications for the identification of novel candidates for COVID-19 infections, Annals of Medicine and Surgery, doi:10.1016/j.amsu.2022.104125

https://sites.google.com/view/coronabank/coronabank/natural-compounds

Maulana et al., In silico screening of potential compounds from begonia genus as 3CL protease (3Cl pro) SARS-CoV-2 inhibitors, Journal of Public Health in Africa, doi:10.4081/jphia.2023.2508

Bansal et al., A clustering and graph deep learning-based framework for COVID-19 drug repurposing, arXiv, doi:10.48550/arXiv.2306.13995

Mittal et al., Identification of potential molecules against COVID-19 main protease through structure-guided virtual screening approach, Journal of Biomolecular Structure and Dynamics, doi:10.1080/07391102.2020.1768151

Moura et al., Converging Paths: A Comprehensive Review of the Synergistic Approach between Complementary Medicines and Western Medicine in Addressing COVID-19 in 2020, BioMed, doi:10.3390/biomed3020025

Islam et al., Molecular-evaluated and explainable drug repurposing for COVID-19 using ensemble knowledge graph embedding, Scientific Reports, doi:10.1038/s41598-023-30095-z

Shah et al., In silico studies on therapeutic agents for COVID-19: Drug repurposing approach, Life Sciences, doi:10.1016/j.lfs.2020.117652

Jamalipour Soufi et al., Potential inhibitors of SARS-CoV-2: recent advances, Journal of Drug Targeting, doi:10.1080/1061186X.2020.1853736

Negru et al., Virtual Screening of Substances Used in the Treatment of SARS-CoV-2 Infection and Analysis of Compounds With Known Action on Structurally Similar Proteins From Other Viruses, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.113432

Frediansyah et al., Antivirals for COVID-19: A critical review, Clinical Epidemiology and Global Health, doi:10.1016/j.cegh.2020.07.006

https://sites.google.com/view/coronabank/coronabank/classical-and-potential-antivirals

Schälter et al., Does methotrexate influence COVID-19 infection? Case series and mechanistic data, Arthritis Research & Therapy, doi:10.1186/s13075-021-02464-4

Caruso et al., Methotrexate inhibits SARS‐CoV‐2 virus replication “in vitro”, Journal of Medical Virology, doi:10.1002/jmv.26512

Kushwaha et al., A comprehensive review on the global efforts on vaccines and repurposed drugs for combating COVID-19, European Journal of Medicinal Chemistry, doi:10.1016/j.ejmech.2023.115719

Oliver et al., Different drug approaches to COVID-19 treatment worldwide: an update of new drugs and drugs repositioning to fight against the novel coronavirus, Therapeutic Advances in Vaccines and Immunotherapy, doi:10.1177/25151355221144845

Chevalier et al., CovAID: Identification of factors associated with severe COVID-19 in patients with inflammatory rheumatism or autoimmune diseases, Frontiers in Medicine, doi:10.3389/fmed.2023.1152587

Atoum et al., Paving New Roads Using Allium sativum as a Repurposed Drug and Analyzing its Antiviral Action Using Artificial Intelligence Technology, Iranian Journal of Pharmaceutical Research, doi:10.5812/ijpr-131577

Zeng et al., Repurpose Open Data to Discover Therapeutics for COVID-19 Using Deep Learning, Journal of Proteome Research, doi:10.1021/acs.jproteome.0c00316

Tomazou et al., Multi-omics data integration and network-based analysis drives a multiplex drug repurposing approach to a shortlist of candidate drugs against COVID-19, Briefings in Bioinformatics, doi:10.1093/bib/bbab114

Sperry et al., Target-agnostic drug prediction integrated with medical record analysis uncovers differential associations of statins with increased survival in COVID-19 patients, PLOS Computational Biology, doi:10.1371/journal.pcbi.1011050 (Table 2)

Issac et al., Improved And Optimized Drug Repurposing For The SARS-CoV-2 Pandemic, bioRxiv, doi:10.1101/2022.03.24.485618

Luedemann et al., Montelukast is a dual-purpose inhibitor of SARS-CoV-2 infection and virus-induced IL-6 expression identified by structure-based drug repurposing, Computational and Structural Biotechnology Journal, doi:10.1016/j.csbj.2022.01.024

Kerget et al., Effect of montelukast therapy on clinical course, pulmonary function, and mortality in patients with COVID‐19, Journal of Medical Virology, doi:10.1002/jmv.27552

Tam et al., Targeting SARS-CoV-2 Non-Structural Proteins, International Journal of Molecular Sciences, doi:10.3390/ijms241613002

Mittal et al., Identification of potential molecules against COVID-19 main protease through structure-guided virtual screening approach, Journal of Biomolecular Structure and Dynamics, doi:10.1080/07391102.2020.1768151

Chen et al., Metabolic alterations upon SARS-CoV-2 infection and potential therapeutic targets against coronavirus infection, Signal Transduction and Targeted Therapy, doi:10.1038/s41392-023-01510-8

Mehyar, N., Coronaviruses SARS-CoV, MERS-CoV, and SARS-CoV-2 helicase inhibitors: A systematic review of in vitro studies, Journal of Virus Eradication, doi:10.1016/j.jve.2023.100327

Oliver et al., Different drug approaches to COVID-19 treatment worldwide: an update of new drugs and drugs repositioning to fight against the novel coronavirus, Therapeutic Advances in Vaccines and Immunotherapy, doi:10.1177/25151355221144845

Wu et al., Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods, Acta Pharmaceutica Sinica B, doi:10.1016/j.apsb.2020.02.008

http://www.biomedrb.com/PDF/brb-9.pdf

https://sites.google.com/view/coronabank/coronabank/immunomodulatory-agents

Abou Baker et al., An overview on medicinal plants used for combating coronavirus: Current potentials and challenges, Journal of Agriculture and Food Research, doi:10.1016/j.jafr.2023.100632

Srivastava et al., A Brief Review on Medicinal Plants-At-Arms against COVID-19, Interdisciplinary Perspectives on Infectious Diseases, doi:10.1155/2023/7598307

Kumar et al., COVID-19 therapeutics: Clinical application of repurposed drugs and futuristic strategies for target-based drug discovery, Genes & Diseases, doi:10.1016/j.gendis.2022.12.019

Giordano et al., Food Plant Secondary Metabolites Antiviral Activity and Their Possible Roles in SARS-CoV-2 Treatment: An Overview, Molecules, doi:10.3390/molecules28062470

Ur Rehman et al., Flavonoids and other polyphenols against SARS-CoV-2, Application of Natural Products in SARS-CoV-2, doi:10.1016/B978-0-323-95047-3.00014-9

Jamshidnia et al., An Update on Promising Agents against COVID-19: Secondary Metabolites and Mechanistic Aspects, Current Pharmaceutical Design, doi:10.2174/1381612828666220722124826

Mukherjee et al., Role of medicinal plants in inhibiting SARS-CoV-2 and in the management of post-COVID-19 complications, Phytomedicine, doi:10.1016/j.phymed.2022.153930

https://sites.google.com/view/coronabank/coronabank/natural-compounds

https://www.sciencedirect.com/science/article/pii/S0223523421007066

https://www.mdpi.com/2304-8158/10/9/2084/htm

He et al., Recent advances towards natural plants as potential inhibitors of SARS-Cov-2 targets, Pharmaceutical Biology, doi:10.1080/13880209.2023.2241518

Fu et al., The mechanism of TCM prevention and treatment of heavy COVID-19 based on data mining and network pharmacology, Drug Combination Therapy, doi:10.53388/DCT20230010

Toigo et al., Flavonoid as possible therapeutic targets against COVID-19: a scoping review of in silico studies, DARU Journal of Pharmaceutical Sciences, doi:10.1007/s40199-023-00461-3

Nasirzadeh et al., Inhibiting IL-6 During Cytokine Storm in COVID-19: Potential Role of Natural Products, MDPI AG, doi:10.20944/preprints202106.0131.v1

Mardaneh et al., Inhibiting NF-κB During Cytokine Storm in COVID-19: Potential Role of Natural Products as a Promising Therapeutic Approach, MDPI AG, doi:10.20944/preprints202106.0130.v1

Ur Rehman et al., Flavonoids and other polyphenols against SARS-CoV-2, Application of Natural Products in SARS-CoV-2, doi:10.1016/B978-0-323-95047-3.00014-9

Aati et al., Garcinia cambogia Phenolics as Potent Anti-COVID-19 Agents: Phytochemical Profiling, Biological Activities, and Molecular Docking, Plants, doi:10.3390/plants11192521

Negru et al., Virtual Screening of Substances Used in the Treatment of SARS-CoV-2 Infection and Analysis of Compounds With Known Action on Structurally Similar Proteins From Other Viruses, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.113432

https://sites.google.com/view/coronabank/coronabank/natural-compounds

http://journal.unhas.ac.id/index.php/ijoab/article/view/25284

Hernández et al., Ozone therapy for patients with COVID-19 pneumonia: Preliminary report of a prospective case-control study, International Immunopharmacology, doi:10.1016/j.intimp.2020.107261

Shah et al., Safety and efficacy of ozone therapy in mild to moderate COVID-19 patients: A phase 1/11 randomized control trial (SEOT study), International Immunopharmacology, doi:10.1016/j.intimp.2020.107301

Tascini et al., Blood ozonization in patients with mild to moderate COVID-19 pneumonia: a single centre experience, Internal and Emergency Medicine, doi:10.1007/s11739-020-02542-6

Araimo et al., Ozone as adjuvant support in the treatment of COVID‐19: A preliminary report of probiozovid trial, Journal of Medical Virology, doi:10.1002/jmv.26636

Fernández-Cuadros et al., Compassionate Use of Rectal Ozone (O3) in Severe COVID-19 Pneumonia: a Case-Control Study, SN Comprehensive Clinical Medicine, doi:10.1007/s42399-021-00849-9

Sozio et al., CORonavirus-19 mild to moderate pneumonia Management with blood Ozonization in patients with Respiratory failure (CORMOR) multicentric prospective randomized clinical trial, International Immunopharmacology, doi:10.1016/j.intimp.2021.107874

Fernández-Cuadros et al., Effect of Rectal Ozone (O3) in Severe COVID-19 Pneumonia: Preliminary Results, SN Comprehensive Clinical Medicine, doi:10.1007/s42399-020-00374-1

Robert Jay et al., A Plausible "Penny" Costing Effective Treatment for Corona Virus - Ozone Therapy, Journal of Infectious Diseases and Epidemiology, doi:10.23937/2474-3658/1510113

Rowen, R., Ozone and oxidation therapies as a solution to the emerging crisis in infectious disease management: a review of current knowledge and experience, Medical Gas Research, doi:10.4103/2045-9912.273962

https://jppres.com/jppres/ozone-in-covid-19/

Toigo et al., Flavonoid as possible therapeutic targets against COVID-19: a scoping review of in silico studies, DARU Journal of Pharmaceutical Sciences, doi:10.1007/s40199-023-00461-3

Srivastava et al., A Brief Review on Medicinal Plants-At-Arms against COVID-19, Interdisciplinary Perspectives on Infectious Diseases, doi:10.1155/2023/7598307

Giordano et al., Food Plant Secondary Metabolites Antiviral Activity and Their Possible Roles in SARS-CoV-2 Treatment: An Overview, Molecules, doi:10.3390/molecules28062470

Tallei et al., Potential of Plant Bioactive Compounds as SARS-CoV-2 Main Protease (Mpro) and Spike (S) Glycoprotein Inhibitors: A Molecular Docking Study, Scientifica, doi:10.1155/2020/6307457

Rahman et al., In silico investigation and potential therapeutic approaches of natural products for COVID-19: Computer-aided drug design perspective, Frontiers in Cellular and Infection Microbiology, doi:10.3389/fcimb.2022.929430

Guerra et al., Critical Review of Plant-Derived Compounds as Possible Inhibitors of SARS-CoV-2 Proteases: A Comparison with Experimentally Validated Molecules, ACS Omega, doi:10.1021/acsomega.2c05766

Glaab et al., Pharmacophore Model for SARS-CoV-2 3CLpro Small-Molecule Inhibitors and in Vitro Experimental Validation of Computationally Screened Inhibitors, Journal of Chemical Information and Modeling, doi:10.1021/acs.jcim.1c00258

Jamalipour Soufi et al., Potential inhibitors of SARS-CoV-2: recent advances, Journal of Drug Targeting, doi:10.1080/1061186X.2020.1853736

Uma Reddy et al., Multifaceted role of plant derived small molecule inhibitors on replication cycle of sars-cov-2, Microbial Pathogenesis, doi:10.1016/j.micpath.2022.105512

Ali et al., Implication of in silico studies in the search for novel inhibitors against SARS‐CoV‐2, Archiv der Pharmazie, doi:10.1002/ardp.202100360

Moura et al., Converging Paths: A Comprehensive Review of the Synergistic Approach between Complementary Medicines and Western Medicine in Addressing COVID-19 in 2020, BioMed, doi:10.3390/biomed3020025

Lundstrom et al., COVID-19 signalome: Potential therapeutic interventions, Cellular Signalling, doi:10.1016/j.cellsig.2022.110559

Gudima et al., Antiviral Therapy of COVID-19, International Journal of Molecular Sciences, doi:10.3390/ijms24108867

Oliver et al., Different drug approaches to COVID-19 treatment worldwide: an update of new drugs and drugs repositioning to fight against the novel coronavirus, Therapeutic Advances in Vaccines and Immunotherapy, doi:10.1177/25151355221144845

Xue et al., Repurposing clinically available drugs and therapies for pathogenic targets to combat SARS‐CoV‐2, MedComm, doi:10.1002/mco2.254

Pati et al., Drug discovery through Covid-19 genome sequencing with siamese graph convolutional neural network, Multimedia Tools and Applications, doi:10.1007/s11042-023-15270-8

Nayak et al., Prospects of Novel and Repurposed Immunomodulatory Drugs against Acute Respiratory Distress Syndrome (ARDS) Associated with COVID-19 Disease, Journal of Personalized Medicine, doi:10.3390/jpm13040664

Kumar et al., COVID-19 therapeutics: Clinical application of repurposed drugs and futuristic strategies for target-based drug discovery, Genes & Diseases, doi:10.1016/j.gendis.2022.12.019

Astasio-Picado et al., Therapeutic Targets in the Virological Mechanism and in the Hyperinflammatory Response of Severe Acute Respiratory Syndrome Coronavirus Type 2 (SARS-CoV-2), Applied Sciences, doi:10.3390/app13074471

https://www.mdpi.com/2571-841X/6/4/45

Mandal et al., In silico anti-viral assessment of phytoconstituents in a traditional (Siddha Medicine) polyherbal formulation – Targeting Mpro and pan-coronavirus post-fusion Spike protein, Journal of Traditional and Complementary Medicine, doi:10.1016/j.jtcme.2023.07.004

Akter et al., Plausibility of natural immunomodulators in the treatment of COVID-19–A comprehensive analysis and future recommendations, Heliyon, doi:10.1016/j.heliyon.2023.e17478

Rafiq et al., A Comprehensive Update of Various Attempts by Medicinal Chemists to Combat COVID-19 through Natural Products, Molecules, doi:10.3390/molecules28124860

Krüger et al., Discovery of Polyphenolic Natural Products as SARS-CoV-2 Mpro Inhibitors for COVID-19, Pharmaceuticals, doi:10.3390/ph16020190

CHANDRA et al., Indian medicinal plants are effective in the treatment and management of COVID-19, BIOCELL, doi:10.32604/biocell.2023.026081

Pang et al., The research progress of SARS-CoV-2 main protease inhibitors from 2020 to 2022, European Journal of Medicinal Chemistry, doi:10.1016/j.ejmech.2023.115491

Rahman et al., In silico investigation and potential therapeutic approaches of natural products for COVID-19: Computer-aided drug design perspective, Frontiers in Cellular and Infection Microbiology, doi:10.3389/fcimb.2022.929430

Heleno et al., Plant Extracts and SARS-CoV-2: Research and Applications, Life, doi:10.3390/life13020386

Uma Reddy et al., Multifaceted role of plant derived small molecule inhibitors on replication cycle of sars-cov-2, Microbial Pathogenesis, doi:10.1016/j.micpath.2022.105512

https://www.mdpi.com/2304-8158/10/9/2084/htm

Jing et al., Pharmacological effects and mechanisms of tannic acid, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.113561

Wang et al., Stand Up to Stand Out: Natural Dietary Polyphenols Curcumin, Resveratrol, and Gossypol as Potential Therapeutic Candidates against Severe Acute Respiratory Syndrome Coronavirus 2 Infection, Nutrients, doi:10.3390/nu15183885

Li et al., Potential inhibitors for blocking the interaction of the coronavirus SARS-CoV-2 spike protein and its host cell receptor ACE2, Journal of Translational Medicine, doi:10.1186/s12967-022-03501-9

Mehyar, N., Coronaviruses SARS-CoV, MERS-CoV, and SARS-CoV-2 helicase inhibitors: A systematic review of in vitro studies, Journal of Virus Eradication, doi:10.1016/j.jve.2023.100327

Abou Baker et al., An overview on medicinal plants used for combating coronavirus: Current potentials and challenges, Journal of Agriculture and Food Research, doi:10.1016/j.jafr.2023.100632

Guerra et al., Critical Review of Plant-Derived Compounds as Possible Inhibitors of SARS-CoV-2 Proteases: A Comparison with Experimentally Validated Molecules, ACS Omega, doi:10.1021/acsomega.2c05766

Yang et al., Potential medicinal plants involved in inhibiting 3CLpro activity: A practical alternate approach to combating COVID-19, Journal of Integrative Medicine, doi:10.1016/j.joim.2022.08.001

Mukherjee et al., Role of medicinal plants in inhibiting SARS-CoV-2 and in the management of post-COVID-19 complications, Phytomedicine, doi:10.1016/j.phymed.2022.153930

https://pubmed.ncbi.nlm.nih.gov/33415017/

https://sites.google.com/view/coronabank/coronabank/natural-compounds

Del Amo, J., Daily tenofovir disoproxil fumarate/emtricitabine and hydroxychloroquine for pre-exposure prophylaxis of COVID-19: a double-blind placebo controlled randomized trial in healthcare workers, medRxiv, doi:10.1101/2022.03.02.22271710

Polo et al., Daily tenofovir disoproxil fumarate/emtricitabine and hydroxychloroquine for pre-exposure prophylaxis of COVID-19: a double-blind placebo controlled randomized trial in healthcare workers, Clinical Microbiology and Infection, doi:10.1016/j.cmi.2022.07.006

Hernán et al., Drug Repurposing and Observational Studies: The Case of Antivirals for the Treatment of COVID-19, Annals of Internal Medicine, doi:10.7326/M22-3582

Lea et al., Human Immunodeficiency Virus Status, Tenofovir Exposure, and the Risk of Poor Coronavirus Disease 19 (COVID-19) Outcomes: Real-World Analysis From 6 United States Cohorts Before Vaccine Rollout, Clinical Infectious Diseases, doi:10.1093/cid/ciad084

Rombini et al., Tenofovir-Containing Antiretroviral Therapy and Clinical Outcomes of SARS-CoV-2 Infection in People Living with HIV, Viruses, doi:10.3390/v15051127

Onyango, O., In Silico Models for Anti-COVID-19 Drug Discovery: A Systematic Review, Advances in Pharmacological and Pharmaceutical Sciences, doi:10.1155/2023/4562974

Oliver et al., Different drug approaches to COVID-19 treatment worldwide: an update of new drugs and drugs repositioning to fight against the novel coronavirus, Therapeutic Advances in Vaccines and Immunotherapy, doi:10.1177/25151355221144845

Tsuji, M., Virtual Screening and Quantum Chemistry Analysis for SARS-CoV-2 RNA-Dependent RNA Polymerase Using the ChEMBL Database: Reproduction of the Remdesivir-RTP and Favipiravir-RTP Binding Modes Obtained from Cryo-EM Experiments with High Binding Affinity, International Journal of Molecular Sciences, doi:10.3390/ijms231911009

Frediansyah et al., Antivirals for COVID-19: A critical review, Clinical Epidemiology and Global Health, doi:10.1016/j.cegh.2020.07.006

https://sites.google.com/view/coronabank/coronabank/classical-and-potential-antivirals

Polanco et al., Caracterización del uso de tofacitinib como tratamiento para covid-19, Revista Colombiana de Reumatología, doi:10.1016/j.rcreu.2022.03.002

Khan et al., Possible therapeutic targets for SARS-CoV-2 infection and COVID-19, Journal of Allergy & Infectious Diseases, doi:10.46439/allergy.2.028

Kushwaha et al., A comprehensive review on the global efforts on vaccines and repurposed drugs for combating COVID-19, European Journal of Medicinal Chemistry, doi:10.1016/j.ejmech.2023.115719

Oliver et al., Different drug approaches to COVID-19 treatment worldwide: an update of new drugs and drugs repositioning to fight against the novel coronavirus, Therapeutic Advances in Vaccines and Immunotherapy, doi:10.1177/25151355221144845

Xue et al., Repurposing clinically available drugs and therapies for pathogenic targets to combat SARS‐CoV‐2, MedComm, doi:10.1002/mco2.254

Ceja-Gálvez et al., Severe COVID-19: Drugs and Clinical Trials, Journal of Clinical Medicine, doi:10.3390/jcm12082893

Nayak et al., Prospects of Novel and Repurposed Immunomodulatory Drugs against Acute Respiratory Distress Syndrome (ARDS) Associated with COVID-19 Disease, Journal of Personalized Medicine, doi:10.3390/jpm13040664

Sarkar et al., Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives, Frontiers in Pharmacology, doi:10.3389/fphar.2020.572870

https://www.mdpi.com/2571-841X/6/4/45

https://sites.google.com/view/coronabank/coronabank/immunomodulatory-agents

Wang et al., Repurposing Drugs for the Treatment of COVID-19 and Its Cardiovascular Manifestations, Circulation Research, doi:10.1161/circresaha.122.321879

Wu et al., Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods, Acta Pharmaceutica Sinica B, doi:10.1016/j.apsb.2020.02.008

Zhou et al., Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2, Cell Discovery, doi:10.1038/s41421-020-0153-3

Cousins et al., Integrative analysis of viral entry networks and clinical outcomes identifies a protective role for spironolactone in severe COVID-19, medRxiv, doi:10.1101/2022.07.02.22277181

Abdel-Halim et al., Identification of Drug Combination Therapies for SARS-CoV-2: A Molecular Dynamics Simulations Approach, Drug Design, Development and Therapy, doi:10.2147/DDDT.S366423

MacFadden et al., Screening Large Population Health Databases for Potential COVID-19 Therapeutics: A Pharmacopeia-Wide Association Study (PWAS) of Commonly Prescribed Medications, Open Forum Infectious Diseases, doi:10.1093/ofid/ofac156

Darquennes et al., Association between Functional Inhibitors of Acid Sphingomyelinase (FIASMAs) and Reduced Risk of Death in COVID-19 Patients: A Retrospective Cohort Study, Pharmaceuticals, doi:10.3390/ph14030226

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7286244/pdf/main.pdf

https://sites.google.com/view/coronabank/coronabank/immunomodulatory-agents

Kushwaha et al., A comprehensive review on the global efforts on vaccines and repurposed drugs for combating COVID-19, European Journal of Medicinal Chemistry, doi:10.1016/j.ejmech.2023.115719

Oliver et al., Different drug approaches to COVID-19 treatment worldwide: an update of new drugs and drugs repositioning to fight against the novel coronavirus, Therapeutic Advances in Vaccines and Immunotherapy, doi:10.1177/25151355221144845

Nayak et al., Prospects of Novel and Repurposed Immunomodulatory Drugs against Acute Respiratory Distress Syndrome (ARDS) Associated with COVID-19 Disease, Journal of Personalized Medicine, doi:10.3390/jpm13040664

Roy et al., G4-binding drugs, chlorpromazine and prochlorperazine, repurposed against COVID-19 infection in hamsters, Frontiers in Molecular Biosciences, doi:10.3389/fmolb.2023.1133123

Homolak et al., Widely available lysosome targeting agents should be considered as potential therapy for COVID-19, International Journal of Antimicrobial Agents, doi:10.1016/j.ijantimicag.2020.106044

Mousavi et al., Novel Drug Design for Treatment of COVID-19: A Systematic Review of Preclinical Studies, Canadian Journal of Infectious Diseases and Medical Microbiology, doi:10.1155/2022/2044282

Sperry et al., Target-agnostic drug prediction integrated with medical record analysis uncovers differential associations of statins with increased survival in COVID-19 patients, PLOS Computational Biology, doi:10.1371/journal.pcbi.1011050 (Table 2)

Issac et al., Improved And Optimized Drug Repurposing For The SARS-CoV-2 Pandemic, bioRxiv, doi:10.1101/2022.03.24.485618

https://sites.google.com/view/coronabank/coronabank/immunomodulatory-agents

He et al., Recent advances towards natural plants as potential inhibitors of SARS-Cov-2 targets, Pharmaceutical Biology, doi:10.1080/13880209.2023.2241518

Akter et al., Plausibility of natural immunomodulators in the treatment of COVID-19–A comprehensive analysis and future recommendations, Heliyon, doi:10.1016/j.heliyon.2023.e17478

Wu et al., Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods, Acta Pharmaceutica Sinica B, doi:10.1016/j.apsb.2020.02.008

Rani et al., Modern drug discovery applications for the identification of novel candidates for COVID-19 infections, Annals of Medicine and Surgery, doi:10.1016/j.amsu.2022.104125

Mukherjee et al., Role of medicinal plants in inhibiting SARS-CoV-2 and in the management of post-COVID-19 complications, Phytomedicine, doi:10.1016/j.phymed.2022.153930

https://sites.google.com/view/coronabank/coronabank/natural-compounds

http://journal.unhas.ac.id/index.php/ijoab/article/view/25284

https://www.sciencedirect.com/science/article/pii/S0223523421007066

https://www.mdpi.com/2304-8158/10/9/2084/htm

Mehyar, N., Coronaviruses SARS-CoV, MERS-CoV, and SARS-CoV-2 helicase inhibitors: A systematic review of in vitro studies, Journal of Virus Eradication, doi:10.1016/j.jve.2023.100327

Oliver et al., Different drug approaches to COVID-19 treatment worldwide: an update of new drugs and drugs repositioning to fight against the novel coronavirus, Therapeutic Advances in Vaccines and Immunotherapy, doi:10.1177/25151355221144845

Atoum et al., Paving New Roads Using Allium sativum as a Repurposed Drug and Analyzing its Antiviral Action Using Artificial Intelligence Technology, Iranian Journal of Pharmaceutical Research, doi:10.5812/ijpr-131577

Chapola et al., A COMPARATIVE STUDY OF COVID-19 TRANSCRIPTIONAL SIGNATURES BETWEEN CLINICAL SAMPLES AND PRECLINICAL CELL MODELS IN THE SEARCH FOR DISEASE MASTER REGULATORS AND DRUG REPOSITIONING CANDIDATES, Virus Research, doi:10.1016/j.virusres.2023.199053

Zeng et al., Repurpose Open Data to Discover Therapeutics for COVID-19 Using Deep Learning, Journal of Proteome Research, doi:10.1021/acs.jproteome.0c00316

Ke et al., Artificial intelligence approach fighting COVID-19 with repurposing drugs, Biomedical Journal, doi:10.1016/j.bj.2020.05.001

Zhong et al., Recent advances in small-molecular therapeutics for COVID-19, Precision Clinical Medicine, doi:10.1093/pcmedi/pbac024

Mirabelli et al., Morphological cell profiling of SARS-CoV-2 infection identifies drug repurposing candidates for COVID-19, Proceedings of the National Academy of Sciences, doi:10.1073/pnas.2105815118

https://sites.google.com/view/coronabank/coronabank/classical-and-potential-antivirals

Kushwaha et al., A comprehensive review on the global efforts on vaccines and repurposed drugs for combating COVID-19, European Journal of Medicinal Chemistry, doi:10.1016/j.ejmech.2023.115719

Oliver et al., Different drug approaches to COVID-19 treatment worldwide: an update of new drugs and drugs repositioning to fight against the novel coronavirus, Therapeutic Advances in Vaccines and Immunotherapy, doi:10.1177/25151355221144845

Kronenberger et al., COVID-19 therapeutics: Small-molecule drug development targeting SARS-CoV-2 main protease, Drug Discovery Today, doi:10.1016/j.drudis.2023.103579

Kumar et al., COVID-19 therapeutics: Clinical application of repurposed drugs and futuristic strategies for target-based drug discovery, Genes & Diseases, doi:10.1016/j.gendis.2022.12.019

Yin et al., Computational Screening of Repurposed Drugs Targeting Sars-Cov-2 Main Protease By Molecular Docking, Sudan Journal of Medical Sciences, doi:10.18502/sjms.v17i3.12125

Talluri, S., Molecular Docking and Virtual Screening Based Prediction of Drugs for COVID-19, Combinatorial Chemistry & High Throughput Screening, doi:10.2174/1386207323666200814132149

Sarkar et al., Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives, Frontiers in Pharmacology, doi:10.3389/fphar.2020.572870

https://sites.google.com/view/coronabank/coronabank/classical-and-potential-antivirals

http://journal.oiu.edu.sd/index.php/FMHS/article/view/2688

Wei et al., Total network controllability analysis discovers explainable drugs for Covid-19 treatment, Biology Direct, doi:10.1186/s13062-023-00410-9

Qu et al., A new integrated framework for the identification of potential virus–drug associations, Frontiers in Microbiology, doi:10.3389/fmicb.2023.1179414

Schake et al., An interaction-based drug discovery screen explains known SARS-CoV-2 inhibitors and predicts new compound scaffolds, Scientific Reports, doi:10.1038/s41598-023-35671-x

Xue et al., Repurposing clinically available drugs and therapies for pathogenic targets to combat SARS‐CoV‐2, MedComm, doi:10.1002/mco2.254

Tomazou et al., Multi-omics data integration and network-based analysis drives a multiplex drug repurposing approach to a shortlist of candidate drugs against COVID-19, Briefings in Bioinformatics, doi:10.1093/bib/bbab114

Tsuji, M., Virtual Screening and Quantum Chemistry Analysis for SARS-CoV-2 RNA-Dependent RNA Polymerase Using the ChEMBL Database: Reproduction of the Remdesivir-RTP and Favipiravir-RTP Binding Modes Obtained from Cryo-EM Experiments with High Binding Affinity, International Journal of Molecular Sciences, doi:10.3390/ijms231911009

Sperry et al., Target-agnostic drug prediction integrated with medical record analysis uncovers differential associations of statins with increased survival in COVID-19 patients, PLOS Computational Biology, doi:10.1371/journal.pcbi.1011050 (Table 2)

Bahadur Gurung et al., An in silico approach unveils the potential of antiviral compounds in preclinical and clinical trials as SARS-CoV-2 Omicron inhibitors, Saudi Journal of Biological Sciences, doi:10.1016/j.sjbs.2022.103297

https://sites.google.com/view/coronabank/coronabank/binding-and-internalisation-inhibitors

Ruan et al., Virtual high-throughput screening: Potential inhibitors targeting aminopeptidase N (CD13) and PIKfyve for SARS-CoV-2, Open Life Sciences, doi:10.1515/biol-2022-0637

Moura et al., Converging Paths: A Comprehensive Review of the Synergistic Approach between Complementary Medicines and Western Medicine in Addressing COVID-19 in 2020, BioMed, doi:10.3390/biomed3020025

Islam et al., Molecular-evaluated and explainable drug repurposing for COVID-19 using ensemble knowledge graph embedding, Scientific Reports, doi:10.1038/s41598-023-30095-z

Ghosh et al., Interactome-Based Machine Learning Predicts Potential Therapeutics for COVID-19, ACS Omega, doi:10.1021/acsomega.3c00030

Shen et al., The antiviral activity of a small molecule drug targeting the NSP1-ribosome complex against Omicron, especially in elderly patients, Frontiers in Cellular and Infection Microbiology, doi:10.3389/fcimb.2023.1141274

Atoum et al., Paving New Roads Using Allium sativum as a Repurposed Drug and Analyzing its Antiviral Action Using Artificial Intelligence Technology, Iranian Journal of Pharmaceutical Research, doi:10.5812/ijpr-131577

Wu et al., In silico identification of drug candidates against COVID-19, Informatics in Medicine Unlocked, doi:10.1016/j.imu.2020.100461

Kadioglu et al., Identification of novel compounds against three targets of SARS CoV-2 coronavirus by combined virtual screening and supervised machine learning, Computers in Biology and Medicine, doi:10.1016/j.compbiomed.2021.104359

https://sites.google.com/view/coronabank/coronabank/binding-and-internalisation-inhibitors

He et al., Recent advances towards natural plants as potential inhibitors of SARS-Cov-2 targets, Pharmaceutical Biology, doi:10.1080/13880209.2023.2241518

Onyango, O., In Silico Models for Anti-COVID-19 Drug Discovery: A Systematic Review, Advances in Pharmacological and Pharmaceutical Sciences, doi:10.1155/2023/4562974

Akter et al., Plausibility of natural immunomodulators in the treatment of COVID-19–A comprehensive analysis and future recommendations, Heliyon, doi:10.1016/j.heliyon.2023.e17478

Corbo et al., Inhibitory potential of phytochemicals on five SARS-CoV-2 proteins: in silico evaluation of endemic plants of Bosnia and Herzegovina, Biotechnology & Biotechnological Equipment, doi:10.1080/13102818.2023.2222196

Oliver et al., Different drug approaches to COVID-19 treatment worldwide: an update of new drugs and drugs repositioning to fight against the novel coronavirus, Therapeutic Advances in Vaccines and Immunotherapy, doi:10.1177/25151355221144845

Toigo et al., Flavonoid as possible therapeutic targets against COVID-19: a scoping review of in silico studies, DARU Journal of Pharmaceutical Sciences, doi:10.1007/s40199-023-00461-3

Srivastava et al., A Brief Review on Medicinal Plants-At-Arms against COVID-19, Interdisciplinary Perspectives on Infectious Diseases, doi:10.1155/2023/7598307

https://sites.google.com/view/coronabank/coronabank/natural-compounds

http://journal.unhas.ac.id/index.php/ijoab/article/view/25284

Sha et al., Current state-of-the-art and potential future therapeutic drugs against COVID-19, Frontiers in Cell and Developmental Biology, doi:10.3389/fcell.2023.1238027

Carabineiro et al., CuFe2O4 Magnetic Nanoparticles as Heterogeneous Catalysts for Synthesis of Dihydropyrimidinones as Inhibitors of SARS-CoV-2 Surface Proteins—Insights from Molecular Docking Studies, Processes, doi:10.3390/pr11082294

Farkaš et al., A Tale of Two Proteases: MPro and TMPRSS2 as Targets for COVID-19 Therapies, Pharmaceuticals, doi:10.3390/ph16060834

Jiang et al., Discovery of novel non-peptidic and non-covalent small-molecule 3CLpro inhibitors as potential candidate for COVID-19 treatment, Signal Transduction and Targeted Therapy, doi:10.1038/s41392-023-01482-9

Pang et al., The research progress of SARS-CoV-2 main protease inhibitors from 2020 to 2022, European Journal of Medicinal Chemistry, doi:10.1016/j.ejmech.2023.115491

Xue et al., Repurposing clinically available drugs and therapies for pathogenic targets to combat SARS‐CoV‐2, MedComm, doi:10.1002/mco2.254

Kronenberger et al., COVID-19 therapeutics: Small-molecule drug development targeting SARS-CoV-2 main protease, Drug Discovery Today, doi:10.1016/j.drudis.2023.103579

Glaab et al., Pharmacophore Model for SARS-CoV-2 3CLpro Small-Molecule Inhibitors and in Vitro Experimental Validation of Computationally Screened Inhibitors, Journal of Chemical Information and Modeling, doi:10.1021/acs.jcim.1c00258

Davarpanah et al., Combination of Spironolactone and Sitagliptin Improves Clinical Outcomes of Outpatients with COVID-19: An Observational Study, medRxiv, doi:10.1101/2022.01.21.22269322

Wang et al., Stand Up to Stand Out: Natural Dietary Polyphenols Curcumin, Resveratrol, and Gossypol as Potential Therapeutic Candidates against Severe Acute Respiratory Syndrome Coronavirus 2 Infection, Nutrients, doi:10.3390/nu15183885

He et al., Recent advances towards natural plants as potential inhibitors of SARS-Cov-2 targets, Pharmaceutical Biology, doi:10.1080/13880209.2023.2241518

CHEN et al., Deciphering suppressive effects of Lianhua Qingwen Capsule on COVID-19 and synergistic effects of its major botanical drug pairs, Chinese Journal of Natural Medicines, doi:10.1016/S1875-5364(23)60455-8

Srivastava et al., A Brief Review on Medicinal Plants-At-Arms against COVID-19, Interdisciplinary Perspectives on Infectious Diseases, doi:10.1155/2023/7598307

Youn et al., Robust therapeutic effects on COVID-19 of novel small molecules: Alleviation of SARS-CoV-2 S protein induction of ACE2/TMPRSS2, NOX2/ROS, and MCP-1, Frontiers in Cardiovascular Medicine, doi:10.3389/fcvm.2022.957340

Choe et al., The Efficacy of Traditional Medicinal Plants in Modulating the Main Protease of SARS‐CoV‐2 and Cytokine Storm, Chemistry & Biodiversity, doi:10.1002/cbdv.202200655

Sharma et al., Nutraceuticals aid in managing COVID-19, World Journal of Pharmaceutical Sciences, doi:10.54037/WJPS.2022.100204

https://sites.google.com/view/coronabank/coronabank/natural-compounds

https://www.sciencedirect.com/science/article/pii/S0223523421007066

Yuan et al., The role of cell death in SARS-CoV-2 infection, Signal Transduction and Targeted Therapy, doi:10.1038/s41392-023-01580-8

Augustin et al., Drug repurposing for COVID-19: current evidence from randomized controlled adaptive platform trials and living systematic reviews, British Medical Bulletin, doi:10.1093/bmb/ldac037

Lundstrom et al., COVID-19 signalome: Potential therapeutic interventions, Cellular Signalling, doi:10.1016/j.cellsig.2022.110559

Oliver et al., Different drug approaches to COVID-19 treatment worldwide: an update of new drugs and drugs repositioning to fight against the novel coronavirus, Therapeutic Advances in Vaccines and Immunotherapy, doi:10.1177/25151355221144845

Xue et al., Repurposing clinically available drugs and therapies for pathogenic targets to combat SARS‐CoV‐2, MedComm, doi:10.1002/mco2.254

Ceja-Gálvez et al., Severe COVID-19: Drugs and Clinical Trials, Journal of Clinical Medicine, doi:10.3390/jcm12082893

Basu et al., Therapeutics for COVID-19 and post COVID-19 complications: An update, Current Research in Pharmacology and Drug Discovery, doi:10.1016/j.crphar.2022.100086

Heimfarth et al., Drug repurposing and cytokine management in response to COVID-19: A review, International Immunopharmacology, doi:10.1016/j.intimp.2020.106947

https://www.mdpi.com/2571-841X/6/4/45

Asadi et al., Efficacy of naproxen in the management of patients hospitalized with COVID-19 infection: A randomized, double-blind, placebo-controlled, clinical trial, Diabetes & Metabolic Syndrome: Clinical Research & Reviews, doi:10.1016/j.dsx.2021.102319

Kushwaha et al., A comprehensive review on the global efforts on vaccines and repurposed drugs for combating COVID-19, European Journal of Medicinal Chemistry, doi:10.1016/j.ejmech.2023.115719

Chen et al., Metabolic alterations upon SARS-CoV-2 infection and potential therapeutic targets against coronavirus infection, Signal Transduction and Targeted Therapy, doi:10.1038/s41392-023-01510-8

Oliver et al., Different drug approaches to COVID-19 treatment worldwide: an update of new drugs and drugs repositioning to fight against the novel coronavirus, Therapeutic Advances in Vaccines and Immunotherapy, doi:10.1177/25151355221144845

Pang et al., The research progress of SARS-CoV-2 main protease inhibitors from 2020 to 2022, European Journal of Medicinal Chemistry, doi:10.1016/j.ejmech.2023.115491

Homolak et al., Widely available lysosome targeting agents should be considered as potential therapy for COVID-19, International Journal of Antimicrobial Agents, doi:10.1016/j.ijantimicag.2020.106044

Sarkar et al., Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives, Frontiers in Pharmacology, doi:10.3389/fphar.2020.572870

https://www.mdpi.com/1420-3049/26/9/2593/htm

https://sites.google.com/view/coronabank/coronabank/immunomodulatory-agents

Harris et al., Association between blood N-3 fatty acid levels and the risk of coronavirus disease 2019 in the UK Biobank, The American Journal of Clinical Nutrition, doi:10.1016/j.ajcnut.2022.11.011

Doaei et al., The effect of omega-3 fatty acid supplementation on clinical and biochemical parameters of critically ill patients with COVID-19: a randomized clinical trial, Journal of Translational Medicine, doi:10.1186/s12967-021-02795-5

Oliver et al., Different drug approaches to COVID-19 treatment worldwide: an update of new drugs and drugs repositioning to fight against the novel coronavirus, Therapeutic Advances in Vaccines and Immunotherapy, doi:10.1177/25151355221144845

Trivedi et al., Antiviral and Anti-Inflammatory Plant-Derived Bioactive Compounds and Their Potential Use in the Treatment of COVID-19-Related Pathologies, Journal of Xenobiotics, doi:10.3390/jox12040020

https://www.sciencedirect.com/science/article/abs/pii/S0952327821000132

https://www.authorea.com/doi/full/10.22541/au.161051252.26168891

https://www.sciencedirect.com/science/article/pii/S2589004221010087

https://www.plefa.com/article/S0952-3278(21)00013-2/fulltext

https://www.nature.com/articles/s41598-021-91794-z

Moura et al., Converging Paths: A Comprehensive Review of the Synergistic Approach between Complementary Medicines and Western Medicine in Addressing COVID-19 in 2020, BioMed, doi:10.3390/biomed3020025

Islam et al., Molecular-evaluated and explainable drug repurposing for COVID-19 using ensemble knowledge graph embedding, Scientific Reports, doi:10.1038/s41598-023-30095-z

Atoum et al., Paving New Roads Using Allium sativum as a Repurposed Drug and Analyzing its Antiviral Action Using Artificial Intelligence Technology, Iranian Journal of Pharmaceutical Research, doi:10.5812/ijpr-131577

Mody et al., Identification of 3-chymotrypsin like protease (3CLPro) inhibitors as potential anti-SARS-CoV-2 agents, Communications Biology, doi:10.1038/s42003-020-01577-x

Negru et al., Virtual Screening of Substances Used in the Treatment of SARS-CoV-2 Infection and Analysis of Compounds With Known Action on Structurally Similar Proteins From Other Viruses, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.113432

Kadioglu et al., Identification of novel compounds against three targets of SARS CoV-2 coronavirus by combined virtual screening and supervised machine learning, Computers in Biology and Medicine, doi:10.1016/j.compbiomed.2021.104359

Frediansyah et al., Antivirals for COVID-19: A critical review, Clinical Epidemiology and Global Health, doi:10.1016/j.cegh.2020.07.006

https://sites.google.com/view/coronabank/coronabank/classical-and-potential-antivirals

https://www.researchgate.net/publication/371219907_Docking_Analysis_of_drugs_used_for_trat..

Wang et al., Stand Up to Stand Out: Natural Dietary Polyphenols Curcumin, Resveratrol, and Gossypol as Potential Therapeutic Candidates against Severe Acute Respiratory Syndrome Coronavirus 2 Infection, Nutrients, doi:10.3390/nu15183885

He et al., Recent advances towards natural plants as potential inhibitors of SARS-Cov-2 targets, Pharmaceutical Biology, doi:10.1080/13880209.2023.2241518

Xue et al., Repurposing clinically available drugs and therapies for pathogenic targets to combat SARS‐CoV‐2, MedComm, doi:10.1002/mco2.254

Srivastava et al., A Brief Review on Medicinal Plants-At-Arms against COVID-19, Interdisciplinary Perspectives on Infectious Diseases, doi:10.1155/2023/7598307

Nasirzadeh et al., Inhibiting IL-6 During Cytokine Storm in COVID-19: Potential Role of Natural Products, MDPI AG, doi:10.20944/preprints202106.0131.v1

de Matos et al., Bioactive compounds as potential angiotensin-converting enzyme II inhibitors against COVID-19: a scoping review, Inflammation Research, doi:10.1007/s00011-022-01642-7

Qi et al., Discovery of TCMs and Derivatives Against the Main Protease of SARS-CoV-2 via High Throughput Screening, ADMET Analysis, and Inhibition Assay in Vitro, Journal of Molecular Structure, doi:10.1016/j.molstruc.2022.133709

https://www.researchgate.net/publication/370491709_Y_Wang_A_E_Tan_O_Chew_A_Hsueh_and_D_E_J..

https://www.sciencedirect.com/science/article/pii/S0223523421007066

Mandal et al., In silico anti-viral assessment of phytoconstituents in a traditional (Siddha Medicine) polyherbal formulation – Targeting Mpro and pan-coronavirus post-fusion Spike protein, Journal of Traditional and Complementary Medicine, doi:10.1016/j.jtcme.2023.07.004

Akter et al., Plausibility of natural immunomodulators in the treatment of COVID-19–A comprehensive analysis and future recommendations, Heliyon, doi:10.1016/j.heliyon.2023.e17478

Fan et al., Pharmaceutical approaches for COVID-19: An update on current therapeutic opportunities, Acta Pharmaceutica, doi:10.2478/acph-2023-0014

England et al., Plants as Biofactories for Therapeutic Proteins and Antiviral Compounds to Combat COVID-19, Life, doi:10.3390/life13030617

Das et al., Inhibition of SARS-CoV2 viral infection with natural antiviral plants constituents: an in-silico approach, Journal of King Saud University - Science, doi:10.1016/j.jksus.2022.102534

Supianto et al., Cluster-based text mining for extracting drug candidates for the prevention of COVID-19 from the biomedical literature, Journal of Taibah University Medical Sciences, doi:10.1016/j.jtumed.2022.12.015

Nag et al., Curcumin inhibits spike protein of new SARS-CoV-2 variant of concern (VOC) Omicron, an in silico study, Computers in Biology and Medicine, doi:10.1016/j.compbiomed.2022.105552

https://sites.google.com/view/coronabank/coronabank/natural-compounds

https://www.jcchems.com/index.php/JCCHEMS/article/download/1802/561

Lu et al., Punicalagin as an allosteric NSP13 helicase inhibitor potently suppresses SARS-CoV-2 replication in vitro, Antiviral Research, doi:10.1016/j.antiviral.2022.105389

Wang et al., Stand Up to Stand Out: Natural Dietary Polyphenols Curcumin, Resveratrol, and Gossypol as Potential Therapeutic Candidates against Severe Acute Respiratory Syndrome Coronavirus 2 Infection, Nutrients, doi:10.3390/nu15183885

Tam et al., Targeting SARS-CoV-2 Non-Structural Proteins, International Journal of Molecular Sciences, doi:10.3390/ijms241613002

Low et al., COVID-19 Therapeutic Potential of Natural Products, International Journal of Molecular Sciences, doi:10.3390/ijms24119589

Mehyar, N., Coronaviruses SARS-CoV, MERS-CoV, and SARS-CoV-2 helicase inhibitors: A systematic review of in vitro studies, Journal of Virus Eradication, doi:10.1016/j.jve.2023.100327

Alexova et al., Anti-COVID-19 Potential of Ellagic Acid and Polyphenols of Punica granatum L., Molecules, doi:10.3390/molecules28093772

Giordano et al., Food Plant Secondary Metabolites Antiviral Activity and Their Possible Roles in SARS-CoV-2 Treatment: An Overview, Molecules, doi:10.3390/molecules28062470

Kadioglu et al., Identification of novel compounds against three targets of SARS CoV-2 coronavirus by combined virtual screening and supervised machine learning, Computers in Biology and Medicine, doi:10.1016/j.compbiomed.2021.104359

https://sites.google.com/view/coronabank/coronabank/natural-compounds

He et al., Recent advances towards natural plants as potential inhibitors of SARS-Cov-2 targets, Pharmaceutical Biology, doi:10.1080/13880209.2023.2241518

Toigo et al., Flavonoid as possible therapeutic targets against COVID-19: a scoping review of in silico studies, DARU Journal of Pharmaceutical Sciences, doi:10.1007/s40199-023-00461-3

Srivastava et al., A Brief Review on Medicinal Plants-At-Arms against COVID-19, Interdisciplinary Perspectives on Infectious Diseases, doi:10.1155/2023/7598307

Giordano et al., Food Plant Secondary Metabolites Antiviral Activity and Their Possible Roles in SARS-CoV-2 Treatment: An Overview, Molecules, doi:10.3390/molecules28062470

Tallei et al., Potential of Plant Bioactive Compounds as SARS-CoV-2 Main Protease (Mpro) and Spike (S) Glycoprotein Inhibitors: A Molecular Docking Study, Scientifica, doi:10.1155/2020/6307457

Rahman et al., In silico investigation and potential therapeutic approaches of natural products for COVID-19: Computer-aided drug design perspective, Frontiers in Cellular and Infection Microbiology, doi:10.3389/fcimb.2022.929430

Jamalipour Soufi et al., Potential inhibitors of SARS-CoV-2: recent advances, Journal of Drug Targeting, doi:10.1080/1061186X.2020.1853736

Uma Reddy et al., Multifaceted role of plant derived small molecule inhibitors on replication cycle of sars-cov-2, Microbial Pathogenesis, doi:10.1016/j.micpath.2022.105512

Ali et al., Implication of in silico studies in the search for novel inhibitors against SARS‐CoV‐2, Archiv der Pharmazie, doi:10.1002/ardp.202100360

Gaitán-Duarte et al., Effectiveness of Rosuvastatin plus Colchicine, Emtricitabine/Tenofovir and a combination of them in Hospitalized Patients with SARS Covid-19, medRxiv, doi:10.1101/2021.07.06.21260085

Chen et al., Metabolic alterations upon SARS-CoV-2 infection and potential therapeutic targets against coronavirus infection, Signal Transduction and Targeted Therapy, doi:10.1038/s41392-023-01510-8

Oliver et al., Different drug approaches to COVID-19 treatment worldwide: an update of new drugs and drugs repositioning to fight against the novel coronavirus, Therapeutic Advances in Vaccines and Immunotherapy, doi:10.1177/25151355221144845

Esam et al., In silico investigation of the therapeutic and prophylactic potential of medicinal substances bearing guanidine moieties against COVID-19, Chemical Papers, doi:10.1007/s11696-022-02528-y

Loucera et al., Real-world evidence with a retrospective cohort of 15,968 Andalusian COVID-19 hospitalized patients suggests 21 new effective treatments and one drug that increases death risk., medRxiv, doi:10.1101/2022.08.14.22278751

Sperry et al., Different HMGCR-inhibiting statins vary in their association with increased survival in patients with COVID-19, medRxiv, doi:10.1101/2022.04.12.22273802

Issac et al., Improved And Optimized Drug Repurposing For The SARS-CoV-2 Pandemic, bioRxiv, doi:10.1101/2022.03.24.485618

https://sites.google.com/view/coronabank/coronabank/immunomodulatory-agents

https://elifesciences.org/articles/68165

Fani et al., Targeting host calcium channels and viroporins: a promising strategy for SARS-CoV-2 therapy, Future Virology, doi:10.2217/fvl-2022-0203

CHANDRA et al., Indian medicinal plants are effective in the treatment and management of COVID-19, BIOCELL, doi:10.32604/biocell.2023.026081

Oliver et al., Different drug approaches to COVID-19 treatment worldwide: an update of new drugs and drugs repositioning to fight against the novel coronavirus, Therapeutic Advances in Vaccines and Immunotherapy, doi:10.1177/25151355221144845

Abou Baker et al., An overview on medicinal plants used for combating coronavirus: Current potentials and challenges, Journal of Agriculture and Food Research, doi:10.1016/j.jafr.2023.100632

Zeng et al., Repurpose Open Data to Discover Therapeutics for COVID-19 Using Deep Learning, Journal of Proteome Research, doi:10.1021/acs.jproteome.0c00316

Dinda et al., Some natural compounds and their analogues having potent anti- SARS-CoV-2 and anti-proteases activities as lead molecules in drug discovery for COVID-19, European Journal of Medicinal Chemistry Reports, doi:10.1016/j.ejmcr.2022.100079

Zhang et al., A cell-based large-scale screening of natural compounds for inhibitors of SARS-CoV-2, Signal Transduction and Targeted Therapy, doi:10.1038/s41392-020-00343-z

https://www.researchgate.net/publication/373256147_A_Critical_Review_on_the_Potency_of_Phy..

https://www.sciencedirect.com/science/article/pii/S2213422021000688

Cao et al., VV116 versus Nirmatrelvir–Ritonavir for Oral Treatment of Covid-19, New England Journal of Medicine, doi:10.1056/NEJMoa2208822

McCarthy, M., VV116 as a potential treatment for COVID-19, Expert Opinion on Pharmacotherapy, doi:10.1080/14656566.2023.2193668

Sha et al., Current state-of-the-art and potential future therapeutic drugs against COVID-19, Frontiers in Cell and Developmental Biology, doi:10.3389/fcell.2023.1238027

Yang et al., Bench-to-bedside: Innovation of small molecule anti-SARS-CoV-2 drugs in China, European Journal of Medicinal Chemistry, doi:10.1016/j.ejmech.2023.115503

Xue et al., Repurposing clinically available drugs and therapies for pathogenic targets to combat SARS‐CoV‐2, MedComm, doi:10.1002/mco2.254

Bekheit et al., Potential RNA-dependent RNA polymerase inhibitors as prospective drug candidates for SARS-CoV-2, European Journal of Medicinal Chemistry, doi:10.1016/j.ejmech.2023.115292

Xu et al., An update on inhibitors targeting RNA-dependent RNA polymerase for COVID-19 treatment: Promises and challenges, Biochemical Pharmacology, doi:10.1016/j.bcp.2022.115279

https://www.trialsitenews.com/p/trialsitenews/novel-chinese-oral-covid-19-treatment-begins..

https://www1.hkexnews.hk/listedco/listconews/sehk/2022/0524/2022052301170.pdf

He et al., Recent advances towards natural plants as potential inhibitors of SARS-Cov-2 targets, Pharmaceutical Biology, doi:10.1080/13880209.2023.2241518

Akter et al., Plausibility of natural immunomodulators in the treatment of COVID-19–A comprehensive analysis and future recommendations, Heliyon, doi:10.1016/j.heliyon.2023.e17478

Giordano et al., Food Plant Secondary Metabolites Antiviral Activity and Their Possible Roles in SARS-CoV-2 Treatment: An Overview, Molecules, doi:10.3390/molecules28062470

Zhao et al., Identification of Potential Lead Compounds Targeting Novel Druggable Cavity of SARS-CoV-2 Spike Trimer by Molecular Dynamics Simulations, International Journal of Molecular Sciences, doi:10.3390/ijms24076281

Nag et al., Curcumin inhibits spike protein of new SARS-CoV-2 variant of concern (VOC) Omicron, an in silico study, Computers in Biology and Medicine, doi:10.1016/j.compbiomed.2022.105552

Mukherjee et al., Role of medicinal plants in inhibiting SARS-CoV-2 and in the management of post-COVID-19 complications, Phytomedicine, doi:10.1016/j.phymed.2022.153930

https://sites.google.com/view/coronabank/coronabank/natural-compounds

http://journal.unhas.ac.id/index.php/ijoab/article/view/25284

Wirnsberger et al., Clinical grade ACE2 as a universal agent to block SARS-CoV-2 variants, bioRxiv, doi:10.1101/2021.09.10.459744

Lundstrom et al., COVID-19 signalome: Potential therapeutic interventions, Cellular Signalling, doi:10.1016/j.cellsig.2022.110559

Talukder et al., Drugs for COVID-19 Treatment: A New Challenge, Applied Biochemistry and Biotechnology, doi:10.1007/s12010-023-04439-4

Raghav et al., Potential treatments of COVID-19: Drug repurposing and therapeutic interventions, Journal of Pharmacological Sciences, doi:10.1016/j.jphs.2023.02.004

Sarkar et al., Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives, Frontiers in Pharmacology, doi:10.3389/fphar.2020.572870

https://clinicaltrials.gov/ct2/show/NCT04335136

https://www.sciencedirect.com/science/article/abs/pii/S0040595721002043

https://www.sciencedirect.com/science/article/pii/S0953620521003071

Singh et al., Medicinal plants, phytoconstituents and traditional formulation as potential